id	sid	tid	token	lemma	pos
iajs-3493	1	1	45	45	NUM
iajs-3493	1	2	©	©	PROPN
iajs-3493	1	3	2024	2024	NUM
iajs-3493	1	4	the	the	DET
iajs-3493	1	5	author(s	author(s	NOUN
iajs-3493	1	6	)	)	PUNCT
iajs-3493	1	7	.	.	PUNCT
iajs-3493	2	1	published	publish	VERB
iajs-3493	2	2	by	by	ADP
iajs-3493	2	3	college	college	NOUN
iajs-3493	2	4	of	of	ADP
iajs-3493	2	5	education	education	NOUN
iajs-3493	2	6	for	for	ADP
iajs-3493	2	7	pure	pure	ADJ
iajs-3493	2	8	science	science	NOUN
iajs-3493	2	9	(	(	PUNCT
iajs-3493	2	10	ibn	ibn	PROPN
iajs-3493	2	11	al	al	PROPN
iajs-3493	2	12	-	-	PUNCT
iajs-3493	2	13	haitham	haitham	PROPN
iajs-3493	2	14	)	)	PUNCT
iajs-3493	2	15	,	,	PUNCT
iajs-3493	2	16	university	university	NOUN
iajs-3493	2	17	of	of	ADP
iajs-3493	2	18	baghdad	baghdad	PROPN
iajs-3493	2	19	.	.	PUNCT
iajs-3493	3	1	this	this	PRON
iajs-3493	3	2	is	be	AUX
iajs-3493	3	3	an	an	DET
iajs-3493	3	4	open	open	ADJ
iajs-3493	3	5	-	-	PUNCT
iajs-3493	3	6	access	access	NOUN
iajs-3493	3	7	article	article	NOUN
iajs-3493	3	8	distributed	distribute	VERB
iajs-3493	3	9	under	under	ADP
iajs-3493	3	10	the	the	DET
iajs-3493	3	11	terms	term	NOUN
iajs-3493	3	12	of	of	ADP
iajs-3493	3	13	the	the	DET
iajs-3493	3	14	creative	creative	ADJ
iajs-3493	3	15	commons	common	NOUN
iajs-3493	3	16	attribution	attribution	NOUN
iajs-3493	3	17	4.0	4.0	NUM
iajs-3493	3	18	international	international	ADJ
iajs-3493	3	19	license	license	NOUN
iajs-3493	3	20	immunological	immunological	ADJ
iajs-3493	3	21	role	role	NOUN
iajs-3493	3	22	of	of	ADP
iajs-3493	3	23	il-3	il-3	NUM
iajs-3493	3	24	,	,	PUNCT
iajs-3493	3	25	il-5	il-5	PRON
iajs-3493	3	26	and	and	CCONJ
iajs-3493	3	27	some	some	DET
iajs-3493	3	28	inflammation	inflammation	NOUN
iajs-3493	3	29	markers	marker	NOUN
iajs-3493	3	30	in	in	ADP
iajs-3493	3	31	a	a	DET
iajs-3493	3	32	sample	sample	NOUN
iajs-3493	3	33	of	of	ADP
iajs-3493	3	34	iraqi	iraqi	ADJ
iajs-3493	3	35	patients	patient	NOUN
iajs-3493	3	36	with	with	ADP
iajs-3493	3	37	rheumatoid	rheumatoid	NOUN
iajs-3493	3	38	arthritis	arthritis	NOUN
iajs-3493	3	39	shams	sham	NOUN
iajs-3493	3	40	a.	a.	PROPN
iajs-3493	3	41	salman1	salman1	PROPN
iajs-3493	3	42	,	,	PUNCT
iajs-3493	3	43	*	*	PUNCT
iajs-3493	3	44	and	and	CCONJ
iajs-3493	3	45	rakad	rakad	VERB
iajs-3493	3	46	m.	m.	NOUN
iajs-3493	3	47	kh	kh	PROPN
iajs-3493	3	48	al	al	PROPN
iajs-3493	3	49	-	-	PUNCT
iajs-3493	3	50	jumaily2	jumaily2	PROPN
iajs-3493	4	1	1,2department	1,2department	NUM
iajs-3493	4	2	of	of	ADP
iajs-3493	4	3	biology	biology	NOUN
iajs-3493	4	4	,	,	PUNCT
iajs-3493	4	5	college	college	NOUN
iajs-3493	4	6	of	of	ADP
iajs-3493	4	7	science	science	NOUN
iajs-3493	4	8	,	,	PUNCT
iajs-3493	4	9	university	university	NOUN
iajs-3493	4	10	of	of	ADP
iajs-3493	4	11	baghdad	baghdad	PROPN
iajs-3493	4	12	,	,	PUNCT
iajs-3493	4	13	baghdad	baghdad	PROPN
iajs-3493	4	14	,	,	PUNCT
iajs-3493	4	15	iraq	iraq	PROPN
iajs-3493	4	16	*	*	PUNCT
iajs-3493	4	17	corresponding	correspond	VERB
iajs-3493	4	18	author	author	NOUN
iajs-3493	4	19	.	.	PUNCT
iajs-3493	5	1	received	receive	VERB
iajs-3493	5	2	:	:	PUNCT
iajs-3493	5	3	14	14	NUM
iajs-3493	5	4	may	may	PROPN
iajs-3493	5	5	2023	2023	NUM
iajs-3493	5	6	accepted	accept	VERB
iajs-3493	5	7	:	:	PUNCT
iajs-3493	5	8	19	19	NUM
iajs-3493	5	9	june	june	PROPN
iajs-3493	5	10	2023	2023	NUM
iajs-3493	5	11	published	publish	VERB
iajs-3493	5	12	:	:	PUNCT
iajs-3493	5	13	20	20	NUM
iajs-3493	5	14	october	october	NOUN
iajs-3493	5	15	2024	2024	NUM
iajs-3493	5	16	doi.org/10.30526/37.4.3493	doi.org/10.30526/37.4.3493	VERB
iajs-3493	5	17	abstract	abstract	ADJ
iajs-3493	5	18	rheumatoid	rheumatoid	NOUN
iajs-3493	5	19	arthritis	arthritis	NOUN
iajs-3493	5	20	(	(	PUNCT
iajs-3493	5	21	ra	ra	NOUN
iajs-3493	5	22	)	)	PUNCT
iajs-3493	5	23	occurs	occur	VERB
iajs-3493	5	24	through	through	ADP
iajs-3493	5	25	joint	joint	ADJ
iajs-3493	5	26	inflammation	inflammation	NOUN
iajs-3493	5	27	and	and	CCONJ
iajs-3493	5	28	affects	affect	VERB
iajs-3493	5	29	approximately	approximately	ADV
iajs-3493	5	30	one	one	NUM
iajs-3493	5	31	in	in	ADP
iajs-3493	5	32	200	200	NUM
iajs-3493	5	33	adults	adult	NOUN
iajs-3493	5	34	worldwide	worldwide	ADV
iajs-3493	5	35	,	,	PUNCT
iajs-3493	5	36	with	with	ADP
iajs-3493	5	37	women	woman	NOUN
iajs-3493	5	38	affected	affect	VERB
iajs-3493	5	39	two	two	NUM
iajs-3493	5	40	to	to	PART
iajs-3493	5	41	three	three	NUM
iajs-3493	5	42	times	time	NOUN
iajs-3493	5	43	more	more	ADV
iajs-3493	5	44	frequently	frequently	ADV
iajs-3493	5	45	than	than	ADP
iajs-3493	5	46	men	man	NOUN
iajs-3493	5	47	.	.	PUNCT
iajs-3493	6	1	the	the	DET
iajs-3493	6	2	design	design	NOUN
iajs-3493	6	3	of	of	ADP
iajs-3493	6	4	this	this	DET
iajs-3493	6	5	study	study	NOUN
iajs-3493	6	6	is	be	AUX
iajs-3493	6	7	to	to	PART
iajs-3493	6	8	examine	examine	VERB
iajs-3493	6	9	serum	serum	NOUN
iajs-3493	6	10	levels	level	NOUN
iajs-3493	6	11	and	and	CCONJ
iajs-3493	6	12	changes	change	NOUN
iajs-3493	6	13	in	in	ADP
iajs-3493	6	14	immunological	immunological	ADJ
iajs-3493	6	15	markers	marker	NOUN
iajs-3493	6	16	in	in	ADP
iajs-3493	6	17	iraqi	iraqi	ADJ
iajs-3493	6	18	patients	patient	NOUN
iajs-3493	6	19	with	with	ADP
iajs-3493	6	20	ra	ra	PROPN
iajs-3493	6	21	.	.	PUNCT
iajs-3493	6	22	to	to	PART
iajs-3493	6	23	evaluate	evaluate	VERB
iajs-3493	6	24	the	the	DET
iajs-3493	6	25	advantages	advantage	NOUN
iajs-3493	6	26	of	of	ADP
iajs-3493	6	27	clinical	clinical	ADJ
iajs-3493	6	28	biomarkers	biomarker	NOUN
iajs-3493	6	29	of	of	ADP
iajs-3493	6	30	autoimmune	autoimmune	ADJ
iajs-3493	6	31	disorderliness	disorderliness	NOUN
iajs-3493	6	32	as	as	ADV
iajs-3493	6	33	well	well	ADV
iajs-3493	6	34	as	as	ADP
iajs-3493	6	35	changes	change	NOUN
iajs-3493	6	36	in	in	ADP
iajs-3493	6	37	some	some	DET
iajs-3493	6	38	immunological	immunological	ADJ
iajs-3493	6	39	markers	marker	NOUN
iajs-3493	6	40	and	and	CCONJ
iajs-3493	6	41	clinical	clinical	ADJ
iajs-3493	6	42	outcomes	outcome	NOUN
iajs-3493	6	43	associated	associate	VERB
iajs-3493	6	44	with	with	ADP
iajs-3493	6	45	iraqi	iraqi	ADJ
iajs-3493	6	46	rheumatoid	rheumatoid	NOUN
iajs-3493	6	47	arthritis	arthritis	NOUN
iajs-3493	6	48	patients	patient	NOUN
iajs-3493	6	49	.	.	PUNCT
iajs-3493	7	1	interleukins-3	interleukins-3	NUM
iajs-3493	7	2	and	and	CCONJ
iajs-3493	7	3	5	5	NUM
iajs-3493	7	4	(	(	PUNCT
iajs-3493	7	5	il-3	il-3	NOUN
iajs-3493	7	6	and	and	CCONJ
iajs-3493	7	7	il-5	il-5	PRON
iajs-3493	7	8	)	)	PUNCT
iajs-3493	7	9	were	be	AUX
iajs-3493	7	10	quantified	quantify	VERB
iajs-3493	7	11	by	by	ADP
iajs-3493	7	12	elisa	elisa	PROPN
iajs-3493	7	13	assay	assay	PROPN
iajs-3493	7	14	kits	kit	NOUN
iajs-3493	7	15	in	in	ADP
iajs-3493	7	16	the	the	DET
iajs-3493	7	17	serum	serum	NOUN
iajs-3493	7	18	of	of	ADP
iajs-3493	7	19	60	60	NUM
iajs-3493	7	20	patients	patient	NOUN
iajs-3493	7	21	with	with	ADP
iajs-3493	7	22	ra	ra	PROPN
iajs-3493	7	23	disease	disease	NOUN
iajs-3493	7	24	(	(	PUNCT
iajs-3493	7	25	age	age	NOUN
iajs-3493	7	26	range	range	NOUN
iajs-3493	7	27	20–60	20–60	NUM
iajs-3493	7	28	years	year	NOUN
iajs-3493	7	29	)	)	PUNCT
iajs-3493	7	30	and	and	CCONJ
iajs-3493	7	31	30	30	NUM
iajs-3493	7	32	age	age	NOUN
iajs-3493	7	33	-	-	PUNCT
iajs-3493	7	34	matched	match	VERB
iajs-3493	7	35	healthy	healthy	ADJ
iajs-3493	7	36	control	control	NOUN
iajs-3493	7	37	groups	group	NOUN
iajs-3493	7	38	.	.	PUNCT
iajs-3493	8	1	the	the	DET
iajs-3493	8	2	bmi	bmi	NOUN
iajs-3493	8	3	(	(	PUNCT
iajs-3493	8	4	body	body	NOUN
iajs-3493	8	5	mass	mass	PROPN
iajs-3493	8	6	index	index	PROPN
iajs-3493	8	7	)	)	PUNCT
iajs-3493	8	8	,	,	PUNCT
iajs-3493	8	9	c	c	NOUN
iajs-3493	8	10	-	-	PUNCT
iajs-3493	8	11	reactive	reactive	ADJ
iajs-3493	8	12	protein	protein	NOUN
iajs-3493	8	13	(	(	PUNCT
iajs-3493	8	14	crp	crp	PROPN
iajs-3493	8	15	)	)	PUNCT
iajs-3493	8	16	,	,	PUNCT
iajs-3493	8	17	erythrocyte	erythrocyte	NOUN
iajs-3493	8	18	sedimentation	sedimentation	NOUN
iajs-3493	8	19	rate	rate	NOUN
iajs-3493	8	20	(	(	PUNCT
iajs-3493	8	21	esr	esr	PROPN
iajs-3493	8	22	)	)	PUNCT
iajs-3493	8	23	,	,	PUNCT
iajs-3493	8	24	anti	anti	ADJ
iajs-3493	8	25	-	-	ADJ
iajs-3493	8	26	cyclic	cyclic	ADJ
iajs-3493	8	27	citrullinated	citrullinate	VERB
iajs-3493	8	28	peptide	peptide	NOUN
iajs-3493	8	29	(	(	PUNCT
iajs-3493	8	30	anti	anti	ADJ
iajs-3493	8	31	-	-	ADJ
iajs-3493	8	32	ccp	ccp	X
iajs-3493	8	33	)	)	PUNCT
iajs-3493	8	34	,	,	PUNCT
iajs-3493	8	35	and	and	CCONJ
iajs-3493	8	36	complete	complete	ADJ
iajs-3493	8	37	blood	blood	NOUN
iajs-3493	8	38	count	count	NOUN
iajs-3493	8	39	(	(	PUNCT
iajs-3493	8	40	cbc	cbc	PROPN
iajs-3493	8	41	)	)	PUNCT
iajs-3493	8	42	were	be	AUX
iajs-3493	8	43	also	also	ADV
iajs-3493	8	44	measured	measure	VERB
iajs-3493	8	45	.	.	PUNCT
iajs-3493	9	1	the	the	DET
iajs-3493	9	2	results	result	NOUN
iajs-3493	9	3	of	of	ADP
iajs-3493	9	4	il-3	il-3	NOUN
iajs-3493	9	5	and	and	CCONJ
iajs-3493	9	6	il-5	il-5	PRON
iajs-3493	9	7	(	(	PUNCT
iajs-3493	9	8	341.56	341.56	NUM
iajs-3493	9	9	±12.10	±12.10	ADJ
iajs-3493	9	10	and	and	CCONJ
iajs-3493	9	11	504.28	504.28	NUM
iajs-3493	9	12	±25.20	±25.20	NOUN
iajs-3493	9	13	)	)	PUNCT
iajs-3493	9	14	levels	level	NOUN
iajs-3493	9	15	displayed	display	VERB
iajs-3493	9	16	a	a	DET
iajs-3493	9	17	significant	significant	ADJ
iajs-3493	9	18	increase	increase	NOUN
iajs-3493	9	19	in	in	ADP
iajs-3493	9	20	ra	ra	PROPN
iajs-3493	9	21	patients	patient	NOUN
iajs-3493	9	22	compared	compare	VERB
iajs-3493	9	23	to	to	ADP
iajs-3493	9	24	control	control	NOUN
iajs-3493	9	25	(	(	PUNCT
iajs-3493	9	26	154.66	154.66	NUM
iajs-3493	9	27	±9.24	±9.24	NOUN
iajs-3493	9	28	and	and	CCONJ
iajs-3493	9	29	117.61	117.61	NUM
iajs-3493	9	30	±3.73	±3.73	NOUN
iajs-3493	9	31	)	)	PUNCT
iajs-3493	9	32	.	.	PUNCT
iajs-3493	10	1	the	the	DET
iajs-3493	10	2	levels	level	NOUN
iajs-3493	10	3	of	of	ADP
iajs-3493	10	4	esr	esr	PROPN
iajs-3493	10	5	and	and	CCONJ
iajs-3493	10	6	ant	ant	PROPN
iajs-3493	10	7	-	-	PUNCT
iajs-3493	10	8	ccp	ccp	PROPN
iajs-3493	10	9	(	(	PUNCT
iajs-3493	10	10	37.60	37.60	NUM
iajs-3493	10	11	±2.72	±2.72	NOUN
iajs-3493	10	12	and	and	CCONJ
iajs-3493	10	13	0.637	0.637	NUM
iajs-3493	10	14	±0.02	±0.02	NOUN
iajs-3493	10	15	)	)	PUNCT
iajs-3493	10	16	increased	increase	VERB
iajs-3493	10	17	significantly	significantly	ADV
iajs-3493	10	18	in	in	ADP
iajs-3493	10	19	ra	ra	PROPN
iajs-3493	10	20	patients	patient	NOUN
iajs-3493	10	21	as	as	SCONJ
iajs-3493	10	22	compared	compare	VERB
iajs-3493	10	23	to	to	ADP
iajs-3493	10	24	control	control	NOUN
iajs-3493	10	25	(	(	PUNCT
iajs-3493	10	26	8.12	8.12	NUM
iajs-3493	10	27	±1.14	±1.14	NOUN
iajs-3493	10	28	and	and	CCONJ
iajs-3493	10	29	0.308	0.308	NUM
iajs-3493	10	30	±0.01	±0.01	NOUN
iajs-3493	10	31	)	)	PUNCT
iajs-3493	10	32	.	.	PUNCT
iajs-3493	11	1	similar	similar	ADJ
iajs-3493	11	2	results	result	NOUN
iajs-3493	11	3	were	be	AUX
iajs-3493	11	4	observed	observe	VERB
iajs-3493	11	5	(	(	PUNCT
iajs-3493	11	6	11.98	11.98	NUM
iajs-3493	11	7	±1.18	±1.18	PROPN
iajs-3493	11	8	)	)	PUNCT
iajs-3493	11	9	with	with	ADP
iajs-3493	11	10	crp	crp	PROPN
iajs-3493	11	11	levels	level	NOUN
iajs-3493	11	12	in	in	ADP
iajs-3493	11	13	ra	ra	PROPN
iajs-3493	11	14	patients	patient	NOUN
iajs-3493	11	15	.	.	PUNCT
iajs-3493	12	1	the	the	DET
iajs-3493	12	2	results	result	NOUN
iajs-3493	12	3	of	of	ADP
iajs-3493	12	4	cbc	cbc	NOUN
iajs-3493	12	5	indicated	indicate	VERB
iajs-3493	12	6	a	a	DET
iajs-3493	12	7	significant	significant	ADJ
iajs-3493	12	8	reduction	reduction	NOUN
iajs-3493	12	9	in	in	ADP
iajs-3493	12	10	hemoglobin	hemoglobin	NOUN
iajs-3493	12	11	(	(	PUNCT
iajs-3493	12	12	hb	hb	PROPN
iajs-3493	12	13	)	)	PUNCT
iajs-3493	12	14	levels	level	NOUN
iajs-3493	12	15	(	(	PUNCT
iajs-3493	12	16	12.42	12.42	NUM
iajs-3493	12	17	±0.34	±0.34	NOUN
iajs-3493	12	18	)	)	PUNCT
iajs-3493	12	19	in	in	ADP
iajs-3493	12	20	ra	ra	PROPN
iajs-3493	12	21	patients	patient	NOUN
iajs-3493	12	22	,	,	PUNCT
iajs-3493	12	23	and	and	CCONJ
iajs-3493	12	24	there	there	PRON
iajs-3493	12	25	were	be	VERB
iajs-3493	12	26	no	no	DET
iajs-3493	12	27	differences	difference	NOUN
iajs-3493	12	28	between	between	ADP
iajs-3493	12	29	other	other	ADJ
iajs-3493	12	30	cbc	cbc	NOUN
iajs-3493	12	31	parameters	parameter	NOUN
iajs-3493	12	32	compared	compare	VERB
iajs-3493	12	33	to	to	ADP
iajs-3493	12	34	healthy	healthy	ADJ
iajs-3493	12	35	controls	control	NOUN
iajs-3493	12	36	.	.	PUNCT
iajs-3493	13	1	these	these	DET
iajs-3493	13	2	findings	finding	NOUN
iajs-3493	13	3	suggest	suggest	VERB
iajs-3493	13	4	that	that	SCONJ
iajs-3493	13	5	it	it	PRON
iajs-3493	13	6	is	be	AUX
iajs-3493	13	7	possible	possible	ADJ
iajs-3493	13	8	to	to	PART
iajs-3493	13	9	use	use	VERB
iajs-3493	13	10	il-3	il-3	PRON
iajs-3493	13	11	and	and	CCONJ
iajs-3493	13	12	il-5	il-5	NOUN
iajs-3493	13	13	as	as	ADP
iajs-3493	13	14	biomarkers	biomarker	NOUN
iajs-3493	13	15	for	for	ADP
iajs-3493	13	16	ra	ra	NOUN
iajs-3493	13	17	diagnosis	diagnosis	NOUN
iajs-3493	13	18	.	.	PUNCT
iajs-3493	14	1	keywords	keyword	NOUN
iajs-3493	14	2	:	:	PUNCT
iajs-3493	14	3	rheumatoid	rheumatoid	VERB
iajs-3493	14	4	arthritis	arthritis	NOUN
iajs-3493	14	5	,	,	PUNCT
iajs-3493	14	6	interleukins-3	interleukins-3	ADV
iajs-3493	14	7	,	,	PUNCT
iajs-3493	14	8	interleukins-5	interleukins-5	NUM
iajs-3493	14	9	,	,	PUNCT
iajs-3493	14	10	c	c	NOUN
iajs-3493	14	11	-	-	PUNCT
iajs-3493	14	12	reactive	reactive	ADJ
iajs-3493	14	13	protein	protein	NOUN
iajs-3493	14	14	.	.	PUNCT
iajs-3493	15	1	1	1	X
iajs-3493	15	2	.	.	X
iajs-3493	15	3	introduction	introduction	NOUN
iajs-3493	15	4	rheumatoid	rheumatoid	NOUN
iajs-3493	15	5	arthritis	arthritis	NOUN
iajs-3493	15	6	(	(	PUNCT
iajs-3493	15	7	ra	ra	NOUN
iajs-3493	15	8	)	)	PUNCT
iajs-3493	15	9	is	be	AUX
iajs-3493	15	10	an	an	DET
iajs-3493	15	11	inflammatory	inflammatory	ADJ
iajs-3493	15	12	disease	disease	NOUN
iajs-3493	15	13	marked	mark	VERB
iajs-3493	15	14	by	by	ADP
iajs-3493	15	15	dysregulation	dysregulation	NOUN
iajs-3493	15	16	of	of	ADP
iajs-3493	15	17	the	the	DET
iajs-3493	15	18	immune	immune	ADJ
iajs-3493	15	19	system	system	NOUN
iajs-3493	15	20	brought	bring	VERB
iajs-3493	15	21	on	on	ADP
iajs-3493	15	22	by	by	ADP
iajs-3493	15	23	a	a	DET
iajs-3493	15	24	complex	complex	ADJ
iajs-3493	15	25	interaction	interaction	NOUN
iajs-3493	15	26	between	between	ADP
iajs-3493	15	27	environmental	environmental	ADJ
iajs-3493	15	28	and	and	CCONJ
iajs-3493	15	29	genetic	genetic	ADJ
iajs-3493	15	30	factors	factor	NOUN
iajs-3493	15	31	[	[	X
iajs-3493	15	32	1	1	NUM
iajs-3493	15	33	]	]	PUNCT
iajs-3493	15	34	.	.	PUNCT
iajs-3493	16	1	aberrant	aberrant	ADJ
iajs-3493	16	2	adaptive	adaptive	ADJ
iajs-3493	16	3	immunity	immunity	NOUN
iajs-3493	16	4	is	be	AUX
iajs-3493	16	5	currently	currently	ADV
iajs-3493	16	6	thought	think	VERB
iajs-3493	16	7	to	to	PART
iajs-3493	16	8	be	be	AUX
iajs-3493	16	9	the	the	DET
iajs-3493	16	10	driving	drive	VERB
iajs-3493	16	11	force	force	NOUN
iajs-3493	16	12	behind	behind	ADP
iajs-3493	16	13	the	the	DET
iajs-3493	16	14	progression	progression	NOUN
iajs-3493	16	15	of	of	ADP
iajs-3493	16	16	rheumatoid	rheumatoid	NOUN
iajs-3493	16	17	arthritis	arthritis	NOUN
iajs-3493	16	18	(	(	PUNCT
iajs-3493	16	19	ra	ra	NOUN
iajs-3493	16	20	)	)	PUNCT
iajs-3493	16	21	from	from	ADP
iajs-3493	16	22	preclinical	preclinical	ADJ
iajs-3493	16	23	illness	illness	NOUN
iajs-3493	16	24	to	to	ADP
iajs-3493	16	25	obvious	obvious	ADJ
iajs-3493	16	26	synovitis	synovitis	NOUN
iajs-3493	16	27	.	.	PUNCT
iajs-3493	17	1	in	in	ADP
iajs-3493	17	2	severe	severe	ADJ
iajs-3493	17	3	cases	case	NOUN
iajs-3493	17	4	,	,	PUNCT
iajs-3493	17	5	joint	joint	ADJ
iajs-3493	17	6	inflammation	inflammation	NOUN
iajs-3493	17	7	can	can	AUX
iajs-3493	17	8	cause	cause	VERB
iajs-3493	17	9	permanent	permanent	ADJ
iajs-3493	17	10	joint	joint	ADJ
iajs-3493	17	11	damage	damage	NOUN
iajs-3493	17	12	and	and	CCONJ
iajs-3493	17	13	disability	disability	NOUN
iajs-3493	17	14	.	.	PUNCT
iajs-3493	18	1	the	the	DET
iajs-3493	18	2	lungs	lung	NOUN
iajs-3493	18	3	,	,	PUNCT
iajs-3493	18	4	heart	heart	NOUN
iajs-3493	18	5	,	,	PUNCT
iajs-3493	18	6	blood	blood	NOUN
iajs-3493	18	7	vessels	vessel	NOUN
iajs-3493	18	8	,	,	PUNCT
iajs-3493	18	9	skin	skin	NOUN
iajs-3493	18	10	,	,	PUNCT
iajs-3493	18	11	and	and	CCONJ
iajs-3493	18	12	eyes	eye	NOUN
iajs-3493	18	13	are	be	AUX
iajs-3493	18	14	just	just	ADV
iajs-3493	18	15	a	a	DET
iajs-3493	18	16	few	few	ADJ
iajs-3493	18	17	of	of	ADP
iajs-3493	18	18	the	the	DET
iajs-3493	18	19	organs	organ	NOUN
iajs-3493	18	20	that	that	PRON
iajs-3493	18	21	could	could	AUX
iajs-3493	18	22	be	be	AUX
iajs-3493	18	23	affected	affect	VERB
iajs-3493	18	24	.	.	PUNCT
iajs-3493	19	1	rheumatoid	rheumatoid	VERB
iajs-3493	19	2	arthritis	arthritis	NOUN
iajs-3493	19	3	affects	affect	VERB
iajs-3493	19	4	approximately	approximately	ADV
iajs-3493	19	5	one	one	NUM
iajs-3493	19	6	in	in	ADP
iajs-3493	19	7	200	200	NUM
iajs-3493	19	8	adults	adult	NOUN
iajs-3493	19	9	worldwide	worldwide	ADV
iajs-3493	19	10	,	,	PUNCT
iajs-3493	19	11	and	and	CCONJ
iajs-3493	19	12	women	woman	NOUN
iajs-3493	19	13	are	be	AUX
iajs-3493	19	14	affected	affect	VERB
iajs-3493	19	15	two	two	NUM
iajs-3493	19	16	to	to	PART
iajs-3493	19	17	three	three	NUM
iajs-3493	19	18	times	time	NOUN
iajs-3493	19	19	more	more	ADV
iajs-3493	19	20	frequently	frequently	ADV
iajs-3493	19	21	than	than	ADP
iajs-3493	19	22	men	man	NOUN
iajs-3493	19	23	[	[	X
iajs-3493	19	24	2	2	NUM
iajs-3493	19	25	,	,	PUNCT
iajs-3493	19	26	3	3	NUM
iajs-3493	19	27	]	]	PUNCT
iajs-3493	19	28	.	.	PUNCT
iajs-3493	20	1	during	during	ADP
iajs-3493	20	2	the	the	DET
iajs-3493	20	3	pathogenesis	pathogenesis	NOUN
iajs-3493	20	4	of	of	ADP
iajs-3493	20	5	ra	ra	PROPN
iajs-3493	20	6	,	,	PUNCT
iajs-3493	20	7	a	a	DET
iajs-3493	20	8	number	number	NOUN
iajs-3493	20	9	of	of	ADP
iajs-3493	20	10	immune	immune	ADJ
iajs-3493	20	11	cells	cell	NOUN
iajs-3493	20	12	migrate	migrate	VERB
iajs-3493	20	13	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
iajs-3493	20	14	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
iajs-3493	20	15	https://orcid.org/my-orcid?orcid=0009-0001-0686-4825	https://orcid.org/my-orcid?orcid=0009-0001-0686-4825	PROPN
iajs-3493	20	16	mailto:shams.ahmed2102@sc.uobaghdad.edu.iq	mailto:shams.ahmed2102@sc.uobaghdad.edu.iq	VERB
iajs-3493	20	17	https://orcid.org/0000-0001-9455-6410	https://orcid.org/0000-0001-9455-6410	PROPN
iajs-3493	20	18	mailto:rakad.aljumaily@sc.uobaghdad.edu.iq	mailto:rakad.aljumaily@sc.uobaghdad.edu.iq	PROPN
iajs-3493	20	19	ihjpas	ihjpas	PROPN
iajs-3493	20	20	.	.	PUNCT
iajs-3493	21	1	2024	2024	NUM
iajs-3493	21	2	,	,	PUNCT
iajs-3493	21	3	37(4	37(4	NOUN
iajs-3493	21	4	)	)	PUNCT
iajs-3493	21	5	46	46	NUM
iajs-3493	21	6	into	into	ADP
iajs-3493	21	7	the	the	DET
iajs-3493	21	8	joint	joint	ADJ
iajs-3493	21	9	tissues	tissue	NOUN
iajs-3493	21	10	activating	activate	VERB
iajs-3493	21	11	resident	resident	ADJ
iajs-3493	21	12	cells	cell	NOUN
iajs-3493	21	13	like	like	ADP
iajs-3493	21	14	synovial	synovial	ADJ
iajs-3493	21	15	fibroblasts	fibroblast	NOUN
iajs-3493	21	16	,	,	PUNCT
iajs-3493	21	17	chondrocytes	chondrocyte	NOUN
iajs-3493	21	18	,	,	PUNCT
iajs-3493	21	19	osteoblasts	osteoblast	NOUN
iajs-3493	21	20	,	,	PUNCT
iajs-3493	21	21	and	and	CCONJ
iajs-3493	21	22	osteoclasts	osteoclast	NOUN
iajs-3493	21	23	.	.	PUNCT
iajs-3493	22	1	these	these	DET
iajs-3493	22	2	immune	immune	ADJ
iajs-3493	22	3	cells	cell	NOUN
iajs-3493	22	4	include	include	VERB
iajs-3493	22	5	macrophages	macrophage	NOUN
iajs-3493	22	6	,	,	PUNCT
iajs-3493	22	7	dendritic	dendritic	ADJ
iajs-3493	22	8	cells	cell	NOUN
iajs-3493	22	9	,	,	PUNCT
iajs-3493	22	10	lymphocytes	lymphocyte	NOUN
iajs-3493	22	11	,	,	PUNCT
iajs-3493	22	12	and	and	CCONJ
iajs-3493	22	13	neutrophils	neutrophil	NOUN
iajs-3493	22	14	.	.	PUNCT
iajs-3493	23	1	there	there	PRON
iajs-3493	23	2	are	be	VERB
iajs-3493	23	3	three	three	NUM
iajs-3493	23	4	overlapping	overlap	VERB
iajs-3493	23	5	mechanisms	mechanism	NOUN
iajs-3493	23	6	in	in	ADP
iajs-3493	23	7	this	this	DET
iajs-3493	23	8	procedure	procedure	NOUN
iajs-3493	23	9	:	:	PUNCT
iajs-3493	23	10	inflammation	inflammation	NOUN
iajs-3493	23	11	,	,	PUNCT
iajs-3493	23	12	synovial	synovial	ADJ
iajs-3493	23	13	hyperplasia	hyperplasia	NOUN
iajs-3493	23	14	,	,	PUNCT
iajs-3493	23	15	and	and	CCONJ
iajs-3493	23	16	an	an	DET
iajs-3493	23	17	altered	altered	ADJ
iajs-3493	23	18	immune	immune	ADJ
iajs-3493	23	19	response	response	NOUN
iajs-3493	23	20	[	[	X
iajs-3493	23	21	4	4	NUM
iajs-3493	23	22	]	]	PUNCT
iajs-3493	23	23	.	.	PUNCT
iajs-3493	24	1	according	accord	VERB
iajs-3493	24	2	to	to	ADP
iajs-3493	24	3	[	[	X
iajs-3493	24	4	5	5	NUM
iajs-3493	24	5	]	]	PUNCT
iajs-3493	24	6	,	,	PUNCT
iajs-3493	24	7	rheumatoid	rheumatoid	VERB
iajs-3493	24	8	arthritis	arthritis	NOUN
iajs-3493	24	9	patients	patient	NOUN
iajs-3493	24	10	commonly	commonly	ADV
iajs-3493	24	11	present	present	ADJ
iajs-3493	24	12	with	with	ADP
iajs-3493	24	13	joint	joint	ADJ
iajs-3493	24	14	agony	agony	NOUN
iajs-3493	24	15	and	and	CCONJ
iajs-3493	24	16	stiffness	stiffness	NOUN
iajs-3493	24	17	across	across	ADP
iajs-3493	24	18	various	various	ADJ
iajs-3493	24	19	joints	joint	NOUN
iajs-3493	24	20	.	.	PUNCT
iajs-3493	25	1	however	however	ADV
iajs-3493	25	2	,	,	PUNCT
iajs-3493	25	3	the	the	DET
iajs-3493	25	4	most	most	ADV
iajs-3493	25	5	frequently	frequently	ADV
iajs-3493	25	6	impacted	impact	VERB
iajs-3493	25	7	joints	joint	NOUN
iajs-3493	25	8	are	be	AUX
iajs-3493	25	9	the	the	DET
iajs-3493	25	10	metacarpophalangeal	metacarpophalangeal	NOUN
iajs-3493	25	11	,	,	PUNCT
iajs-3493	25	12	proximal	proximal	ADJ
iajs-3493	25	13	interphalangeal	interphalangeal	NOUN
iajs-3493	25	14	,	,	PUNCT
iajs-3493	25	15	and	and	CCONJ
iajs-3493	25	16	wrist	wrist	NOUN
iajs-3493	26	1	[	[	X
iajs-3493	26	2	6	6	NUM
iajs-3493	26	3	,	,	PUNCT
iajs-3493	26	4	7	7	NUM
iajs-3493	26	5	]	]	PUNCT
iajs-3493	26	6	.	.	PUNCT
iajs-3493	27	1	the	the	DET
iajs-3493	27	2	name	name	NOUN
iajs-3493	27	3	interleukin-3	interleukin-3	NUM
iajs-3493	27	4	was	be	AUX
iajs-3493	27	5	primarily	primarily	ADV
iajs-3493	27	6	used	use	VERB
iajs-3493	27	7	to	to	PART
iajs-3493	27	8	describe	describe	VERB
iajs-3493	27	9	a	a	DET
iajs-3493	27	10	t	t	NOUN
iajs-3493	27	11	-	-	PUNCT
iajs-3493	27	12	cell	cell	NOUN
iajs-3493	27	13	-	-	PUNCT
iajs-3493	27	14	derived	derive	VERB
iajs-3493	27	15	lymphokine	lymphokine	NOUN
iajs-3493	27	16	that	that	PRON
iajs-3493	27	17	induces	induce	VERB
iajs-3493	27	18	the	the	DET
iajs-3493	27	19	expression	expression	NOUN
iajs-3493	27	20	of	of	ADP
iajs-3493	27	21	20	20	NUM
iajs-3493	27	22	-	-	PUNCT
iajs-3493	27	23	alpha	alpha	NOUN
iajs-3493	27	24	hydroxysteroid	hydroxysteroid	PROPN
iajs-3493	27	25	dehydrogenase	dehydrogenase	NOUN
iajs-3493	27	26	(	(	PUNCT
iajs-3493	27	27	sdh	sdh	PROPN
iajs-3493	27	28	)	)	PUNCT
iajs-3493	27	29	in	in	ADP
iajs-3493	27	30	cultures	culture	NOUN
iajs-3493	27	31	of	of	ADP
iajs-3493	27	32	nude	nude	ADJ
iajs-3493	27	33	mouse	mouse	NOUN
iajs-3493	27	34	splenic	splenic	ADJ
iajs-3493	27	35	lymphocytes	lymphocyte	NOUN
iajs-3493	27	36	.	.	PUNCT
iajs-3493	28	1	recent	recent	ADJ
iajs-3493	28	2	research	research	NOUN
iajs-3493	28	3	shows	show	VERB
iajs-3493	28	4	that	that	SCONJ
iajs-3493	28	5	il-3	il-3	PRON
iajs-3493	28	6	has	have	VERB
iajs-3493	28	7	different	different	ADJ
iajs-3493	28	8	biological	biological	ADJ
iajs-3493	28	9	properties	property	NOUN
iajs-3493	28	10	and	and	CCONJ
iajs-3493	28	11	mechanisms	mechanism	NOUN
iajs-3493	28	12	by	by	ADP
iajs-3493	28	13	which	which	PRON
iajs-3493	28	14	it	it	PRON
iajs-3493	28	15	promotes	promote	VERB
iajs-3493	28	16	differentiation	differentiation	NOUN
iajs-3493	28	17	and	and	CCONJ
iajs-3493	28	18	hematopoietic	hematopoietic	ADJ
iajs-3493	28	19	cell	cell	NOUN
iajs-3493	28	20	growth	growth	NOUN
iajs-3493	28	21	[	[	X
iajs-3493	28	22	8	8	NUM
iajs-3493	28	23	,	,	PUNCT
iajs-3493	28	24	9	9	NUM
iajs-3493	28	25	]	]	PUNCT
iajs-3493	28	26	.	.	PUNCT
iajs-3493	29	1	these	these	DET
iajs-3493	29	2	operations	operation	NOUN
iajs-3493	29	3	are	be	AUX
iajs-3493	29	4	controlled	control	VERB
iajs-3493	29	5	by	by	ADP
iajs-3493	29	6	a	a	DET
iajs-3493	29	7	number	number	NOUN
iajs-3493	29	8	of	of	ADP
iajs-3493	29	9	cytokines	cytokine	NOUN
iajs-3493	29	10	produced	produce	VERB
iajs-3493	29	11	by	by	ADP
iajs-3493	29	12	some	some	DET
iajs-3493	29	13	cells	cell	NOUN
iajs-3493	29	14	,	,	PUNCT
iajs-3493	29	15	including	include	VERB
iajs-3493	29	16	activated	activate	VERB
iajs-3493	29	17	t	t	NOUN
iajs-3493	29	18	cells	cell	NOUN
iajs-3493	29	19	,	,	PUNCT
iajs-3493	29	20	macrophages	macrophage	NOUN
iajs-3493	29	21	,	,	PUNCT
iajs-3493	29	22	and	and	CCONJ
iajs-3493	29	23	stromal	stromal	ADJ
iajs-3493	29	24	cells	cell	NOUN
iajs-3493	29	25	.	.	PUNCT
iajs-3493	30	1	interleukin	interleukin	NOUN
iajs-3493	30	2	3	3	NUM
iajs-3493	30	3	and	and	CCONJ
iajs-3493	30	4	granulocyte	granulocyte	ADJ
iajs-3493	30	5	-	-	PUNCT
iajs-3493	30	6	macrophage	macrophage	ADJ
iajs-3493	30	7	colonystimulating	colonystimulate	VERB
iajs-3493	30	8	factor	factor	NOUN
iajs-3493	30	9	(	(	PUNCT
iajs-3493	30	10	gm	gm	PROPN
iajs-3493	30	11	-	-	PUNCT
iajs-3493	30	12	csf	csf	NOUN
iajs-3493	30	13	)	)	PUNCT
iajs-3493	30	14	are	be	AUX
iajs-3493	30	15	two	two	NUM
iajs-3493	30	16	of	of	ADP
iajs-3493	30	17	these	these	DET
iajs-3493	30	18	cytokines	cytokine	NOUN
iajs-3493	30	19	that	that	PRON
iajs-3493	30	20	stimulate	stimulate	VERB
iajs-3493	30	21	multiple	multiple	ADJ
iajs-3493	30	22	hematopoietic	hematopoietic	ADJ
iajs-3493	30	23	cell	cell	NOUN
iajs-3493	30	24	lineages	lineage	NOUN
iajs-3493	30	25	,	,	PUNCT
iajs-3493	30	26	and	and	CCONJ
iajs-3493	30	27	depending	depend	VERB
iajs-3493	30	28	on	on	ADP
iajs-3493	30	29	the	the	DET
iajs-3493	30	30	target	target	NOUN
iajs-3493	30	31	cells	cell	NOUN
iajs-3493	30	32	,	,	PUNCT
iajs-3493	30	33	il-3	il-3	PRON
iajs-3493	30	34	performs	perform	VERB
iajs-3493	30	35	a	a	DET
iajs-3493	30	36	variety	variety	NOUN
iajs-3493	30	37	of	of	ADP
iajs-3493	30	38	biological	biological	ADJ
iajs-3493	30	39	functions	function	NOUN
iajs-3493	30	40	because	because	SCONJ
iajs-3493	30	41	they	they	PRON
iajs-3493	30	42	target	target	VERB
iajs-3493	30	43	a	a	DET
iajs-3493	30	44	broad	broad	ADJ
iajs-3493	30	45	range	range	NOUN
iajs-3493	30	46	of	of	ADP
iajs-3493	30	47	cells	cell	NOUN
iajs-3493	30	48	.	.	PUNCT
iajs-3493	31	1	on	on	ADP
iajs-3493	31	2	the	the	DET
iajs-3493	31	3	other	other	ADJ
iajs-3493	31	4	hand	hand	NOUN
iajs-3493	31	5	,	,	PUNCT
iajs-3493	31	6	il-5	il-5	PRON
iajs-3493	31	7	mostly	mostly	ADV
iajs-3493	31	8	encourages	encourage	VERB
iajs-3493	31	9	eosinophil	eosinophil	ADJ
iajs-3493	31	10	colony	colony	NOUN
iajs-3493	31	11	formation	formation	NOUN
iajs-3493	31	12	and	and	CCONJ
iajs-3493	31	13	some	some	DET
iajs-3493	31	14	murine	murine	ADJ
iajs-3493	31	15	b	b	NOUN
iajs-3493	31	16	cell	cell	NOUN
iajs-3493	31	17	proliferation	proliferation	NOUN
iajs-3493	31	18	and	and	CCONJ
iajs-3493	31	19	differentiation	differentiation	NOUN
iajs-3493	31	20	[	[	X
iajs-3493	31	21	10	10	NUM
iajs-3493	31	22	,	,	PUNCT
iajs-3493	31	23	11	11	NUM
iajs-3493	31	24	]	]	PUNCT
iajs-3493	31	25	.	.	PUNCT
iajs-3493	32	1	however	however	ADV
iajs-3493	32	2	,	,	PUNCT
iajs-3493	32	3	the	the	DET
iajs-3493	32	4	information	information	NOUN
iajs-3493	32	5	about	about	ADP
iajs-3493	32	6	the	the	DET
iajs-3493	32	7	role	role	NOUN
iajs-3493	32	8	of	of	ADP
iajs-3493	32	9	il-3	il-3	NOUN
iajs-3493	32	10	and	and	CCONJ
iajs-3493	32	11	il-5	il-5	PRON
iajs-3493	32	12	in	in	ADP
iajs-3493	32	13	the	the	DET
iajs-3493	32	14	pathogenesis	pathogenesis	NOUN
iajs-3493	32	15	of	of	ADP
iajs-3493	32	16	ra	ra	PROPN
iajs-3493	32	17	is	be	AUX
iajs-3493	32	18	still	still	ADV
iajs-3493	32	19	very	very	ADV
iajs-3493	32	20	poor	poor	ADJ
iajs-3493	32	21	,	,	PUNCT
iajs-3493	32	22	but	but	CCONJ
iajs-3493	32	23	it	it	PRON
iajs-3493	32	24	suggests	suggest	VERB
iajs-3493	32	25	that	that	SCONJ
iajs-3493	32	26	il-3	il-3	PRON
iajs-3493	32	27	has	have	VERB
iajs-3493	32	28	a	a	DET
iajs-3493	32	29	potential	potential	ADJ
iajs-3493	32	30	role	role	NOUN
iajs-3493	32	31	in	in	ADP
iajs-3493	32	32	the	the	DET
iajs-3493	32	33	regulation	regulation	NOUN
iajs-3493	32	34	of	of	ADP
iajs-3493	32	35	the	the	DET
iajs-3493	32	36	inflammatory	inflammatory	ADJ
iajs-3493	32	37	response	response	NOUN
iajs-3493	32	38	and	and	CCONJ
iajs-3493	32	39	bone	bone	NOUN
iajs-3493	32	40	and	and	CCONJ
iajs-3493	32	41	cartilage	cartilage	NOUN
iajs-3493	32	42	loss	loss	NOUN
iajs-3493	32	43	in	in	ADP
iajs-3493	32	44	the	the	DET
iajs-3493	32	45	arthritis	arthritis	NOUN
iajs-3493	32	46	of	of	ADP
iajs-3493	32	47	mice	mouse	NOUN
iajs-3493	32	48	[	[	X
iajs-3493	32	49	12	12	NUM
iajs-3493	32	50	]	]	PUNCT
iajs-3493	32	51	.	.	PUNCT
iajs-3493	33	1	the	the	DET
iajs-3493	33	2	erythrocyte	erythrocyte	PROPN
iajs-3493	33	3	sedimentation	sedimentation	NOUN
iajs-3493	33	4	rate	rate	NOUN
iajs-3493	33	5	(	(	PUNCT
iajs-3493	33	6	esr	esr	PROPN
iajs-3493	33	7	)	)	PUNCT
iajs-3493	33	8	is	be	AUX
iajs-3493	33	9	one	one	NUM
iajs-3493	33	10	of	of	ADP
iajs-3493	33	11	the	the	DET
iajs-3493	33	12	hematological	hematological	ADJ
iajs-3493	33	13	tests	test	NOUN
iajs-3493	33	14	used	use	VERB
iajs-3493	33	15	to	to	PART
iajs-3493	33	16	determine	determine	VERB
iajs-3493	33	17	body	body	NOUN
iajs-3493	33	18	-	-	PUNCT
iajs-3493	33	19	inflammatory	inflammatory	ADJ
iajs-3493	33	20	activity	activity	NOUN
iajs-3493	33	21	.	.	PUNCT
iajs-3493	34	1	the	the	DET
iajs-3493	34	2	presence	presence	NOUN
iajs-3493	34	3	of	of	ADP
iajs-3493	34	4	inflammation	inflammation	NOUN
iajs-3493	34	5	is	be	AUX
iajs-3493	34	6	indicated	indicate	VERB
iajs-3493	34	7	by	by	ADP
iajs-3493	34	8	an	an	DET
iajs-3493	34	9	increase	increase	NOUN
iajs-3493	34	10	in	in	ADP
iajs-3493	34	11	the	the	DET
iajs-3493	34	12	rate	rate	NOUN
iajs-3493	34	13	of	of	ADP
iajs-3493	34	14	settling	settling	NOUN
iajs-3493	34	15	of	of	ADP
iajs-3493	34	16	red	red	ADJ
iajs-3493	34	17	blood	blood	NOUN
iajs-3493	34	18	cells	cell	NOUN
iajs-3493	34	19	(	(	PUNCT
iajs-3493	34	20	rbcs	rbc	NOUN
iajs-3493	34	21	)	)	PUNCT
iajs-3493	34	22	in	in	ADP
iajs-3493	34	23	the	the	DET
iajs-3493	34	24	blood	blood	NOUN
iajs-3493	34	25	sample	sample	NOUN
iajs-3493	34	26	's	's	PART
iajs-3493	34	27	test	test	NOUN
iajs-3493	34	28	tube	tube	NOUN
iajs-3493	34	29	,	,	PUNCT
iajs-3493	34	30	which	which	PRON
iajs-3493	34	31	is	be	AUX
iajs-3493	34	32	measured	measure	VERB
iajs-3493	34	33	by	by	ADP
iajs-3493	34	34	this	this	DET
iajs-3493	34	35	analysis	analysis	NOUN
iajs-3493	34	36	.	.	PUNCT
iajs-3493	35	1	it	it	PRON
iajs-3493	35	2	is	be	AUX
iajs-3493	35	3	important	important	ADJ
iajs-3493	35	4	to	to	PART
iajs-3493	35	5	note	note	VERB
iajs-3493	35	6	that	that	SCONJ
iajs-3493	35	7	,	,	PUNCT
iajs-3493	35	8	despite	despite	SCONJ
iajs-3493	35	9	the	the	DET
iajs-3493	35	10	fact	fact	NOUN
iajs-3493	35	11	that	that	SCONJ
iajs-3493	35	12	esr	esr	PROPN
iajs-3493	35	13	is	be	AUX
iajs-3493	35	14	a	a	DET
iajs-3493	35	15	nonspecific	nonspecific	ADJ
iajs-3493	35	16	analysis	analysis	NOUN
iajs-3493	35	17	,	,	PUNCT
iajs-3493	35	18	the	the	DET
iajs-3493	35	19	location	location	NOUN
iajs-3493	35	20	of	of	ADP
iajs-3493	35	21	inflammation	inflammation	NOUN
iajs-3493	35	22	was	be	AUX
iajs-3493	35	23	not	not	PART
iajs-3493	35	24	found	find	VERB
iajs-3493	35	25	[	[	X
iajs-3493	35	26	13	13	NUM
iajs-3493	35	27	]	]	PUNCT
iajs-3493	35	28	.	.	PUNCT
iajs-3493	36	1	creactive	creactive	ADJ
iajs-3493	36	2	protein	protein	NOUN
iajs-3493	36	3	can	can	AUX
iajs-3493	36	4	be	be	AUX
iajs-3493	36	5	utilized	utilize	VERB
iajs-3493	36	6	as	as	ADP
iajs-3493	36	7	a	a	DET
iajs-3493	36	8	timely	timely	ADJ
iajs-3493	36	9	marker	marker	NOUN
iajs-3493	36	10	of	of	ADP
iajs-3493	36	11	active	active	ADJ
iajs-3493	36	12	inflammation	inflammation	NOUN
iajs-3493	36	13	,	,	PUNCT
iajs-3493	36	14	making	make	VERB
iajs-3493	36	15	it	it	PRON
iajs-3493	36	16	preferable	preferable	ADJ
iajs-3493	36	17	to	to	ADP
iajs-3493	36	18	the	the	DET
iajs-3493	36	19	esr	esr	PROPN
iajs-3493	36	20	in	in	ADP
iajs-3493	36	21	inflammatory	inflammatory	ADJ
iajs-3493	36	22	conditions	condition	NOUN
iajs-3493	36	23	[	[	X
iajs-3493	36	24	14	14	NUM
iajs-3493	36	25	,	,	PUNCT
iajs-3493	36	26	15	15	NUM
iajs-3493	36	27	]	]	PUNCT
iajs-3493	36	28	.	.	PUNCT
iajs-3493	37	1	numerous	numerous	ADJ
iajs-3493	37	2	studies	study	NOUN
iajs-3493	37	3	have	have	AUX
iajs-3493	37	4	demonstrated	demonstrate	VERB
iajs-3493	37	5	a	a	DET
iajs-3493	37	6	correlation	correlation	NOUN
iajs-3493	37	7	between	between	ADP
iajs-3493	37	8	c	c	NOUN
iajs-3493	37	9	-	-	PUNCT
iajs-3493	37	10	reactive	reactive	ADJ
iajs-3493	37	11	protein	protein	NOUN
iajs-3493	37	12	levels	level	NOUN
iajs-3493	37	13	and	and	CCONJ
iajs-3493	37	14	an	an	DET
iajs-3493	37	15	increased	increase	VERB
iajs-3493	37	16	rate	rate	NOUN
iajs-3493	37	17	of	of	ADP
iajs-3493	37	18	radiological	radiological	ADJ
iajs-3493	37	19	progression	progression	NOUN
iajs-3493	37	20	in	in	ADP
iajs-3493	37	21	rheumatoid	rheumatoid	NOUN
iajs-3493	37	22	arthritis	arthritis	NOUN
iajs-3493	37	23	[	[	X
iajs-3493	37	24	16	16	NUM
iajs-3493	37	25	,	,	PUNCT
iajs-3493	37	26	17	17	NUM
iajs-3493	37	27	]	]	PUNCT
iajs-3493	37	28	.	.	PUNCT
iajs-3493	38	1	anti	anti	NOUN
iajs-3493	38	2	-	-	ADJ
iajs-3493	38	3	ccp	ccp	PROPN
iajs-3493	38	4	is	be	AUX
iajs-3493	38	5	one	one	NUM
iajs-3493	38	6	of	of	ADP
iajs-3493	38	7	the	the	DET
iajs-3493	38	8	anti	anti	ADJ
iajs-3493	38	9	-	-	ADJ
iajs-3493	38	10	flagging	flagging	ADJ
iajs-3493	38	11	family	family	NOUN
iajs-3493	38	12	members	member	NOUN
iajs-3493	38	13	that	that	PRON
iajs-3493	38	14	interacts	interact	VERB
iajs-3493	38	15	with	with	ADP
iajs-3493	38	16	the	the	DET
iajs-3493	38	17	antigenic	antigenic	ADJ
iajs-3493	38	18	determinant	determinant	ADJ
iajs-3493	38	19	containing	contain	VERB
iajs-3493	38	20	citrullinated	citrullinate	VERB
iajs-3493	38	21	arginine	arginine	NOUN
iajs-3493	38	22	residues	residue	NOUN
iajs-3493	38	23	.	.	PUNCT
iajs-3493	39	1	ant	ant	PROPN
iajs-3493	39	2	-	-	PUNCT
iajs-3493	39	3	ccp	ccp	PROPN
iajs-3493	39	4	has	have	AUX
iajs-3493	39	5	been	be	AUX
iajs-3493	39	6	used	use	VERB
iajs-3493	39	7	for	for	ADP
iajs-3493	39	8	many	many	ADJ
iajs-3493	39	9	years	year	NOUN
iajs-3493	39	10	along	along	ADP
iajs-3493	39	11	with	with	ADP
iajs-3493	39	12	rheumatoid	rheumatoid	NOUN
iajs-3493	39	13	factor	factor	NOUN
iajs-3493	39	14	(	(	PUNCT
iajs-3493	39	15	rf	rf	NOUN
iajs-3493	39	16	)	)	PUNCT
iajs-3493	39	17	to	to	PART
iajs-3493	39	18	help	help	VERB
iajs-3493	39	19	diagnose	diagnose	VERB
iajs-3493	39	20	ra	ra	NOUN
iajs-3493	40	1	[	[	X
iajs-3493	40	2	18	18	NUM
iajs-3493	40	3	]	]	PUNCT
iajs-3493	40	4	.	.	PUNCT
iajs-3493	41	1	this	this	DET
iajs-3493	41	2	study	study	NOUN
iajs-3493	41	3	aimed	aim	VERB
iajs-3493	41	4	to	to	PART
iajs-3493	41	5	examine	examine	VERB
iajs-3493	41	6	the	the	DET
iajs-3493	41	7	changes	change	NOUN
iajs-3493	41	8	in	in	ADP
iajs-3493	41	9	immunological	immunological	ADJ
iajs-3493	41	10	markers	marker	NOUN
iajs-3493	41	11	at	at	ADP
iajs-3493	41	12	serum	serum	NOUN
iajs-3493	41	13	levels	level	NOUN
iajs-3493	41	14	as	as	ADV
iajs-3493	41	15	well	well	ADV
iajs-3493	41	16	as	as	ADP
iajs-3493	41	17	the	the	DET
iajs-3493	41	18	clinical	clinical	ADJ
iajs-3493	41	19	outcomes	outcome	NOUN
iajs-3493	41	20	associated	associate	VERB
iajs-3493	41	21	with	with	ADP
iajs-3493	41	22	these	these	DET
iajs-3493	41	23	markers	marker	NOUN
iajs-3493	41	24	in	in	ADP
iajs-3493	41	25	iraqi	iraqi	ADJ
iajs-3493	41	26	rheumatoid	rheumatoid	NOUN
iajs-3493	41	27	arthritis	arthritis	NOUN
iajs-3493	41	28	patients	patient	NOUN
iajs-3493	41	29	.	.	PUNCT
iajs-3493	42	1	2	2	X
iajs-3493	42	2	.	.	X
iajs-3493	42	3	materials	material	NOUN
iajs-3493	42	4	and	and	CCONJ
iajs-3493	42	5	methods	method	NOUN
iajs-3493	42	6	2.1	2.1	NUM
iajs-3493	42	7	study	study	NOUN
iajs-3493	42	8	groups	group	NOUN
iajs-3493	42	9	this	this	DET
iajs-3493	42	10	study	study	NOUN
iajs-3493	42	11	was	be	AUX
iajs-3493	42	12	performed	perform	VERB
iajs-3493	42	13	on	on	ADP
iajs-3493	42	14	sixty	sixty	NUM
iajs-3493	42	15	ra	ra	PROPN
iajs-3493	42	16	patients	patient	NOUN
iajs-3493	42	17	with	with	ADP
iajs-3493	42	18	an	an	DET
iajs-3493	42	19	age	age	NOUN
iajs-3493	42	20	range	range	NOUN
iajs-3493	42	21	of	of	ADP
iajs-3493	42	22	20–70	20–70	NUM
iajs-3493	42	23	years	year	NOUN
iajs-3493	42	24	and	and	CCONJ
iajs-3493	42	25	30	30	NUM
iajs-3493	42	26	healthy	healthy	ADJ
iajs-3493	42	27	controls	control	NOUN
iajs-3493	42	28	with	with	ADP
iajs-3493	42	29	an	an	DET
iajs-3493	42	30	age	age	NOUN
iajs-3493	42	31	range	range	NOUN
iajs-3493	42	32	of	of	ADP
iajs-3493	42	33	20–60	20–60	NUM
iajs-3493	42	34	years	year	NOUN
iajs-3493	42	35	.	.	PUNCT
iajs-3493	43	1	patients	patient	NOUN
iajs-3493	43	2	were	be	AUX
iajs-3493	43	3	admitted	admit	VERB
iajs-3493	43	4	to	to	ADP
iajs-3493	43	5	the	the	DET
iajs-3493	43	6	al	al	PROPN
iajs-3493	43	7	-	-	PUNCT
iajs-3493	43	8	yarmouk	yarmouk	ADV
iajs-3493	43	9	teaching	teaching	NOUN
iajs-3493	43	10	hospital	hospital	NOUN
iajs-3493	43	11	,	,	PUNCT
iajs-3493	43	12	baghdad	baghdad	PROPN
iajs-3493	43	13	,	,	PUNCT
iajs-3493	43	14	iraq	iraq	PROPN
iajs-3493	43	15	,	,	PUNCT
iajs-3493	43	16	from	from	ADP
iajs-3493	43	17	october	october	PROPN
iajs-3493	43	18	to	to	ADP
iajs-3493	43	19	december	december	PROPN
iajs-3493	43	20	2022	2022	NUM
iajs-3493	43	21	.	.	PUNCT
iajs-3493	44	1	the	the	DET
iajs-3493	44	2	diagnosis	diagnosis	NOUN
iajs-3493	44	3	was	be	AUX
iajs-3493	44	4	made	make	VERB
iajs-3493	44	5	by	by	ADP
iajs-3493	44	6	the	the	DET
iajs-3493	44	7	consulting	consult	VERB
iajs-3493	44	8	medical	medical	ADJ
iajs-3493	44	9	staff	staff	NOUN
iajs-3493	44	10	.	.	PUNCT
iajs-3493	45	1	2.2	2.2	NUM
iajs-3493	45	2	blood	blood	NOUN
iajs-3493	45	3	collection	collection	NOUN
iajs-3493	45	4	venous	venous	ADJ
iajs-3493	45	5	(	(	PUNCT
iajs-3493	45	6	5	5	NUM
iajs-3493	45	7	ml	ml	NOUN
iajs-3493	45	8	each	each	PRON
iajs-3493	45	9	)	)	PUNCT
iajs-3493	45	10	blood	blood	NOUN
iajs-3493	45	11	samples	sample	NOUN
iajs-3493	45	12	were	be	AUX
iajs-3493	45	13	collected	collect	VERB
iajs-3493	45	14	into	into	ADP
iajs-3493	45	15	a	a	DET
iajs-3493	45	16	serum	serum	NOUN
iajs-3493	45	17	geltube	geltube	NOUN
iajs-3493	45	18	from	from	ADP
iajs-3493	45	19	ra	ra	PROPN
iajs-3493	45	20	patients	patient	NOUN
iajs-3493	45	21	and	and	CCONJ
iajs-3493	45	22	controls	control	NOUN
iajs-3493	45	23	.	.	PUNCT
iajs-3493	46	1	the	the	DET
iajs-3493	46	2	tube	tube	NOUN
iajs-3493	46	3	was	be	AUX
iajs-3493	46	4	centrifuged	centrifuge	VERB
iajs-3493	46	5	at	at	ADP
iajs-3493	46	6	5000	5000	NUM
iajs-3493	46	7	rpm	rpm	NOUN
iajs-3493	46	8	for	for	ADP
iajs-3493	46	9	ten	ten	NUM
iajs-3493	46	10	minutes	minute	NOUN
iajs-3493	46	11	after	after	ADP
iajs-3493	46	12	clot	clot	NOUN
iajs-3493	46	13	formation	formation	NOUN
iajs-3493	46	14	at	at	ADP
iajs-3493	46	15	room	room	NOUN
iajs-3493	46	16	temperature	temperature	NOUN
iajs-3493	46	17	.	.	PUNCT
iajs-3493	47	1	the	the	DET
iajs-3493	47	2	serum	serum	NOUN
iajs-3493	47	3	was	be	AUX
iajs-3493	47	4	kept	keep	VERB
iajs-3493	47	5	in	in	ADP
iajs-3493	47	6	1.5	1.5	NUM
iajs-3493	47	7	ml	ml	NOUN
iajs-3493	47	8	eppendorf	eppendorf	PROPN
iajs-3493	47	9	tubes	tube	NOUN
iajs-3493	47	10	at	at	ADP
iajs-3493	47	11	a	a	DET
iajs-3493	47	12	freezing	freezing	ADJ
iajs-3493	47	13	temperature	temperature	NOUN
iajs-3493	47	14	of	of	ADP
iajs-3493	47	15	-20	-20	NUM
iajs-3493	47	16	̊c	̊c	NUM
iajs-3493	47	17	until	until	ADP
iajs-3493	47	18	use	use	NOUN
iajs-3493	47	19	for	for	ADP
iajs-3493	47	20	the	the	DET
iajs-3493	47	21	serological	serological	ADJ
iajs-3493	47	22	test	test	NOUN
iajs-3493	47	23	.	.	PUNCT
iajs-3493	48	1	ihjpas	ihjpas	PROPN
iajs-3493	48	2	.	.	PUNCT
iajs-3493	49	1	2024	2024	NUM
iajs-3493	49	2	,	,	PUNCT
iajs-3493	49	3	37(4	37(4	PROPN
iajs-3493	49	4	)	)	PUNCT
iajs-3493	49	5	47	47	NUM
iajs-3493	49	6	2.3	2.3	NUM
iajs-3493	49	7	measurements	measurement	NOUN
iajs-3493	49	8	of	of	ADP
iajs-3493	49	9	studied	study	VERB
iajs-3493	49	10	markers	marker	NOUN
iajs-3493	49	11	interleukin-3	interleukin-3	PROPN
iajs-3493	49	12	and	and	CCONJ
iajs-3493	49	13	interleukin-5	interleukin-5	PROPN
iajs-3493	49	14	were	be	AUX
iajs-3493	49	15	assessed	assess	VERB
iajs-3493	49	16	quantitatively	quantitatively	ADV
iajs-3493	49	17	in	in	ADP
iajs-3493	49	18	serum	serum	NOUN
iajs-3493	49	19	samples	sample	NOUN
iajs-3493	49	20	using	use	VERB
iajs-3493	49	21	commercial	commercial	ADJ
iajs-3493	49	22	enzyme	enzyme	NOUN
iajs-3493	49	23	-	-	PUNCT
iajs-3493	49	24	linked	link	VERB
iajs-3493	49	25	immunosorbent	immunosorbent	NOUN
iajs-3493	49	26	assay	assay	PROPN
iajs-3493	49	27	(	(	PUNCT
iajs-3493	49	28	elisa	elisa	NOUN
iajs-3493	49	29	)	)	PUNCT
iajs-3493	49	30	kits	kit	NOUN
iajs-3493	49	31	(	(	PUNCT
iajs-3493	49	32	sun	sun	PROPN
iajs-3493	49	33	long	long	ADV
iajs-3493	49	34	,	,	PUNCT
iajs-3493	49	35	china	china	PROPN
iajs-3493	49	36	)	)	PUNCT
iajs-3493	49	37	.	.	PUNCT
iajs-3493	50	1	according	accord	VERB
iajs-3493	50	2	to	to	ADP
iajs-3493	50	3	the	the	DET
iajs-3493	50	4	manufacturer	manufacturer	NOUN
iajs-3493	50	5	's	's	PART
iajs-3493	50	6	guidelines	guideline	NOUN
iajs-3493	50	7	.	.	PUNCT
iajs-3493	51	1	the	the	DET
iajs-3493	51	2	analysis	analysis	NOUN
iajs-3493	51	3	of	of	ADP
iajs-3493	51	4	esr	esr	PROPN
iajs-3493	51	5	and	and	CCONJ
iajs-3493	51	6	cbc	cbc	NOUN
iajs-3493	51	7	was	be	AUX
iajs-3493	51	8	done	do	VERB
iajs-3493	51	9	by	by	ADP
iajs-3493	51	10	adding	add	VERB
iajs-3493	51	11	2	2	NUM
iajs-3493	51	12	ml	ml	NOUN
iajs-3493	51	13	of	of	ADP
iajs-3493	51	14	blood	blood	NOUN
iajs-3493	51	15	sample	sample	NOUN
iajs-3493	51	16	inside	inside	ADP
iajs-3493	51	17	an	an	DET
iajs-3493	51	18	ethylene	ethylene	NOUN
iajs-3493	51	19	diamine	diamine	NOUN
iajs-3493	51	20	tetra	tetra	NOUN
iajs-3493	51	21	acetic	acetic	ADJ
iajs-3493	51	22	acid	acid	NOUN
iajs-3493	51	23	(	(	PUNCT
iajs-3493	51	24	edta	edta	NOUN
iajs-3493	51	25	)	)	PUNCT
iajs-3493	51	26	tube	tube	NOUN
iajs-3493	51	27	,	,	PUNCT
iajs-3493	51	28	which	which	PRON
iajs-3493	51	29	is	be	AUX
iajs-3493	51	30	a	a	DET
iajs-3493	51	31	vial	vial	ADJ
iajs-3493	51	32	specially	specially	ADV
iajs-3493	51	33	designed	design	VERB
iajs-3493	51	34	to	to	PART
iajs-3493	51	35	prevent	prevent	VERB
iajs-3493	51	36	clotting	clot	VERB
iajs-3493	51	37	blood	blood	NOUN
iajs-3493	51	38	.	.	PUNCT
iajs-3493	52	1	the	the	DET
iajs-3493	52	2	sample	sample	NOUN
iajs-3493	52	3	was	be	AUX
iajs-3493	52	4	then	then	ADV
iajs-3493	52	5	put	put	VERB
iajs-3493	52	6	into	into	ADP
iajs-3493	52	7	a	a	DET
iajs-3493	52	8	machine	machine	NOUN
iajs-3493	52	9	for	for	ADP
iajs-3493	52	10	analysis	analysis	NOUN
iajs-3493	52	11	.	.	PUNCT
iajs-3493	53	1	one	one	NUM
iajs-3493	53	2	drop	drop	NOUN
iajs-3493	53	3	of	of	ADP
iajs-3493	53	4	serum	serum	NOUN
iajs-3493	53	5	for	for	ADP
iajs-3493	53	6	the	the	DET
iajs-3493	53	7	crp	crp	PROPN
iajs-3493	53	8	test	test	NOUN
iajs-3493	53	9	is	be	AUX
iajs-3493	53	10	put	put	VERB
iajs-3493	53	11	on	on	ADP
iajs-3493	53	12	a	a	DET
iajs-3493	53	13	circle	circle	NOUN
iajs-3493	53	14	on	on	ADP
iajs-3493	53	15	a	a	DET
iajs-3493	53	16	glass	glass	NOUN
iajs-3493	53	17	slide	slide	NOUN
iajs-3493	53	18	.	.	PUNCT
iajs-3493	54	1	one	one	NUM
iajs-3493	54	2	drop	drop	NOUN
iajs-3493	54	3	of	of	ADP
iajs-3493	54	4	reagent	reagent	ADJ
iajs-3493	54	5	latex	latex	NOUN
iajs-3493	54	6	was	be	AUX
iajs-3493	54	7	added	add	VERB
iajs-3493	54	8	to	to	ADP
iajs-3493	54	9	all	all	DET
iajs-3493	54	10	the	the	DET
iajs-3493	54	11	circles	circle	NOUN
iajs-3493	54	12	with	with	ADP
iajs-3493	54	13	separate	separate	ADJ
iajs-3493	54	14	sticks	stick	NOUN
iajs-3493	54	15	,	,	PUNCT
iajs-3493	54	16	mixing	mix	VERB
iajs-3493	54	17	and	and	CCONJ
iajs-3493	54	18	spreading	spread	VERB
iajs-3493	54	19	the	the	DET
iajs-3493	54	20	fluid	fluid	NOUN
iajs-3493	54	21	over	over	ADP
iajs-3493	54	22	the	the	DET
iajs-3493	54	23	area	area	NOUN
iajs-3493	54	24	of	of	ADP
iajs-3493	54	25	the	the	DET
iajs-3493	54	26	cell	cell	NOUN
iajs-3493	54	27	back	back	ADV
iajs-3493	54	28	and	and	CCONJ
iajs-3493	54	29	forth	forth	ADV
iajs-3493	54	30	for	for	ADP
iajs-3493	54	31	2	2	NUM
iajs-3493	54	32	minutes	minute	NOUN
iajs-3493	54	33	,	,	PUNCT
iajs-3493	54	34	slowly	slowly	ADV
iajs-3493	54	35	agglutinating	agglutinating	ADJ
iajs-3493	54	36	,	,	PUNCT
iajs-3493	54	37	and	and	CCONJ
iajs-3493	54	38	observing	observe	VERB
iajs-3493	54	39	under	under	ADP
iajs-3493	54	40	artificial	artificial	ADJ
iajs-3493	54	41	light	light	NOUN
iajs-3493	54	42	,	,	PUNCT
iajs-3493	54	43	preferably	preferably	ADV
iajs-3493	54	44	.	.	PUNCT
iajs-3493	55	1	2.4	2.4	NUM
iajs-3493	55	2	statistical	statistical	ADJ
iajs-3493	55	3	analysis	analysis	NOUN
iajs-3493	55	4	the	the	DET
iajs-3493	55	5	statistical	statistical	ADJ
iajs-3493	55	6	analysis	analysis	NOUN
iajs-3493	55	7	program	program	NOUN
iajs-3493	55	8	(	(	PUNCT
iajs-3493	55	9	spps	spps	X
iajs-3493	55	10	)	)	PUNCT
iajs-3493	55	11	version	version	NOUN
iajs-3493	55	12	23	23	NUM
iajs-3493	55	13	was	be	AUX
iajs-3493	55	14	used	use	VERB
iajs-3493	55	15	to	to	PART
iajs-3493	55	16	test	test	VERB
iajs-3493	55	17	the	the	DET
iajs-3493	55	18	differences	difference	NOUN
iajs-3493	55	19	between	between	ADP
iajs-3493	55	20	the	the	DET
iajs-3493	55	21	means	mean	NOUN
iajs-3493	55	22	of	of	ADP
iajs-3493	55	23	the	the	DET
iajs-3493	55	24	study	study	NOUN
iajs-3493	55	25	groups	group	NOUN
iajs-3493	55	26	.	.	PUNCT
iajs-3493	56	1	a	a	DET
iajs-3493	56	2	statistical	statistical	ADJ
iajs-3493	56	3	comparison	comparison	NOUN
iajs-3493	56	4	between	between	ADP
iajs-3493	56	5	groups	group	NOUN
iajs-3493	56	6	was	be	AUX
iajs-3493	56	7	analyzed	analyze	VERB
iajs-3493	56	8	using	use	VERB
iajs-3493	56	9	a	a	DET
iajs-3493	56	10	ttest	ttest	NOUN
iajs-3493	56	11	and	and	CCONJ
iajs-3493	56	12	p	p	X
iajs-3493	56	13	<	<	X
iajs-3493	56	14	0.05	0.05	NUM
iajs-3493	56	15	was	be	AUX
iajs-3493	56	16	considered	consider	VERB
iajs-3493	56	17	a	a	DET
iajs-3493	56	18	significant	significant	ADJ
iajs-3493	56	19	value	value	NOUN
iajs-3493	56	20	.	.	PUNCT
iajs-3493	57	1	3	3	X
iajs-3493	57	2	.	.	X
iajs-3493	57	3	results	result	NOUN
iajs-3493	57	4	interleukin-3	interleukin-3	PRON
iajs-3493	57	5	and	and	CCONJ
iajs-3493	57	6	il-5	il-5	PRON
iajs-3493	57	7	were	be	AUX
iajs-3493	57	8	significantly	significantly	ADV
iajs-3493	57	9	increased	increase	VERB
iajs-3493	57	10	in	in	ADP
iajs-3493	57	11	ra	ra	PROPN
iajs-3493	57	12	patients	patient	NOUN
iajs-3493	57	13	as	as	SCONJ
iajs-3493	57	14	compared	compare	VERB
iajs-3493	57	15	to	to	ADP
iajs-3493	57	16	the	the	DET
iajs-3493	57	17	control	control	NOUN
iajs-3493	57	18	group	group	NOUN
iajs-3493	57	19	(	(	PUNCT
iajs-3493	57	20	table	table	NOUN
iajs-3493	57	21	1	1	NUM
iajs-3493	57	22	)	)	PUNCT
iajs-3493	57	23	.	.	PUNCT
iajs-3493	58	1	table	table	NOUN
iajs-3493	58	2	1	1	NUM
iajs-3493	58	3	.	.	X
iajs-3493	58	4	comparison	comparison	NOUN
iajs-3493	58	5	between	between	ADP
iajs-3493	58	6	ra	ra	PROPN
iajs-3493	58	7	patients	patient	NOUN
iajs-3493	58	8	and	and	CCONJ
iajs-3493	58	9	control	control	NOUN
iajs-3493	58	10	groups	group	NOUN
iajs-3493	58	11	in	in	ADP
iajs-3493	58	12	il-3	il-3	NOUN
iajs-3493	58	13	and	and	CCONJ
iajs-3493	58	14	il-5	il-5	PRON
iajs-3493	58	15	.	.	PUNCT
iajs-3493	59	1	groups	group	NOUN
iajs-3493	59	2	il-3	il-3	X
iajs-3493	59	3	(	(	PUNCT
iajs-3493	59	4	pq	pq	INTJ
iajs-3493	59	5	/	/	SYM
iajs-3493	59	6	ml	ml	NOUN
iajs-3493	59	7	)	)	PUNCT
iajs-3493	59	8	il-5	il-5	PROPN
iajs-3493	59	9	(	(	PUNCT
iajs-3493	59	10	pq	pq	NOUN
iajs-3493	59	11	/	/	SYM
iajs-3493	59	12	ml	ml	ADJ
iajs-3493	59	13	)	)	PUNCT
iajs-3493	59	14	patients	patient	NOUN
iajs-3493	59	15	341.56	341.56	NUM
iajs-3493	59	16	±12.10	±12.10	ADJ
iajs-3493	59	17	504.28	504.28	NUM
iajs-3493	59	18	±25.20	±25.20	NOUN
iajs-3493	59	19	control	control	NOUN
iajs-3493	59	20	154.66	154.66	NUM
iajs-3493	59	21	±9.24	±9.24	NOUN
iajs-3493	59	22	117.61	117.61	NUM
iajs-3493	59	23	±3.73	±3.73	PROPN
iajs-3493	59	24	t	t	NOUN
iajs-3493	59	25	-	-	PUNCT
iajs-3493	59	26	test	test	NOUN
iajs-3493	59	27	p	p	NOUN
iajs-3493	59	28	-	-	PUNCT
iajs-3493	59	29	value	value	NOUN
iajs-3493	59	30	33.88	33.88	NUM
iajs-3493	59	31	*	*	PUNCT
iajs-3493	59	32	*	*	PUNCT
iajs-3493	59	33	0.0001	0.0001	NUM
iajs-3493	59	34	68.697	68.697	NUM
iajs-3493	59	35	*	*	PUNCT
iajs-3493	59	36	*	*	SYM
iajs-3493	59	37	0.0001	0.0001	NUM
iajs-3493	59	38	data	datum	NOUN
iajs-3493	59	39	are	be	AUX
iajs-3493	59	40	presented	present	VERB
iajs-3493	59	41	as	as	ADP
iajs-3493	59	42	mean	mean	NOUN
iajs-3493	59	43	±	±	NUM
iajs-3493	59	44	standard	standard	ADJ
iajs-3493	59	45	error	error	NOUN
iajs-3493	59	46	(	(	PUNCT
iajs-3493	59	47	se	se	ADJ
iajs-3493	59	48	)	)	PUNCT
iajs-3493	59	49	.	.	PUNCT
iajs-3493	60	1	*	*	PUNCT
iajs-3493	60	2	*	*	PUNCT
iajs-3493	60	3	p<0.01	p<0.01	PROPN
iajs-3493	60	4	.	.	PUNCT
iajs-3493	61	1	the	the	DET
iajs-3493	61	2	wbc	wbc	PROPN
iajs-3493	61	3	levels	level	NOUN
iajs-3493	61	4	did	do	AUX
iajs-3493	61	5	n’t	not	PART
iajs-3493	61	6	differ	differ	VERB
iajs-3493	61	7	significantly	significantly	ADV
iajs-3493	61	8	in	in	ADP
iajs-3493	61	9	ra	ra	PROPN
iajs-3493	61	10	patients	patient	NOUN
iajs-3493	61	11	compared	compare	VERB
iajs-3493	61	12	to	to	ADP
iajs-3493	61	13	healthy	healthy	ADJ
iajs-3493	61	14	controls	control	NOUN
iajs-3493	61	15	,	,	PUNCT
iajs-3493	61	16	as	as	SCONJ
iajs-3493	61	17	illustrated	illustrate	VERB
iajs-3493	61	18	in	in	ADP
iajs-3493	61	19	table	table	NOUN
iajs-3493	61	20	2	2	NUM
iajs-3493	61	21	.	.	PUNCT
iajs-3493	62	1	also	also	ADV
iajs-3493	62	2	,	,	PUNCT
iajs-3493	62	3	lymphocyte	lymphocyte	ADJ
iajs-3493	62	4	levels	level	NOUN
iajs-3493	62	5	did	do	AUX
iajs-3493	62	6	n’t	not	PART
iajs-3493	62	7	differ	differ	VERB
iajs-3493	62	8	significantly	significantly	ADV
iajs-3493	62	9	in	in	ADP
iajs-3493	62	10	ra	ra	PROPN
iajs-3493	62	11	patients	patient	NOUN
iajs-3493	62	12	compared	compare	VERB
iajs-3493	62	13	to	to	ADP
iajs-3493	62	14	healthy	healthy	ADJ
iajs-3493	62	15	controls	control	NOUN
iajs-3493	62	16	,	,	PUNCT
iajs-3493	62	17	as	as	SCONJ
iajs-3493	62	18	indicated	indicate	VERB
iajs-3493	62	19	in	in	ADP
iajs-3493	62	20	table	table	NOUN
iajs-3493	62	21	2	2	NUM
iajs-3493	62	22	.	.	PUNCT
iajs-3493	62	23	monocyte	monocyte	NOUN
iajs-3493	62	24	levels	level	NOUN
iajs-3493	62	25	were	be	AUX
iajs-3493	62	26	significantly	significantly	ADV
iajs-3493	62	27	higher	high	ADJ
iajs-3493	62	28	in	in	ADP
iajs-3493	62	29	patients	patient	NOUN
iajs-3493	62	30	with	with	ADP
iajs-3493	62	31	ra	ra	PROPN
iajs-3493	62	32	as	as	SCONJ
iajs-3493	62	33	compared	compare	VERB
iajs-3493	62	34	to	to	ADP
iajs-3493	62	35	the	the	DET
iajs-3493	62	36	control	control	NOUN
iajs-3493	62	37	group	group	NOUN
iajs-3493	62	38	.	.	PUNCT
iajs-3493	63	1	in	in	ADP
iajs-3493	63	2	contrast	contrast	NOUN
iajs-3493	63	3	,	,	PUNCT
iajs-3493	63	4	the	the	DET
iajs-3493	63	5	rbc	rbc	PROPN
iajs-3493	63	6	levels	level	NOUN
iajs-3493	63	7	were	be	AUX
iajs-3493	63	8	significantly	significantly	ADV
iajs-3493	63	9	lower	low	ADJ
iajs-3493	63	10	in	in	ADP
iajs-3493	63	11	ra	ra	PROPN
iajs-3493	63	12	patients	patient	NOUN
iajs-3493	63	13	as	as	SCONJ
iajs-3493	63	14	compared	compare	VERB
iajs-3493	63	15	to	to	ADP
iajs-3493	63	16	the	the	DET
iajs-3493	63	17	control	control	NOUN
iajs-3493	63	18	group	group	NOUN
iajs-3493	63	19	.	.	PUNCT
iajs-3493	64	1	the	the	DET
iajs-3493	64	2	results	result	NOUN
iajs-3493	64	3	of	of	ADP
iajs-3493	64	4	table	table	NOUN
iajs-3493	64	5	2	2	NUM
iajs-3493	64	6	also	also	ADV
iajs-3493	64	7	indicated	indicate	VERB
iajs-3493	64	8	that	that	SCONJ
iajs-3493	64	9	hgb	hgb	PROPN
iajs-3493	64	10	levels	level	NOUN
iajs-3493	64	11	were	be	AUX
iajs-3493	64	12	significantly	significantly	ADV
iajs-3493	64	13	different	different	ADJ
iajs-3493	64	14	in	in	ADP
iajs-3493	64	15	ra	ra	PROPN
iajs-3493	64	16	patients	patient	NOUN
iajs-3493	64	17	than	than	ADP
iajs-3493	64	18	in	in	ADP
iajs-3493	64	19	the	the	DET
iajs-3493	64	20	control	control	NOUN
iajs-3493	64	21	group	group	NOUN
iajs-3493	64	22	.	.	PUNCT
iajs-3493	65	1	table	table	NOUN
iajs-3493	65	2	2	2	NUM
iajs-3493	65	3	.	.	PUNCT
iajs-3493	66	1	a	a	DET
iajs-3493	66	2	comparative	comparative	ADJ
iajs-3493	66	3	analysis	analysis	NOUN
iajs-3493	66	4	of	of	ADP
iajs-3493	66	5	wbc	wbc	PROPN
iajs-3493	66	6	,	,	PUNCT
iajs-3493	66	7	lymph	lymph	NOUN
iajs-3493	66	8	,	,	PUNCT
iajs-3493	66	9	mono	mono	PROPN
iajs-3493	66	10	,	,	PUNCT
iajs-3493	66	11	rbc	rbc	PROPN
iajs-3493	66	12	and	and	CCONJ
iajs-3493	66	13	hgb	hgb	PROPN
iajs-3493	66	14	between	between	ADP
iajs-3493	66	15	studies	study	NOUN
iajs-3493	66	16	groups	group	NOUN
iajs-3493	66	17	.	.	PUNCT
iajs-3493	67	1	groups	group	NOUN
iajs-3493	67	2	wbc	wbc	PROPN
iajs-3493	67	3	lymphocyte%	lymphocyte%	PUNCT
iajs-3493	67	4	monocyte%	monocyte%	PUNCT
iajs-3493	67	5	rbc	rbc	PROPN
iajs-3493	67	6	hgb	hgb	PROPN
iajs-3493	67	7	patients	patient	NOUN
iajs-3493	67	8	7.64	7.64	NUM
iajs-3493	67	9	±0.41	±0.41	NOUN
iajs-3493	67	10	33.04	33.04	NUM
iajs-3493	67	11	±1.60	±1.60	PROPN
iajs-3493	67	12	8.84	8.84	NUM
iajs-3493	67	13	±0.35	±0.35	PROPN
iajs-3493	67	14	4.81	4.81	NUM
iajs-3493	67	15	±0.09	±0.09	PROPN
iajs-3493	67	16	12.42	12.42	NUM
iajs-3493	67	17	±0.34	±0.34	PROPN
iajs-3493	67	18	control	control	NOUN
iajs-3493	67	19	6.24	6.24	NUM
iajs-3493	67	20	±0.39	±0.39	SYM
iajs-3493	67	21	26.83	26.83	NUM
iajs-3493	67	22	±2.72	±2.72	PROPN
iajs-3493	67	23	6.82	6.82	NUM
iajs-3493	67	24	±0.30	±0.30	PROPN
iajs-3493	67	25	5.36	5.36	NUM
iajs-3493	67	26	±0.14	±0.14	PROPN
iajs-3493	67	27	13.81	13.81	NUM
iajs-3493	67	28	±0.34	±0.34	PROPN
iajs-3493	67	29	t	t	PROPN
iajs-3493	67	30	-	-	PUNCT
iajs-3493	67	31	test	test	NOUN
iajs-3493	67	32	1.470	1.470	NUM
iajs-3493	67	33	ns	ns	NUM
iajs-3493	67	34	6.3716	6.3716	NUM
iajs-3493	67	35	ns	ns	NUM
iajs-3493	67	36	1.278	1.278	NUM
iajs-3493	67	37	*	*	PUNCT
iajs-3493	67	38	*	*	PUNCT
iajs-3493	67	39	0.376	0.376	NUM
iajs-3493	67	40	*	*	PUNCT
iajs-3493	67	41	*	*	NOUN
iajs-3493	68	1	1.246	1.246	NUM
iajs-3493	68	2	*	*	PUNCT
iajs-3493	68	3	p	p	X
iajs-3493	68	4	-	-	PUNCT
iajs-3493	68	5	value	value	NOUN
iajs-3493	68	6	0.0632	0.0632	NUM
iajs-3493	68	7	0.0571	0.0571	NUM
iajs-3493	68	8	0.0025	0.0025	NUM
iajs-3493	68	9	0.0052	0.0052	NUM
iajs-3493	68	10	0.0296	0.0296	NUM
iajs-3493	68	11	data	datum	NOUN
iajs-3493	68	12	are	be	AUX
iajs-3493	68	13	presented	present	VERB
iajs-3493	68	14	as	as	ADP
iajs-3493	68	15	mean	mean	NOUN
iajs-3493	68	16	±	±	NUM
iajs-3493	68	17	standard	standard	ADJ
iajs-3493	68	18	error	error	NOUN
iajs-3493	68	19	(	(	PUNCT
iajs-3493	68	20	se	se	ADJ
iajs-3493	68	21	)	)	PUNCT
iajs-3493	68	22	.	.	PUNCT
iajs-3493	69	1	*	*	PUNCT
iajs-3493	69	2	p≤0.05	p≤0.05	NOUN
iajs-3493	69	3	;	;	PUNCT
iajs-3493	69	4	*	*	PUNCT
iajs-3493	69	5	*	*	PUNCT
iajs-3493	69	6	p≤0.01	p≤0.01	NOUN
iajs-3493	69	7	.	.	PUNCT
iajs-3493	70	1	ns	ns	NUM
iajs-3493	70	2	:	:	PUNCT
iajs-3493	70	3	non	non	ADJ
iajs-3493	70	4	-	-	ADJ
iajs-3493	70	5	significant	significant	ADJ
iajs-3493	70	6	the	the	DET
iajs-3493	70	7	statistical	statistical	ADJ
iajs-3493	70	8	testing	testing	NOUN
iajs-3493	70	9	showed	show	VERB
iajs-3493	70	10	there	there	PRON
iajs-3493	70	11	was	be	VERB
iajs-3493	70	12	no	no	DET
iajs-3493	70	13	significant	significant	ADJ
iajs-3493	70	14	change	change	NOUN
iajs-3493	70	15	in	in	ADP
iajs-3493	70	16	the	the	DET
iajs-3493	70	17	il-3	il-3	ADJ
iajs-3493	70	18	levels	level	NOUN
iajs-3493	70	19	among	among	ADP
iajs-3493	70	20	the	the	DET
iajs-3493	70	21	male	male	ADJ
iajs-3493	70	22	and	and	CCONJ
iajs-3493	70	23	female	female	ADJ
iajs-3493	70	24	ra	ra	PROPN
iajs-3493	70	25	patients	patient	NOUN
iajs-3493	70	26	(	(	PUNCT
iajs-3493	70	27	table	table	NOUN
iajs-3493	70	28	3	3	NUM
iajs-3493	70	29	)	)	PUNCT
iajs-3493	70	30	.	.	PUNCT
iajs-3493	71	1	conversely	conversely	ADV
iajs-3493	71	2	,	,	PUNCT
iajs-3493	71	3	a	a	DET
iajs-3493	71	4	significant	significant	ADJ
iajs-3493	71	5	difference	difference	NOUN
iajs-3493	71	6	in	in	ADP
iajs-3493	71	7	the	the	DET
iajs-3493	71	8	level	level	NOUN
iajs-3493	71	9	of	of	ADP
iajs-3493	71	10	il-5	il-5	PRON
iajs-3493	71	11	among	among	ADP
iajs-3493	71	12	the	the	DET
iajs-3493	71	13	male	male	ADJ
iajs-3493	71	14	and	and	CCONJ
iajs-3493	71	15	female	female	ADJ
iajs-3493	71	16	ra	ra	PROPN
iajs-3493	71	17	patients	patient	NOUN
iajs-3493	71	18	was	be	AUX
iajs-3493	71	19	observed	observe	VERB
iajs-3493	71	20	,	,	PUNCT
iajs-3493	71	21	as	as	SCONJ
iajs-3493	71	22	illustrated	illustrate	VERB
iajs-3493	71	23	in	in	ADP
iajs-3493	71	24	table	table	NOUN
iajs-3493	71	25	3	3	NUM
iajs-3493	71	26	.	.	PUNCT
iajs-3493	71	27	ihjpas	ihjpas	PROPN
iajs-3493	71	28	.	.	PUNCT
iajs-3493	72	1	2024	2024	NUM
iajs-3493	72	2	,	,	PUNCT
iajs-3493	72	3	37(4	37(4	NOUN
iajs-3493	72	4	)	)	PUNCT
iajs-3493	72	5	48	48	NUM
iajs-3493	72	6	table	table	NOUN
iajs-3493	72	7	3	3	NUM
iajs-3493	72	8	.	.	PUNCT
iajs-3493	72	9	effect	effect	NOUN
iajs-3493	72	10	of	of	ADP
iajs-3493	72	11	gender	gender	NOUN
iajs-3493	72	12	in	in	ADP
iajs-3493	72	13	parameters	parameter	NOUN
iajs-3493	72	14	of	of	ADP
iajs-3493	72	15	sample	sample	NOUN
iajs-3493	72	16	study	study	NOUN
iajs-3493	72	17	.	.	PUNCT
iajs-3493	73	1	gender	gender	NOUN
iajs-3493	73	2	il-3	il-3	X
iajs-3493	73	3	(	(	PUNCT
iajs-3493	73	4	pq	pq	INTJ
iajs-3493	73	5	/	/	SYM
iajs-3493	73	6	ml	ml	NOUN
iajs-3493	73	7	)	)	PUNCT
iajs-3493	73	8	il-5	il-5	PROPN
iajs-3493	73	9	(	(	PUNCT
iajs-3493	73	10	pq	pq	NOUN
iajs-3493	73	11	/	/	SYM
iajs-3493	73	12	ml	ml	NOUN
iajs-3493	73	13	)	)	PUNCT
iajs-3493	73	14	male	male	NOUN
iajs-3493	73	15	331.96	331.96	NUM
iajs-3493	73	16	±24.69	±24.69	ADP
iajs-3493	73	17	574.04	574.04	NUM
iajs-3493	73	18	±50.49	±50.49	ADP
iajs-3493	73	19	female	female	ADJ
iajs-3493	73	20	346.58	346.58	NUM
iajs-3493	73	21	±13.52	±13.52	PRON
iajs-3493	73	22	473.18	473.18	NUM
iajs-3493	73	23	±28.56	±28.56	NOUN
iajs-3493	73	24	p	p	NOUN
iajs-3493	73	25	-	-	PUNCT
iajs-3493	73	26	value	value	NOUN
iajs-3493	73	27	0.574	0.574	NUM
iajs-3493	73	28	ns	ns	NUM
iajs-3493	73	29	0.050	0.050	NUM
iajs-3493	73	30	*	*	PUNCT
iajs-3493	73	31	data	datum	NOUN
iajs-3493	73	32	are	be	AUX
iajs-3493	73	33	presented	present	VERB
iajs-3493	73	34	as	as	ADP
iajs-3493	73	35	mean	mean	NOUN
iajs-3493	73	36	±	±	NUM
iajs-3493	73	37	standard	standard	ADJ
iajs-3493	73	38	error	error	NOUN
iajs-3493	73	39	(	(	PUNCT
iajs-3493	73	40	se	se	ADJ
iajs-3493	73	41	)	)	PUNCT
iajs-3493	73	42	.	.	PUNCT
iajs-3493	74	1	*	*	PUNCT
iajs-3493	74	2	p≤0.05	p≤0.05	NOUN
iajs-3493	74	3	;	;	PUNCT
iajs-3493	74	4	ns	ns	NUM
iajs-3493	74	5	:	:	PUNCT
iajs-3493	74	6	non	non	ADJ
iajs-3493	74	7	-	-	ADJ
iajs-3493	74	8	significant	significant	ADJ
iajs-3493	74	9	group	group	NOUN
iajs-3493	74	10	of	of	ADP
iajs-3493	74	11	ra	ra	PROPN
iajs-3493	74	12	patients	patient	NOUN
iajs-3493	74	13	was	be	AUX
iajs-3493	74	14	split	split	VERB
iajs-3493	74	15	into	into	ADP
iajs-3493	74	16	three	three	NUM
iajs-3493	74	17	groups	group	NOUN
iajs-3493	74	18	based	base	VERB
iajs-3493	74	19	on	on	ADP
iajs-3493	74	20	age	age	NOUN
iajs-3493	74	21	(	(	PUNCT
iajs-3493	74	22	20–40	20–40	NUM
iajs-3493	74	23	years	year	NOUN
iajs-3493	74	24	,	,	PUNCT
iajs-3493	74	25	41–60	41–60	NUM
iajs-3493	74	26	years	year	NOUN
iajs-3493	74	27	and	and	CCONJ
iajs-3493	74	28	>	>	SYM
iajs-3493	74	29	60	60	NUM
iajs-3493	74	30	years	year	NOUN
iajs-3493	74	31	)	)	PUNCT
iajs-3493	74	32	,	,	PUNCT
iajs-3493	74	33	as	as	SCONJ
iajs-3493	74	34	shown	show	VERB
iajs-3493	74	35	in	in	ADP
iajs-3493	74	36	table	table	NOUN
iajs-3493	74	37	4	4	NUM
iajs-3493	74	38	.	.	PUNCT
iajs-3493	75	1	the	the	DET
iajs-3493	75	2	statistical	statistical	ADJ
iajs-3493	75	3	analysis	analysis	NOUN
iajs-3493	75	4	indicated	indicate	VERB
iajs-3493	75	5	there	there	PRON
iajs-3493	75	6	was	be	VERB
iajs-3493	75	7	no	no	DET
iajs-3493	75	8	significant	significant	ADJ
iajs-3493	75	9	difference	difference	NOUN
iajs-3493	75	10	in	in	ADP
iajs-3493	75	11	the	the	DET
iajs-3493	75	12	il-3	il-3	ADJ
iajs-3493	75	13	levels	level	NOUN
iajs-3493	75	14	among	among	ADP
iajs-3493	75	15	different	different	ADJ
iajs-3493	75	16	age	age	NOUN
iajs-3493	75	17	groups	group	NOUN
iajs-3493	75	18	of	of	ADP
iajs-3493	75	19	ra	ra	PROPN
iajs-3493	75	20	patients	patient	NOUN
iajs-3493	75	21	.	.	PUNCT
iajs-3493	76	1	however	however	ADV
iajs-3493	76	2	,	,	PUNCT
iajs-3493	76	3	the	the	DET
iajs-3493	76	4	level	level	NOUN
iajs-3493	76	5	of	of	ADP
iajs-3493	76	6	il-5	il-5	PRON
iajs-3493	76	7	indicated	indicate	VERB
iajs-3493	76	8	significant	significant	ADJ
iajs-3493	76	9	differences	difference	NOUN
iajs-3493	76	10	between	between	ADP
iajs-3493	76	11	the	the	DET
iajs-3493	76	12	(	(	PUNCT
iajs-3493	76	13	20–40	20–40	NUM
iajs-3493	76	14	yr	yr	NOUN
iajs-3493	76	15	.	.	PUNCT
iajs-3493	76	16	)	)	PUNCT
iajs-3493	77	1	and	and	CCONJ
iajs-3493	77	2	(	(	PUNCT
iajs-3493	77	3	40–60	40–60	NUM
iajs-3493	77	4	yr	yr	NOUN
iajs-3493	77	5	.	.	PROPN
iajs-3493	77	6	,	,	PUNCT
iajs-3493	77	7	>	>	PUNCT
iajs-3493	77	8	60	60	NUM
iajs-3493	77	9	yr	yr	NOUN
iajs-3493	77	10	.	.	PUNCT
iajs-3493	77	11	)	)	PUNCT
iajs-3493	78	1	groups	group	NOUN
iajs-3493	78	2	(	(	PUNCT
iajs-3493	78	3	table	table	NOUN
iajs-3493	78	4	4	4	NUM
iajs-3493	78	5	)	)	PUNCT
iajs-3493	78	6	.	.	PUNCT
iajs-3493	79	1	table	table	NOUN
iajs-3493	79	2	4	4	NUM
iajs-3493	79	3	.	.	PUNCT
iajs-3493	79	4	effect	effect	NOUN
iajs-3493	79	5	of	of	ADP
iajs-3493	79	6	age	age	NOUN
iajs-3493	79	7	groups	group	NOUN
iajs-3493	79	8	in	in	ADP
iajs-3493	79	9	parameters	parameter	NOUN
iajs-3493	79	10	of	of	ADP
iajs-3493	79	11	sample	sample	NOUN
iajs-3493	79	12	studied	study	VERB
iajs-3493	79	13	.	.	PUNCT
iajs-3493	80	1	groups	group	NOUN
iajs-3493	80	2	il-3	il-3	X
iajs-3493	80	3	(	(	PUNCT
iajs-3493	80	4	pq	pq	INTJ
iajs-3493	80	5	/	/	SYM
iajs-3493	80	6	ml	ml	NOUN
iajs-3493	80	7	)	)	PUNCT
iajs-3493	80	8	il-5	il-5	PROPN
iajs-3493	80	9	(	(	PUNCT
iajs-3493	80	10	pq	pq	NOUN
iajs-3493	80	11	/	/	SYM
iajs-3493	80	12	ml	ml	NOUN
iajs-3493	80	13	)	)	PUNCT
iajs-3493	80	14	20	20	NUM
iajs-3493	80	15	-	-	SYM
iajs-3493	80	16	40	40	NUM
iajs-3493	80	17	yr	yr	NOUN
iajs-3493	80	18	.	.	PROPN
iajs-3493	81	1	331.96	331.96	NUM
iajs-3493	81	2	±	±	NUM
iajs-3493	81	3	24.68	24.68	NUM
iajs-3493	81	4	613.38	613.38	NUM
iajs-3493	81	5	±	±	NOUN
iajs-3493	81	6	49.64	49.64	NUM
iajs-3493	81	7	a	a	DET
iajs-3493	81	8	41	41	NUM
iajs-3493	81	9	-	-	SYM
iajs-3493	81	10	60	60	NUM
iajs-3493	81	11	yr	yr	NOUN
iajs-3493	81	12	.	.	PROPN
iajs-3493	82	1	342.35	342.35	NUM
iajs-3493	82	2	±	±	NUM
iajs-3493	82	3	14.62	14.62	NUM
iajs-3493	82	4	467.41	467.41	NUM
iajs-3493	82	5	±	±	NOUN
iajs-3493	82	6	28.85	28.85	NUM
iajs-3493	82	7	b	b	X
iajs-3493	82	8	>	>	SYM
iajs-3493	82	9	60	60	NUM
iajs-3493	82	10	yr	yr	NOUN
iajs-3493	82	11	.	.	PROPN
iajs-3493	83	1	386.77	386.77	NUM
iajs-3493	83	2	±	±	NUM
iajs-3493	83	3	6.41	6.41	NUM
iajs-3493	83	4	416.36	416.36	NUM
iajs-3493	83	5	±	±	NUM
iajs-3493	83	6	102.72	102.72	NUM
iajs-3493	83	7	b	b	NOUN
iajs-3493	83	8	p	p	ADJ
iajs-3493	83	9	-	-	PUNCT
iajs-3493	83	10	value	value	NOUN
iajs-3493	83	11	0.595	0.595	NUM
iajs-3493	83	12	ns	ns	NUM
iajs-3493	83	13	0.032	0.032	NUM
iajs-3493	83	14	*	*	PUNCT
iajs-3493	83	15	data	datum	NOUN
iajs-3493	83	16	are	be	AUX
iajs-3493	83	17	presented	present	VERB
iajs-3493	83	18	as	as	ADP
iajs-3493	83	19	mean	mean	NOUN
iajs-3493	83	20	±	±	NUM
iajs-3493	83	21	standard	standard	ADJ
iajs-3493	83	22	error	error	NOUN
iajs-3493	83	23	(	(	PUNCT
iajs-3493	83	24	se	se	ADJ
iajs-3493	83	25	)	)	PUNCT
iajs-3493	83	26	.	.	PUNCT
iajs-3493	84	1	different	different	ADJ
iajs-3493	84	2	letters	letter	NOUN
iajs-3493	84	3	in	in	ADP
iajs-3493	84	4	same	same	ADJ
iajs-3493	84	5	column	column	NOUN
iajs-3493	84	6	referred	refer	VERB
iajs-3493	84	7	to	to	ADP
iajs-3493	84	8	significant	significant	ADJ
iajs-3493	84	9	value	value	NOUN
iajs-3493	84	10	.	.	PUNCT
iajs-3493	85	1	*	*	PUNCT
iajs-3493	85	2	(	(	PUNCT
iajs-3493	85	3	p≤0.05	p≤0.05	NOUN
iajs-3493	85	4	)	)	PUNCT
iajs-3493	85	5	.	.	PUNCT
iajs-3493	86	1	the	the	DET
iajs-3493	86	2	levels	level	NOUN
iajs-3493	86	3	of	of	ADP
iajs-3493	86	4	esr	esr	PROPN
iajs-3493	86	5	and	and	CCONJ
iajs-3493	86	6	ant	ant	PROPN
iajs-3493	86	7	-	-	PUNCT
iajs-3493	86	8	ccp	ccp	PROPN
iajs-3493	86	9	increased	increase	VERB
iajs-3493	86	10	significantly	significantly	ADV
iajs-3493	86	11	in	in	ADP
iajs-3493	86	12	ra	ra	PROPN
iajs-3493	86	13	patients	patient	NOUN
iajs-3493	86	14	as	as	SCONJ
iajs-3493	86	15	compared	compare	VERB
iajs-3493	86	16	to	to	ADP
iajs-3493	86	17	controls	control	NOUN
iajs-3493	86	18	.	.	PUNCT
iajs-3493	87	1	similar	similar	ADJ
iajs-3493	87	2	results	result	NOUN
iajs-3493	87	3	were	be	AUX
iajs-3493	87	4	also	also	ADV
iajs-3493	87	5	observed	observe	VERB
iajs-3493	87	6	with	with	ADP
iajs-3493	87	7	crp	crp	PROPN
iajs-3493	87	8	levels	level	NOUN
iajs-3493	87	9	in	in	ADP
iajs-3493	87	10	ra	ra	PROPN
iajs-3493	87	11	patients	patient	NOUN
iajs-3493	87	12	,	,	PUNCT
iajs-3493	87	13	as	as	SCONJ
iajs-3493	87	14	illustrated	illustrate	VERB
iajs-3493	87	15	in	in	ADP
iajs-3493	87	16	table	table	NOUN
iajs-3493	87	17	5	5	NUM
iajs-3493	87	18	.	.	PUNCT
iajs-3493	87	19	table	table	NOUN
iajs-3493	87	20	5	5	NUM
iajs-3493	87	21	.	.	PUNCT
iajs-3493	88	1	a	a	DET
iajs-3493	88	2	comparative	comparative	ADJ
iajs-3493	88	3	analysis	analysis	NOUN
iajs-3493	88	4	of	of	ADP
iajs-3493	88	5	esr	esr	PROPN
iajs-3493	88	6	,	,	PUNCT
iajs-3493	88	7	crp	crp	PROPN
iajs-3493	88	8	and	and	CCONJ
iajs-3493	88	9	anti	anti	PROPN
iajs-3493	88	10	-	-	NOUN
iajs-3493	88	11	ccp	ccp	PROPN
iajs-3493	88	12	between	between	ADP
iajs-3493	88	13	studies	study	NOUN
iajs-3493	88	14	groups	group	NOUN
iajs-3493	88	15	.	.	PUNCT
iajs-3493	89	1	groups	group	NOUN
iajs-3493	89	2	esr(mm	esr(mm	PROPN
iajs-3493	89	3	/	/	SYM
iajs-3493	89	4	h	h	NOUN
iajs-3493	89	5	)	)	PUNCT
iajs-3493	89	6	crp(mg	crp(mg	PROPN
iajs-3493	89	7	/	/	SYM
iajs-3493	89	8	l	l	NOUN
iajs-3493	89	9	)	)	PUNCT
iajs-3493	89	10	anti	anti	ADJ
iajs-3493	89	11	-	-	ADJ
iajs-3493	89	12	cp)u	cp)u	ADJ
iajs-3493	89	13	/	/	SYM
iajs-3493	89	14	ml	ml	NOUN
iajs-3493	89	15	)	)	PUNCT
iajs-3493	89	16	patients	patient	NOUN
iajs-3493	89	17	37.60	37.60	NUM
iajs-3493	89	18	±2.72	±2.72	PROPN
iajs-3493	89	19	11.98	11.98	NUM
iajs-3493	89	20	±1.18	±1.18	PROPN
iajs-3493	89	21	0.637	0.637	NUM
iajs-3493	89	22	±0.02	±0.02	PROPN
iajs-3493	89	23	control	control	NOUN
iajs-3493	89	24	8.12	8.12	NUM
iajs-3493	89	25	±1.14	±1.14	PROPN
iajs-3493	89	26	4.83	4.83	NUM
iajs-3493	89	27	±0.38	±0.38	PROPN
iajs-3493	89	28	0.308	0.308	NUM
iajs-3493	89	29	±0	±0	NOUN
iajs-3493	89	30	.01	.01	NUM
iajs-3493	89	31	t	t	NOUN
iajs-3493	89	32	-	-	PUNCT
iajs-3493	89	33	test	test	NOUN
iajs-3493	89	34	7.490	7.490	NUM
iajs-3493	89	35	*	*	PUNCT
iajs-3493	89	36	*	*	PUNCT
iajs-3493	89	37	3.511	3.511	NUM
iajs-3493	89	38	*	*	SYM
iajs-3493	89	39	*	*	PUNCT
iajs-3493	89	40	0.0735	0.0735	NUM
iajs-3493	89	41	*	*	PUNCT
iajs-3493	89	42	*	*	PUNCT
iajs-3493	89	43	p	p	NOUN
iajs-3493	89	44	-	-	PUNCT
iajs-3493	89	45	value	value	NOUN
iajs-3493	89	46	0.0001	0.0001	NUM
iajs-3493	89	47	0.0001	0.0001	NUM
iajs-3493	89	48	0.0001	0.0001	NUM
iajs-3493	89	49	data	datum	NOUN
iajs-3493	89	50	are	be	AUX
iajs-3493	89	51	presented	present	VERB
iajs-3493	89	52	as	as	ADP
iajs-3493	89	53	mean	mean	NOUN
iajs-3493	89	54	±	±	NUM
iajs-3493	89	55	standard	standard	ADJ
iajs-3493	89	56	error	error	NOUN
iajs-3493	89	57	(	(	PUNCT
iajs-3493	89	58	se	se	ADJ
iajs-3493	89	59	)	)	PUNCT
iajs-3493	89	60	.	.	PUNCT
iajs-3493	90	1	*	*	PUNCT
iajs-3493	90	2	*	*	PUNCT
iajs-3493	90	3	p≤0.01	p≤0.01	NOUN
iajs-3493	90	4	.	.	PUNCT
iajs-3493	91	1	4	4	X
iajs-3493	91	2	.	.	X
iajs-3493	91	3	discussion	discussion	NOUN
iajs-3493	91	4	the	the	DET
iajs-3493	91	5	results	result	NOUN
iajs-3493	91	6	of	of	ADP
iajs-3493	91	7	this	this	DET
iajs-3493	91	8	study	study	NOUN
iajs-3493	91	9	indicated	indicate	VERB
iajs-3493	91	10	that	that	SCONJ
iajs-3493	91	11	il-3	il-3	PRON
iajs-3493	91	12	and	and	CCONJ
iajs-3493	91	13	il-5	il-5	PRON
iajs-3493	91	14	were	be	AUX
iajs-3493	91	15	significantly	significantly	ADV
iajs-3493	91	16	higher	high	ADJ
iajs-3493	91	17	in	in	ADP
iajs-3493	91	18	ra	ra	PROPN
iajs-3493	91	19	patients	patient	NOUN
iajs-3493	91	20	as	as	SCONJ
iajs-3493	91	21	compared	compare	VERB
iajs-3493	91	22	to	to	ADP
iajs-3493	91	23	the	the	DET
iajs-3493	91	24	control	control	NOUN
iajs-3493	91	25	group	group	NOUN
iajs-3493	91	26	.	.	PUNCT
iajs-3493	92	1	interleukin-3	interleukin-3	PRON
iajs-3493	92	2	is	be	AUX
iajs-3493	92	3	a	a	DET
iajs-3493	92	4	cytokine	cytokine	NOUN
iajs-3493	92	5	secreted	secrete	VERB
iajs-3493	92	6	by	by	ADP
iajs-3493	92	7	specific	specific	ADJ
iajs-3493	92	8	immune	immune	ADJ
iajs-3493	92	9	cells	cell	NOUN
iajs-3493	92	10	called	call	VERB
iajs-3493	92	11	th	th	NOUN
iajs-3493	92	12	cells	cell	NOUN
iajs-3493	92	13	.	.	PUNCT
iajs-3493	93	1	interleukin-3	interleukin-3	PRON
iajs-3493	93	2	has	have	VERB
iajs-3493	93	3	a	a	DET
iajs-3493	93	4	role	role	NOUN
iajs-3493	93	5	in	in	ADP
iajs-3493	93	6	links	link	NOUN
iajs-3493	93	7	between	between	ADP
iajs-3493	93	8	the	the	DET
iajs-3493	93	9	immune	immune	ADJ
iajs-3493	93	10	response	response	NOUN
iajs-3493	93	11	and	and	CCONJ
iajs-3493	93	12	the	the	DET
iajs-3493	93	13	hematopoietic	hematopoietic	ADJ
iajs-3493	93	14	system	system	NOUN
iajs-3493	93	15	.	.	PUNCT
iajs-3493	94	1	it	it	PRON
iajs-3493	94	2	has	have	AUX
iajs-3493	94	3	been	be	AUX
iajs-3493	94	4	suggested	suggest	VERB
iajs-3493	94	5	that	that	SCONJ
iajs-3493	94	6	il-3	il-3	PRON
iajs-3493	94	7	has	have	VERB
iajs-3493	94	8	a	a	DET
iajs-3493	94	9	potent	potent	ADJ
iajs-3493	94	10	inhibitory	inhibitory	ADJ
iajs-3493	94	11	role	role	NOUN
iajs-3493	94	12	in	in	ADP
iajs-3493	94	13	inflammatory	inflammatory	ADJ
iajs-3493	94	14	arthritis	arthritis	NOUN
iajs-3493	94	15	and	and	CCONJ
iajs-3493	94	16	pathological	pathological	ADJ
iajs-3493	94	17	bone	bone	NOUN
iajs-3493	94	18	resorption	resorption	NOUN
iajs-3493	94	19	[	[	X
iajs-3493	94	20	19	19	NUM
iajs-3493	94	21	,	,	PUNCT
iajs-3493	94	22	20	20	NUM
iajs-3493	94	23	]	]	PUNCT
iajs-3493	94	24	.	.	PUNCT
iajs-3493	95	1	in	in	ADP
iajs-3493	95	2	addition	addition	NOUN
iajs-3493	95	3	,	,	PUNCT
iajs-3493	95	4	il-3	il-3	PRON
iajs-3493	95	5	plays	play	VERB
iajs-3493	95	6	a	a	DET
iajs-3493	95	7	vital	vital	ADJ
iajs-3493	95	8	role	role	NOUN
iajs-3493	95	9	in	in	ADP
iajs-3493	95	10	modulating	modulate	VERB
iajs-3493	95	11	treg	treg	PROPN
iajs-3493	95	12	cell	cell	NOUN
iajs-3493	95	13	development	development	NOUN
iajs-3493	95	14	under	under	ADP
iajs-3493	95	15	different	different	ADJ
iajs-3493	95	16	conditions	condition	NOUN
iajs-3493	95	17	.	.	PUNCT
iajs-3493	96	1	similar	similar	ADJ
iajs-3493	96	2	results	result	NOUN
iajs-3493	96	3	were	be	AUX
iajs-3493	96	4	obtained	obtain	VERB
iajs-3493	96	5	by	by	ADP
iajs-3493	96	6	investigating	investigate	VERB
iajs-3493	96	7	the	the	DET
iajs-3493	96	8	role	role	NOUN
iajs-3493	96	9	of	of	ADP
iajs-3493	96	10	il-5	il-5	NOUN
iajs-3493	96	11	in	in	ADP
iajs-3493	96	12	stimulating	stimulate	VERB
iajs-3493	96	13	rheumatoid	rheumatoid	NOUN
iajs-3493	96	14	arthritis	arthritis	NOUN
iajs-3493	96	15	in	in	ADP
iajs-3493	96	16	specific	specific	ADJ
iajs-3493	96	17	cases	case	NOUN
iajs-3493	96	18	[	[	X
iajs-3493	96	19	21	21	NUM
iajs-3493	96	20	-	-	SYM
iajs-3493	96	21	23	23	NUM
iajs-3493	96	22	]	]	PUNCT
iajs-3493	96	23	.	.	PUNCT
iajs-3493	97	1	to	to	PART
iajs-3493	97	2	better	well	ADV
iajs-3493	97	3	understand	understand	VERB
iajs-3493	97	4	the	the	DET
iajs-3493	97	5	role	role	NOUN
iajs-3493	97	6	of	of	ADP
iajs-3493	97	7	il-3	il-3	NOUN
iajs-3493	97	8	and	and	CCONJ
iajs-3493	97	9	il-5	il-5	PRON
iajs-3493	97	10	in	in	ADP
iajs-3493	97	11	the	the	DET
iajs-3493	97	12	regulation	regulation	NOUN
iajs-3493	97	13	of	of	ADP
iajs-3493	97	14	immune	immune	ADJ
iajs-3493	97	15	responses	response	NOUN
iajs-3493	97	16	in	in	ADP
iajs-3493	97	17	ra	ra	PROPN
iajs-3493	97	18	,	,	PUNCT
iajs-3493	97	19	more	more	ADJ
iajs-3493	97	20	investigation	investigation	NOUN
iajs-3493	97	21	is	be	AUX
iajs-3493	97	22	necessary	necessary	ADJ
iajs-3493	97	23	.	.	PUNCT
iajs-3493	98	1	also	also	ADV
iajs-3493	98	2	,	,	PUNCT
iajs-3493	98	3	the	the	DET
iajs-3493	98	4	results	result	NOUN
iajs-3493	98	5	showed	show	VERB
iajs-3493	98	6	the	the	DET
iajs-3493	98	7	lymphocyte	lymphocyte	ADJ
iajs-3493	98	8	levels	level	NOUN
iajs-3493	98	9	did	do	AUX
iajs-3493	98	10	n’t	not	PART
iajs-3493	98	11	differ	differ	VERB
iajs-3493	98	12	significantly	significantly	ADV
iajs-3493	98	13	in	in	ADP
iajs-3493	98	14	ra	ra	PROPN
iajs-3493	98	15	patients	patient	NOUN
iajs-3493	98	16	compared	compare	VERB
iajs-3493	98	17	to	to	ADP
iajs-3493	98	18	the	the	DET
iajs-3493	98	19	controls	control	NOUN
iajs-3493	98	20	.	.	PUNCT
iajs-3493	99	1	however	however	ADV
iajs-3493	99	2	,	,	PUNCT
iajs-3493	99	3	these	these	DET
iajs-3493	99	4	findings	finding	NOUN
iajs-3493	99	5	disagree	disagree	VERB
iajs-3493	99	6	with	with	ADP
iajs-3493	99	7	[	[	X
iajs-3493	99	8	24	24	NUM
iajs-3493	99	9	]	]	PUNCT
iajs-3493	99	10	results	result	NOUN
iajs-3493	99	11	that	that	PRON
iajs-3493	99	12	showed	show	VERB
iajs-3493	99	13	the	the	DET
iajs-3493	99	14	neutrophil	neutrophil	NOUN
iajs-3493	99	15	-	-	PUNCT
iajs-3493	99	16	to	to	ADP
iajs-3493	99	17	-	-	PUNCT
iajs-3493	99	18	lymphocyte	lymphocyte	NOUN
iajs-3493	99	19	ratio	ratio	NOUN
iajs-3493	99	20	(	(	PUNCT
iajs-3493	99	21	nlr	nlr	PROPN
iajs-3493	99	22	)	)	PUNCT
iajs-3493	99	23	was	be	AUX
iajs-3493	99	24	significantly	significantly	ADV
iajs-3493	99	25	increased	increase	VERB
iajs-3493	99	26	in	in	ADP
iajs-3493	99	27	ra	ra	PROPN
iajs-3493	99	28	patients	patient	NOUN
iajs-3493	99	29	,	,	PUNCT
iajs-3493	99	30	and	and	CCONJ
iajs-3493	99	31	no	no	DET
iajs-3493	99	32	significant	significant	ADJ
iajs-3493	99	33	difference	difference	NOUN
iajs-3493	99	34	was	be	AUX
iajs-3493	99	35	found	find	VERB
iajs-3493	99	36	between	between	ADP
iajs-3493	99	37	male	male	ADJ
iajs-3493	99	38	and	and	CCONJ
iajs-3493	99	39	female	female	ADJ
iajs-3493	99	40	ra	ra	PROPN
iajs-3493	99	41	patients	patient	NOUN
iajs-3493	99	42	with	with	ADP
iajs-3493	99	43	ihjpas	ihjpas	PROPN
iajs-3493	99	44	.	.	PUNCT
iajs-3493	100	1	2024	2024	NUM
iajs-3493	100	2	,	,	PUNCT
iajs-3493	100	3	37(4	37(4	NOUN
iajs-3493	100	4	)	)	PUNCT
iajs-3493	100	5	49	49	NUM
iajs-3493	100	6	regard	regard	NOUN
iajs-3493	100	7	to	to	ADP
iajs-3493	100	8	the	the	DET
iajs-3493	100	9	nlr	nlr	PROPN
iajs-3493	100	10	ratio	ratio	NOUN
iajs-3493	100	11	.	.	PUNCT
iajs-3493	101	1	measures	measure	NOUN
iajs-3493	101	2	of	of	ADP
iajs-3493	101	3	anemia	anemia	NOUN
iajs-3493	101	4	and	and	CCONJ
iajs-3493	101	5	proinflammatory	proinflammatory	ADJ
iajs-3493	101	6	cytokines	cytokine	NOUN
iajs-3493	101	7	in	in	ADP
iajs-3493	101	8	ra	ra	PROPN
iajs-3493	101	9	patients	patient	NOUN
iajs-3493	101	10	are	be	AUX
iajs-3493	101	11	correlated	correlate	VERB
iajs-3493	101	12	.	.	PUNCT
iajs-3493	102	1	the	the	DET
iajs-3493	102	2	overall	overall	ADJ
iajs-3493	102	3	levels	level	NOUN
iajs-3493	102	4	of	of	ADP
iajs-3493	102	5	hemoglobin	hemoglobin	NOUN
iajs-3493	102	6	were	be	AUX
iajs-3493	102	7	inversely	inversely	ADV
iajs-3493	102	8	correlated	correlate	VERB
iajs-3493	102	9	with	with	ADP
iajs-3493	102	10	the	the	DET
iajs-3493	102	11	levels	level	NOUN
iajs-3493	102	12	of	of	ADP
iajs-3493	102	13	some	some	DET
iajs-3493	102	14	interleukins	interleukin	NOUN
iajs-3493	102	15	,	,	PUNCT
iajs-3493	102	16	such	such	ADJ
iajs-3493	102	17	as	as	ADP
iajs-3493	102	18	il-6	il-6	PRON
iajs-3493	102	19	.	.	PUNCT
iajs-3493	103	1	this	this	DET
iajs-3493	103	2	study	study	NOUN
iajs-3493	103	3	shows	show	VERB
iajs-3493	103	4	hgb	hgb	PROPN
iajs-3493	103	5	levels	level	NOUN
iajs-3493	103	6	were	be	AUX
iajs-3493	103	7	significantly	significantly	ADV
iajs-3493	103	8	lower	low	ADJ
iajs-3493	103	9	in	in	ADP
iajs-3493	103	10	ra	ra	PROPN
iajs-3493	103	11	patients	patient	NOUN
iajs-3493	103	12	than	than	ADP
iajs-3493	103	13	in	in	ADP
iajs-3493	103	14	healthy	healthy	ADJ
iajs-3493	103	15	controls	control	NOUN
iajs-3493	103	16	.	.	PUNCT
iajs-3493	104	1	the	the	DET
iajs-3493	104	2	ra	ra	PROPN
iajs-3493	104	3	disease	disease	NOUN
iajs-3493	104	4	is	be	AUX
iajs-3493	104	5	common	common	ADJ
iajs-3493	104	6	and	and	CCONJ
iajs-3493	104	7	frequently	frequently	ADV
iajs-3493	104	8	involves	involve	VERB
iajs-3493	104	9	anemia	anemia	NOUN
iajs-3493	104	10	.	.	PUNCT
iajs-3493	105	1	however	however	ADV
iajs-3493	105	2	,	,	PUNCT
iajs-3493	105	3	a	a	DET
iajs-3493	105	4	recent	recent	ADJ
iajs-3493	105	5	review	review	NOUN
iajs-3493	105	6	suggested	suggest	VERB
iajs-3493	105	7	that	that	SCONJ
iajs-3493	105	8	regardless	regardless	ADV
iajs-3493	105	9	of	of	ADP
iajs-3493	105	10	the	the	DET
iajs-3493	105	11	underlying	underlying	ADJ
iajs-3493	105	12	illness	illness	NOUN
iajs-3493	105	13	process	process	NOUN
iajs-3493	105	14	that	that	PRON
iajs-3493	105	15	causes	cause	VERB
iajs-3493	105	16	the	the	DET
iajs-3493	105	17	anemia	anemia	NOUN
iajs-3493	105	18	,	,	PUNCT
iajs-3493	105	19	untreated	untreated	ADJ
iajs-3493	105	20	anemia	anemia	NOUN
iajs-3493	105	21	is	be	AUX
iajs-3493	105	22	possible	possible	ADJ
iajs-3493	105	23	to	to	PART
iajs-3493	105	24	have	have	VERB
iajs-3493	105	25	severe	severe	ADJ
iajs-3493	105	26	clinical	clinical	ADJ
iajs-3493	105	27	results	result	NOUN
iajs-3493	105	28	practically	practically	ADV
iajs-3493	105	29	in	in	ADP
iajs-3493	105	30	ra	ra	PROPN
iajs-3493	105	31	disease	disease	NOUN
iajs-3493	106	1	[	[	X
iajs-3493	106	2	25	25	NUM
iajs-3493	106	3	-	-	SYM
iajs-3493	106	4	27	27	NUM
iajs-3493	106	5	]	]	PUNCT
iajs-3493	106	6	.	.	PUNCT
iajs-3493	107	1	this	this	DET
iajs-3493	107	2	study	study	NOUN
iajs-3493	107	3	indicated	indicate	VERB
iajs-3493	107	4	that	that	SCONJ
iajs-3493	107	5	levels	level	NOUN
iajs-3493	107	6	of	of	ADP
iajs-3493	107	7	esr	esr	PROPN
iajs-3493	107	8	,	,	PUNCT
iajs-3493	107	9	crp	crp	PROPN
iajs-3493	107	10	,	,	PUNCT
iajs-3493	107	11	and	and	CCONJ
iajs-3493	107	12	anti	anti	NOUN
iajs-3493	107	13	-	-	ADJ
iajs-3493	107	14	ccp	ccp	PROPN
iajs-3493	107	15	were	be	AUX
iajs-3493	107	16	significantly	significantly	ADV
iajs-3493	107	17	higher	high	ADJ
iajs-3493	107	18	in	in	ADP
iajs-3493	107	19	ra	ra	PROPN
iajs-3493	107	20	patients	patient	NOUN
iajs-3493	107	21	than	than	ADP
iajs-3493	107	22	in	in	ADP
iajs-3493	107	23	the	the	DET
iajs-3493	107	24	control	control	NOUN
iajs-3493	107	25	group	group	NOUN
iajs-3493	107	26	.	.	PUNCT
iajs-3493	108	1	many	many	ADJ
iajs-3493	108	2	studies	study	NOUN
iajs-3493	108	3	have	have	AUX
iajs-3493	108	4	suggested	suggest	VERB
iajs-3493	108	5	that	that	SCONJ
iajs-3493	108	6	crp	crp	PROPN
iajs-3493	108	7	and	and	CCONJ
iajs-3493	108	8	esr	esr	PROPN
iajs-3493	108	9	are	be	AUX
iajs-3493	108	10	considered	consider	VERB
iajs-3493	108	11	clear	clear	ADJ
iajs-3493	108	12	markers	marker	NOUN
iajs-3493	108	13	for	for	ADP
iajs-3493	108	14	ra	ra	PROPN
iajs-3493	108	15	.	.	PUNCT
iajs-3493	109	1	however	however	ADV
iajs-3493	109	2	,	,	PUNCT
iajs-3493	109	3	concerning	concern	VERB
iajs-3493	109	4	the	the	DET
iajs-3493	109	5	relationship	relationship	NOUN
iajs-3493	109	6	between	between	ADP
iajs-3493	109	7	ra	ra	PROPN
iajs-3493	109	8	and	and	CCONJ
iajs-3493	109	9	crp	crp	PROPN
iajs-3493	109	10	concentrations	concentration	NOUN
iajs-3493	109	11	,	,	PUNCT
iajs-3493	109	12	contradictory	contradictory	ADJ
iajs-3493	109	13	findings	finding	NOUN
iajs-3493	109	14	have	have	AUX
iajs-3493	109	15	been	be	AUX
iajs-3493	109	16	presented	present	VERB
iajs-3493	109	17	.	.	PUNCT
iajs-3493	110	1	the	the	DET
iajs-3493	110	2	disparity	disparity	NOUN
iajs-3493	110	3	might	might	AUX
iajs-3493	110	4	be	be	AUX
iajs-3493	110	5	made	make	VERB
iajs-3493	110	6	sense	sense	NOUN
iajs-3493	110	7	of	of	ADP
iajs-3493	110	8	by	by	ADP
iajs-3493	110	9	the	the	DET
iajs-3493	110	10	likelihood	likelihood	NOUN
iajs-3493	110	11	that	that	SCONJ
iajs-3493	110	12	crp	crp	PROPN
iajs-3493	110	13	is	be	AUX
iajs-3493	110	14	a	a	DET
iajs-3493	110	15	great	great	ADJ
iajs-3493	110	16	-	-	PUNCT
iajs-3493	110	17	stage	stage	NOUN
iajs-3493	110	18	protein	protein	NOUN
iajs-3493	110	19	in	in	ADP
iajs-3493	110	20	the	the	DET
iajs-3493	110	21	liver	liver	NOUN
iajs-3493	110	22	that	that	PRON
iajs-3493	110	23	is	be	AUX
iajs-3493	110	24	extremely	extremely	ADV
iajs-3493	110	25	delicate	delicate	ADJ
iajs-3493	110	26	to	to	ADP
iajs-3493	110	27	momentary	momentary	ADJ
iajs-3493	110	28	changes	change	NOUN
iajs-3493	110	29	in	in	ADP
iajs-3493	110	30	aggravation	aggravation	NOUN
iajs-3493	110	31	.	.	PUNCT
iajs-3493	111	1	crp	crp	PROPN
iajs-3493	111	2	concentrations	concentration	NOUN
iajs-3493	111	3	suggest	suggest	VERB
iajs-3493	111	4	they	they	PRON
iajs-3493	111	5	may	may	AUX
iajs-3493	111	6	not	not	PART
iajs-3493	111	7	rise	rise	VERB
iajs-3493	111	8	in	in	ADP
iajs-3493	111	9	ra	ra	PROPN
iajs-3493	111	10	patients	patient	NOUN
iajs-3493	111	11	through	through	ADP
iajs-3493	111	12	chronic	chronic	ADJ
iajs-3493	111	13	,	,	PUNCT
iajs-3493	111	14	long	long	ADJ
iajs-3493	111	15	-	-	PUNCT
iajs-3493	111	16	term	term	NOUN
iajs-3493	111	17	inflammation	inflammation	NOUN
iajs-3493	111	18	.	.	PUNCT
iajs-3493	112	1	the	the	DET
iajs-3493	112	2	level	level	NOUN
iajs-3493	112	3	of	of	ADP
iajs-3493	112	4	esr	esr	NOUN
iajs-3493	112	5	,	,	PUNCT
iajs-3493	112	6	on	on	ADP
iajs-3493	112	7	the	the	DET
iajs-3493	112	8	other	other	ADJ
iajs-3493	112	9	hand	hand	NOUN
iajs-3493	112	10	,	,	PUNCT
iajs-3493	112	11	is	be	AUX
iajs-3493	112	12	an	an	DET
iajs-3493	112	13	indicator	indicator	NOUN
iajs-3493	112	14	of	of	ADP
iajs-3493	112	15	acute	acute	ADJ
iajs-3493	112	16	-	-	PUNCT
iajs-3493	112	17	phase	phase	NOUN
iajs-3493	112	18	protein	protein	NOUN
iajs-3493	112	19	and	and	CCONJ
iajs-3493	112	20	is	be	AUX
iajs-3493	112	21	indirect	indirect	ADJ
iajs-3493	112	22	and	and	CCONJ
iajs-3493	112	23	slowly	slowly	ADV
iajs-3493	112	24	responds	respond	VERB
iajs-3493	112	25	to	to	PART
iajs-3493	112	26	stimulation	stimulation	VERB
iajs-3493	112	27	.	.	PUNCT
iajs-3493	113	1	it	it	PRON
iajs-3493	113	2	is	be	AUX
iajs-3493	113	3	also	also	ADV
iajs-3493	113	4	sensitive	sensitive	ADJ
iajs-3493	113	5	to	to	ADP
iajs-3493	113	6	nonacute	nonacute	ADJ
iajs-3493	113	7	-	-	PUNCT
iajs-3493	113	8	phase	phase	NOUN
iajs-3493	113	9	proteins	protein	NOUN
iajs-3493	113	10	such	such	ADJ
iajs-3493	113	11	as	as	ADP
iajs-3493	113	12	rheumatoid	rheumatoid	NOUN
iajs-3493	113	13	factor	factor	NOUN
iajs-3493	113	14	and	and	CCONJ
iajs-3493	113	15	may	may	AUX
iajs-3493	113	16	be	be	AUX
iajs-3493	113	17	an	an	DET
iajs-3493	113	18	indicator	indicator	NOUN
iajs-3493	113	19	better	well	ADJ
iajs-3493	113	20	for	for	ADP
iajs-3493	113	21	the	the	DET
iajs-3493	113	22	assessment	assessment	NOUN
iajs-3493	113	23	of	of	ADP
iajs-3493	113	24	subclinical	subclinical	ADJ
iajs-3493	113	25	inflammation	inflammation	NOUN
iajs-3493	113	26	than	than	ADP
iajs-3493	113	27	crp	crp	PROPN
iajs-3493	114	1	[	[	X
iajs-3493	114	2	28	28	NUM
iajs-3493	114	3	,	,	PUNCT
iajs-3493	114	4	29	29	NUM
iajs-3493	114	5	]	]	PUNCT
iajs-3493	114	6	.	.	PUNCT
iajs-3493	115	1	in	in	ADP
iajs-3493	115	2	addition	addition	NOUN
iajs-3493	115	3	,	,	PUNCT
iajs-3493	115	4	it	it	PRON
iajs-3493	115	5	suggests	suggest	VERB
iajs-3493	115	6	that	that	SCONJ
iajs-3493	115	7	a	a	DET
iajs-3493	115	8	healthy	healthy	ADJ
iajs-3493	115	9	individual	individual	NOUN
iajs-3493	115	10	with	with	ADP
iajs-3493	115	11	a	a	DET
iajs-3493	115	12	positive	positive	ADJ
iajs-3493	115	13	anti	anti	ADJ
iajs-3493	115	14	-	-	ADJ
iajs-3493	115	15	ccp	ccp	ADJ
iajs-3493	115	16	antibody	antibody	NOUN
iajs-3493	115	17	test	test	NOUN
iajs-3493	115	18	runs	run	VERB
iajs-3493	115	19	a	a	DET
iajs-3493	115	20	significant	significant	ADJ
iajs-3493	115	21	risk	risk	NOUN
iajs-3493	115	22	of	of	ADP
iajs-3493	115	23	developing	develop	VERB
iajs-3493	115	24	ra	ra	PROPN
iajs-3493	115	25	in	in	ADP
iajs-3493	115	26	the	the	DET
iajs-3493	115	27	future	future	NOUN
iajs-3493	116	1	[	[	X
iajs-3493	116	2	30,31	30,31	PROPN
iajs-3493	116	3	]	]	X
iajs-3493	116	4	.	.	PUNCT
iajs-3493	117	1	5	5	X
iajs-3493	117	2	.	.	X
iajs-3493	117	3	conclusions	conclusion	NOUN
iajs-3493	117	4	these	these	DET
iajs-3493	117	5	findings	finding	NOUN
iajs-3493	117	6	suggest	suggest	VERB
iajs-3493	117	7	that	that	SCONJ
iajs-3493	117	8	it	it	PRON
iajs-3493	117	9	is	be	AUX
iajs-3493	117	10	possible	possible	ADJ
iajs-3493	117	11	to	to	PART
iajs-3493	117	12	use	use	VERB
iajs-3493	117	13	il-3	il-3	PRON
iajs-3493	117	14	and	and	CCONJ
iajs-3493	117	15	il-5	il-5	NOUN
iajs-3493	117	16	as	as	ADP
iajs-3493	117	17	biomarkers	biomarker	NOUN
iajs-3493	117	18	for	for	ADP
iajs-3493	117	19	ra	ra	NOUN
iajs-3493	117	20	diagnosis	diagnosis	NOUN
iajs-3493	117	21	.	.	PUNCT
iajs-3493	118	1	conflict	conflict	NOUN
iajs-3493	118	2	of	of	ADP
iajs-3493	118	3	interest	interest	NOUN
iajs-3493	118	4	there	there	PRON
iajs-3493	118	5	is	be	VERB
iajs-3493	118	6	no	no	DET
iajs-3493	118	7	conflict	conflict	NOUN
iajs-3493	118	8	of	of	ADP
iajs-3493	118	9	interest	interest	NOUN
iajs-3493	118	10	.	.	PUNCT
iajs-3493	119	1	funding	funding	NOUN
iajs-3493	119	2	there	there	PRON
iajs-3493	119	3	is	be	VERB
iajs-3493	119	4	no	no	DET
iajs-3493	119	5	funding	funding	NOUN
iajs-3493	119	6	for	for	ADP
iajs-3493	119	7	the	the	DET
iajs-3493	119	8	article	article	NOUN
iajs-3493	119	9	.	.	PUNCT
iajs-3493	120	1	ethical	ethical	ADJ
iajs-3493	120	2	clearance	clearance	NOUN
iajs-3493	120	3	this	this	DET
iajs-3493	120	4	study	study	NOUN
iajs-3493	120	5	was	be	AUX
iajs-3493	120	6	authorized	authorize	VERB
iajs-3493	120	7	by	by	ADP
iajs-3493	120	8	the	the	DET
iajs-3493	120	9	department	department	PROPN
iajs-3493	120	10	of	of	ADP
iajs-3493	120	11	biology	biology	NOUN
iajs-3493	120	12	,	,	PUNCT
iajs-3493	120	13	college	college	NOUN
iajs-3493	120	14	of	of	ADP
iajs-3493	120	15	science	science	NOUN
iajs-3493	120	16	,	,	PUNCT
iajs-3493	120	17	university	university	NOUN
iajs-3493	120	18	of	of	ADP
iajs-3493	120	19	baghdad	baghdad	PROPN
iajs-3493	120	20	's	's	PART
iajs-3493	120	21	ethical	ethical	PROPN
iajs-3493	120	22	committee	committee	NOUN
iajs-3493	120	23	(	(	PUNCT
iajs-3493	120	24	ref	ref	NOUN
iajs-3493	120	25	.	.	PUNCT
iajs-3493	120	26	:	:	PUNCT
iajs-3493	121	1	csec/0922/0111	csec/0922/0111	PROPN
iajs-3493	121	2	,	,	PUNCT
iajs-3493	121	3	september	september	PROPN
iajs-3493	121	4	29	29	NUM
iajs-3493	121	5	,	,	PUNCT
iajs-3493	121	6	2022	2022	NUM
iajs-3493	121	7	)	)	PUNCT
iajs-3493	121	8	.	.	PUNCT
iajs-3493	122	1	this	this	DET
iajs-3493	122	2	study	study	NOUN
iajs-3493	122	3	was	be	AUX
iajs-3493	122	4	guided	guide	VERB
iajs-3493	122	5	by	by	ADP
iajs-3493	122	6	the	the	DET
iajs-3493	122	7	declaration	declaration	NOUN
iajs-3493	122	8	of	of	ADP
iajs-3493	122	9	helsinki	helsinki	PROPN
iajs-3493	122	10	,	,	PUNCT
iajs-3493	122	11	the	the	DET
iajs-3493	122	12	code	code	NOUN
iajs-3493	122	13	of	of	ADP
iajs-3493	122	14	ethical	ethical	ADJ
iajs-3493	122	15	principles	principle	NOUN
iajs-3493	122	16	for	for	ADP
iajs-3493	122	17	medical	medical	ADJ
iajs-3493	122	18	studies	study	NOUN
iajs-3493	122	19	using	use	VERB
iajs-3493	122	20	human	human	ADJ
iajs-3493	122	21	subjects	subject	NOUN
iajs-3493	122	22	.	.	PUNCT
iajs-3493	123	1	references	reference	NOUN
iajs-3493	123	2	1	1	NUM
iajs-3493	123	3	.	.	X
iajs-3493	124	1	wang	wang	PROPN
iajs-3493	124	2	,	,	PUNCT
iajs-3493	124	3	x.	x.	PROPN
iajs-3493	124	4	;	;	PUNCT
iajs-3493	124	5	fan	fan	PROPN
iajs-3493	124	6	,	,	PUNCT
iajs-3493	124	7	d.	d.	PROPN
iajs-3493	124	8	;	;	PUNCT
iajs-3493	124	9	cao	cao	PROPN
iajs-3493	124	10	,	,	PUNCT
iajs-3493	124	11	x.	x.	NOUN
iajs-3493	124	12	;	;	PUNCT
iajs-3493	124	13	ye	ye	PRON
iajs-3493	124	14	,	,	PUNCT
iajs-3493	124	15	q.	q.	PROPN
iajs-3493	124	16	;	;	PUNCT
iajs-3493	124	17	wang	wang	PROPN
iajs-3493	124	18	,	,	PUNCT
iajs-3493	124	19	q.	q.	PROPN
iajs-3493	124	20	;	;	PUNCT
iajs-3493	124	21	zhang	zhang	PROPN
iajs-3493	124	22	,	,	PUNCT
iajs-3493	124	23	m.	m.	NOUN
iajs-3493	124	24	;	;	PUNCT
iajs-3493	124	25	xiao	xiao	PROPN
iajs-3493	124	26	,	,	PUNCT
iajs-3493	124	27	c.	c.	PROPN
iajs-3493	124	28	the	the	DET
iajs-3493	124	29	role	role	NOUN
iajs-3493	124	30	of	of	ADP
iajs-3493	124	31	reactive	reactive	ADJ
iajs-3493	124	32	oxygen	oxygen	NOUN
iajs-3493	124	33	species	specie	NOUN
iajs-3493	124	34	in	in	ADP
iajs-3493	124	35	the	the	DET
iajs-3493	124	36	rheumatoid	rheumatoid	NOUN
iajs-3493	124	37	arthritis	arthritis	NOUN
iajs-3493	124	38	-	-	PUNCT
iajs-3493	124	39	associated	associate	VERB
iajs-3493	124	40	synovial	synovial	ADJ
iajs-3493	124	41	microenvironment	microenvironment	NOUN
iajs-3493	124	42	.	.	PUNCT
iajs-3493	125	1	antioxidants	antioxidant	NOUN
iajs-3493	125	2	2022	2022	NUM
iajs-3493	125	3	,	,	PUNCT
iajs-3493	125	4	11	11	NUM
iajs-3493	125	5	,	,	PUNCT
iajs-3493	125	6	1153	1153	NUM
iajs-3493	125	7	.	.	PUNCT
iajs-3493	126	1	https://doi.org/10.3390/antiox11061153	https://doi.org/10.3390/antiox11061153	NOUN
iajs-3493	126	2	.	.	PUNCT
iajs-3493	127	1	2	2	X
iajs-3493	127	2	.	.	X
iajs-3493	127	3	farhat	farhat	PROPN
iajs-3493	127	4	,	,	PUNCT
iajs-3493	127	5	h.	h.	PROPN
iajs-3493	127	6	;	;	PUNCT
iajs-3493	127	7	irfan	irfan	PROPN
iajs-3493	127	8	,	,	PUNCT
iajs-3493	127	9	h.	h.	PROPN
iajs-3493	127	10	;	;	PUNCT
iajs-3493	127	11	muthiah	muthiah	PROPN
iajs-3493	127	12	,	,	PUNCT
iajs-3493	127	13	k.	k.	PROPN
iajs-3493	127	14	;	;	PUNCT
iajs-3493	127	15	pallipamu	pallipamu	VERB
iajs-3493	127	16	,	,	PUNCT
iajs-3493	127	17	n.	n.	NOUN
iajs-3493	127	18	;	;	PUNCT
iajs-3493	127	19	taheri	taheri	NOUN
iajs-3493	127	20	,	,	PUNCT
iajs-3493	127	21	s.	s.	PROPN
iajs-3493	127	22	;	;	PUNCT
iajs-3493	128	1	thiagaraj	thiagaraj	PROPN
iajs-3493	128	2	,	,	PUNCT
iajs-3493	128	3	s.s	s.s	PROPN
iajs-3493	128	4	.	.	PROPN
iajs-3493	128	5	;	;	PUNCT
iajs-3493	128	6	shukla	shukla	PROPN
iajs-3493	128	7	,	,	PUNCT
iajs-3493	128	8	t.s	t.s	PROPN
iajs-3493	128	9	.	.	PROPN
iajs-3493	128	10	;	;	PUNCT
iajs-3493	128	11	gutlapalli	gutlapalli	PROPN
iajs-3493	128	12	,	,	PUNCT
iajs-3493	128	13	s.d	s.d	PROPN
iajs-3493	128	14	.	.	PROPN
iajs-3493	128	15	;	;	PUNCT
iajs-3493	128	16	giva	giva	PROPN
iajs-3493	128	17	,	,	PUNCT
iajs-3493	128	18	s.	s.	PROPN
iajs-3493	128	19	;	;	PUNCT
iajs-3493	128	20	penumetcha	penumetcha	NOUN
iajs-3493	128	21	,	,	PUNCT
iajs-3493	128	22	s.s	s.s	PROPN
iajs-3493	128	23	.	.	PROPN
iajs-3493	128	24	increased	increase	VERB
iajs-3493	128	25	risk	risk	NOUN
iajs-3493	128	26	of	of	ADP
iajs-3493	128	27	cardiovascular	cardiovascular	ADJ
iajs-3493	128	28	diseases	disease	NOUN
iajs-3493	128	29	in	in	ADP
iajs-3493	128	30	rheumatoid	rheumatoid	NOUN
iajs-3493	128	31	arthritis	arthritis	NOUN
iajs-3493	128	32	:	:	PUNCT
iajs-3493	128	33	a	a	DET
iajs-3493	128	34	systematic	systematic	ADJ
iajs-3493	128	35	review	review	NOUN
iajs-3493	128	36	.	.	PUNCT
iajs-3493	129	1	cureus	cureus	PROPN
iajs-3493	129	2	2022	2022	NUM
iajs-3493	129	3	,	,	PUNCT
iajs-3493	129	4	14(12	14(12	NUM
iajs-3493	129	5	)	)	PUNCT
iajs-3493	129	6	,	,	PUNCT
iajs-3493	129	7	e32308	e32308	PROPN
iajs-3493	129	8	.	.	PUNCT
iajs-3493	130	1	https://doi.org/10.7759/cureus.32308	https://doi.org/10.7759/cureus.32308	NOUN
iajs-3493	130	2	.	.	PUNCT
iajs-3493	131	1	3	3	X
iajs-3493	131	2	.	.	X
iajs-3493	131	3	smith	smith	PROPN
iajs-3493	131	4	,	,	PUNCT
iajs-3493	131	5	m.h	m.h	PROPN
iajs-3493	131	6	.	.	PROPN
iajs-3493	131	7	and	and	CCONJ
iajs-3493	131	8	berman	berman	PROPN
iajs-3493	131	9	,	,	PUNCT
iajs-3493	131	10	j.r	j.r	PROPN
iajs-3493	131	11	.	.	PROPN
iajs-3493	132	1	what	what	PRON
iajs-3493	132	2	is	be	AUX
iajs-3493	132	3	rheumatoid	rheumatoid	VERB
iajs-3493	132	4	arthritis	arthritis	NOUN
iajs-3493	132	5	?	?	PUNCT
iajs-3493	133	1	jama	jama	PROPN
iajs-3493	133	2	2022	2022	NUM
iajs-3493	133	3	,	,	PUNCT
iajs-3493	133	4	327	327	NUM
iajs-3493	133	5	,	,	PUNCT
iajs-3493	133	6	11941194	11941194	NUM
iajs-3493	133	7	https://doi.org/10.1001/jama.2022.0786	https://doi.org/10.1001/jama.2022.0786	PROPN
iajs-3493	133	8	.	.	PROPN
iajs-3493	133	9	4	4	NUM
iajs-3493	133	10	.	.	X
iajs-3493	133	11	fang	fang	PROPN
iajs-3493	133	12	,	,	PUNCT
iajs-3493	133	13	q.	q.	PROPN
iajs-3493	133	14	;	;	PUNCT
iajs-3493	133	15	zhou	zhou	PROPN
iajs-3493	133	16	,	,	PUNCT
iajs-3493	133	17	c.	c.	PROPN
iajs-3493	133	18	;	;	PUNCT
iajs-3493	133	19	nandakumar	nandakumar	PROPN
iajs-3493	133	20	,	,	PUNCT
iajs-3493	133	21	k.s	k.s	PROPN
iajs-3493	133	22	.	.	PROPN
iajs-3493	133	23	molecular	molecular	ADJ
iajs-3493	133	24	and	and	CCONJ
iajs-3493	133	25	cellular	cellular	ADJ
iajs-3493	133	26	pathways	pathway	NOUN
iajs-3493	133	27	contributing	contribute	VERB
iajs-3493	133	28	to	to	ADP
iajs-3493	133	29	joint	joint	ADJ
iajs-3493	133	30	damage	damage	NOUN
iajs-3493	133	31	in	in	ADP
iajs-3493	133	32	rheumatoid	rheumatoid	NOUN
iajs-3493	133	33	arthritis	arthritis	NOUN
iajs-3493	133	34	.	.	PUNCT
iajs-3493	134	1	mediators	mediator	NOUN
iajs-3493	134	2	of	of	ADP
iajs-3493	134	3	inflammation	inflammation	NOUN
iajs-3493	134	4	2020	2020	NUM
iajs-3493	134	5	,	,	PUNCT
iajs-3493	134	6	3830212	3830212	NUM
iajs-3493	134	7	.	.	PUNCT
iajs-3493	135	1	https://doi.org/10.1155/2020/3830212	https://doi.org/10.1155/2020/3830212	PROPN
iajs-3493	135	2	.	.	PUNCT
iajs-3493	136	1	https://doi.org/10.7759/cureus.32308	https://doi.org/10.7759/cureus.32308	PROPN
iajs-3493	136	2	https://doi.org/10.1001/jama.2022.0786	https://doi.org/10.1001/jama.2022.0786	PROPN
iajs-3493	136	3	https://doi.org/10.1155/2020/3830212	https://doi.org/10.1155/2020/3830212	PROPN
iajs-3493	136	4	ihjpas	ihjpa	VERB
iajs-3493	136	5	.	.	PUNCT
iajs-3493	137	1	2024	2024	NUM
iajs-3493	137	2	,	,	PUNCT
iajs-3493	137	3	37(4	37(4	NOUN
iajs-3493	137	4	)	)	PUNCT
iajs-3493	137	5	50	50	NUM
iajs-3493	137	6	5	5	NUM
iajs-3493	137	7	.	.	PUNCT
iajs-3493	138	1	littlejohn	littlejohn	PROPN
iajs-3493	138	2	,	,	PUNCT
iajs-3493	138	3	e.a	e.a	PROPN
iajs-3493	138	4	.	.	PROPN
iajs-3493	138	5	;	;	PUNCT
iajs-3493	138	6	monrad	monrad	PROPN
iajs-3493	138	7	,	,	PUNCT
iajs-3493	138	8	s.u	s.u	PROPN
iajs-3493	138	9	.	.	PROPN
iajs-3493	138	10	early	early	ADJ
iajs-3493	138	11	diagnosis	diagnosis	NOUN
iajs-3493	138	12	and	and	CCONJ
iajs-3493	138	13	treatment	treatment	NOUN
iajs-3493	138	14	of	of	ADP
iajs-3493	138	15	rheumatoid	rheumatoid	NOUN
iajs-3493	138	16	arthritis	arthritis	NOUN
iajs-3493	138	17	.	.	PUNCT
iajs-3493	139	1	primary	primary	ADJ
iajs-3493	139	2	care	care	NOUN
iajs-3493	139	3	:	:	PUNCT
iajs-3493	139	4	clinics	clinic	NOUN
iajs-3493	139	5	in	in	ADP
iajs-3493	139	6	office	office	NOUN
iajs-3493	139	7	practice	practice	NOUN
iajs-3493	139	8	2018	2018	NUM
iajs-3493	139	9	,	,	PUNCT
iajs-3493	139	10	45	45	NUM
iajs-3493	139	11	,	,	PUNCT
iajs-3493	139	12	237	237	NUM
iajs-3493	139	13	-	-	SYM
iajs-3493	139	14	255	255	NUM
iajs-3493	139	15	.	.	PUNCT
iajs-3493	140	1	https://doi.org/10.1016/j.pop.2018.02.010	https://doi.org/10.1016/j.pop.2018.02.010	NOUN
iajs-3493	140	2	.	.	PROPN
iajs-3493	141	1	6	6	NUM
iajs-3493	141	2	.	.	X
iajs-3493	141	3	carpanen	carpanen	PROPN
iajs-3493	141	4	,	,	PUNCT
iajs-3493	141	5	d.	d.	PROPN
iajs-3493	141	6	;	;	PUNCT
iajs-3493	141	7	kedgley	kedgley	PROPN
iajs-3493	141	8	,	,	PUNCT
iajs-3493	141	9	a.e	a.e	PROPN
iajs-3493	141	10	.	.	PROPN
iajs-3493	141	11	;	;	PUNCT
iajs-3493	141	12	shah	shah	PROPN
iajs-3493	141	13	,	,	PUNCT
iajs-3493	141	14	d.s	d.s	PROPN
iajs-3493	141	15	.	.	PROPN
iajs-3493	141	16	;	;	PUNCT
iajs-3493	141	17	edwards	edwards	PROPN
iajs-3493	141	18	,	,	PUNCT
iajs-3493	141	19	d.s	d.s	PROPN
iajs-3493	141	20	.	.	PROPN
iajs-3493	141	21	;	;	PUNCT
iajs-3493	141	22	plant	plant	NOUN
iajs-3493	141	23	,	,	PUNCT
iajs-3493	141	24	d.j	d.j	PROPN
iajs-3493	141	25	.	.	PROPN
iajs-3493	141	26	;	;	PUNCT
iajs-3493	141	27	masouros	masouros	PROPN
iajs-3493	141	28	,	,	PUNCT
iajs-3493	141	29	s.d	s.d	PROPN
iajs-3493	141	30	.	.	PROPN
iajs-3493	141	31	injury	injury	PROPN
iajs-3493	141	32	risk	risk	NOUN
iajs-3493	141	33	of	of	ADP
iajs-3493	141	34	interphalangeal	interphalangeal	ADJ
iajs-3493	141	35	and	and	CCONJ
iajs-3493	141	36	metacarpophalangeal	metacarpophalangeal	ADJ
iajs-3493	141	37	joints	joint	NOUN
iajs-3493	141	38	under	under	ADP
iajs-3493	141	39	impact	impact	NOUN
iajs-3493	141	40	loading	loading	NOUN
iajs-3493	141	41	.	.	PUNCT
iajs-3493	142	1	journal	journal	NOUN
iajs-3493	142	2	of	of	ADP
iajs-3493	142	3	the	the	DET
iajs-3493	142	4	mechanical	mechanical	ADJ
iajs-3493	142	5	behavior	behavior	NOUN
iajs-3493	142	6	of	of	ADP
iajs-3493	142	7	biomedical	biomedical	ADJ
iajs-3493	142	8	materials	material	NOUN
iajs-3493	142	9	2019	2019	NUM
iajs-3493	142	10	,	,	PUNCT
iajs-3493	142	11	97	97	NUM
iajs-3493	142	12	,	,	PUNCT
iajs-3493	142	13	306	306	NUM
iajs-3493	142	14	-	-	SYM
iajs-3493	142	15	311	311	NUM
iajs-3493	142	16	.	.	PUNCT
iajs-3493	143	1	https://doi.org/10.1016/j.jmbbm.2019.05.037	https://doi.org/10.1016/j.jmbbm.2019.05.037	PROPN
iajs-3493	143	2	.	.	PUNCT
iajs-3493	144	1	7	7	X
iajs-3493	144	2	.	.	X
iajs-3493	144	3	mo	mo	PROPN
iajs-3493	144	4	,	,	PUNCT
iajs-3493	144	5	y.-q	y.-q	PROPN
iajs-3493	144	6	.	.	PUNCT
iajs-3493	144	7	;	;	PUNCT
iajs-3493	144	8	yang	yang	PROPN
iajs-3493	144	9	,	,	PUNCT
iajs-3493	144	10	z.-h	z.-h	PROPN
iajs-3493	144	11	.	.	PUNCT
iajs-3493	144	12	;	;	PUNCT
iajs-3493	145	1	wang	wang	PROPN
iajs-3493	145	2	,	,	PUNCT
iajs-3493	145	3	j.-w	j.-w	PROPN
iajs-3493	145	4	.	.	PUNCT
iajs-3493	145	5	;	;	PUNCT
iajs-3493	145	6	li	li	PROPN
iajs-3493	145	7	,	,	PUNCT
iajs-3493	145	8	q.-h	q.-h	PROPN
iajs-3493	145	9	.	.	PUNCT
iajs-3493	145	10	;	;	PUNCT
iajs-3493	145	11	du	du	X
iajs-3493	145	12	,	,	PUNCT
iajs-3493	145	13	x.-y	x.-y	NOUN
iajs-3493	145	14	.	.	PUNCT
iajs-3493	145	15	;	;	PUNCT
iajs-3493	145	16	huizinga	huizinga	ADV
iajs-3493	145	17	,	,	PUNCT
iajs-3493	145	18	t.	t.	PROPN
iajs-3493	145	19	;	;	PUNCT
iajs-3493	145	20	matthijssen	matthijssen	PROPN
iajs-3493	145	21	,	,	PUNCT
iajs-3493	145	22	x.	x.	PROPN
iajs-3493	145	23	;	;	PUNCT
iajs-3493	145	24	shi	shi	PROPN
iajs-3493	145	25	,	,	PUNCT
iajs-3493	145	26	g.z	g.z	PROPN
iajs-3493	145	27	.	.	PROPN
iajs-3493	145	28	;	;	PUNCT
iajs-3493	145	29	shen	shen	PROPN
iajs-3493	145	30	,	,	PUNCT
iajs-3493	145	31	j.	j.	PROPN
iajs-3493	145	32	;	;	PUNCT
iajs-3493	145	33	dai	dai	PROPN
iajs-3493	145	34	,	,	PUNCT
iajs-3493	145	35	l.	l.	X
iajs-3493	145	36	the	the	DET
iajs-3493	145	37	value	value	NOUN
iajs-3493	145	38	of	of	ADP
iajs-3493	145	39	mri	mri	NOUN
iajs-3493	145	40	examination	examination	NOUN
iajs-3493	145	41	on	on	ADP
iajs-3493	145	42	bilateral	bilateral	ADJ
iajs-3493	145	43	hands	hand	NOUN
iajs-3493	145	44	including	include	VERB
iajs-3493	145	45	proximal	proximal	ADJ
iajs-3493	145	46	interphalangeal	interphalangeal	ADJ
iajs-3493	145	47	joints	joint	NOUN
iajs-3493	145	48	for	for	ADP
iajs-3493	145	49	disease	disease	NOUN
iajs-3493	145	50	assessment	assessment	NOUN
iajs-3493	145	51	in	in	ADP
iajs-3493	145	52	patients	patient	NOUN
iajs-3493	145	53	with	with	ADP
iajs-3493	145	54	early	early	ADJ
iajs-3493	145	55	rheumatoid	rheumatoid	NOUN
iajs-3493	145	56	arthritis	arthritis	NOUN
iajs-3493	145	57	:	:	PUNCT
iajs-3493	145	58	a	a	DET
iajs-3493	145	59	crosssectional	crosssectional	ADJ
iajs-3493	145	60	cohort	cohort	NOUN
iajs-3493	145	61	study	study	NOUN
iajs-3493	145	62	.	.	PUNCT
iajs-3493	146	1	arthritis	arthritis	NOUN
iajs-3493	146	2	research	research	PROPN
iajs-3493	146	3	&	&	CCONJ
iajs-3493	146	4	therapy	therapy	NOUN
iajs-3493	146	5	2019	2019	NUM
iajs-3493	146	6	,	,	PUNCT
iajs-3493	146	7	21	21	NUM
iajs-3493	146	8	,	,	PUNCT
iajs-3493	146	9	1	1	NUM
iajs-3493	146	10	-	-	SYM
iajs-3493	146	11	12	12	NUM
iajs-3493	146	12	.	.	PUNCT
iajs-3493	147	1	https://arthritisresearch.biomedcentral.com/articles/10.1186/s13075-019-2061-1	https://arthritisresearch.biomedcentral.com/articles/10.1186/s13075-019-2061-1	ADJ
iajs-3493	147	2	.	.	NOUN
iajs-3493	148	1	8	8	X
iajs-3493	148	2	.	.	X
iajs-3493	149	1	srivastava	srivastava	PROPN
iajs-3493	149	2	,	,	PUNCT
iajs-3493	149	3	r.k	r.k	PROPN
iajs-3493	149	4	.	.	PROPN
iajs-3493	149	5	;	;	PUNCT
iajs-3493	149	6	tomar	tomar	ADJ
iajs-3493	149	7	,	,	PUNCT
iajs-3493	149	8	g.b	g.b	PROPN
iajs-3493	149	9	.	.	PROPN
iajs-3493	149	10	;	;	PUNCT
iajs-3493	149	11	barhanpurkar	barhanpurkar	PROPN
iajs-3493	149	12	,	,	PUNCT
iajs-3493	149	13	a.p	a.p	PROPN
iajs-3493	149	14	.	.	PROPN
iajs-3493	149	15	il-3	il-3	X
iajs-3493	149	16	attenuates	attenuate	VERB
iajs-3493	149	17	collagen	collagen	NOUN
iajs-3493	149	18	-	-	PUNCT
iajs-3493	149	19	induced	induce	VERB
iajs-3493	149	20	arthritis	arthritis	NOUN
iajs-3493	149	21	by	by	ADP
iajs-3493	149	22	modulating	modulate	VERB
iajs-3493	149	23	the	the	DET
iajs-3493	149	24	development	development	NOUN
iajs-3493	149	25	of	of	ADP
iajs-3493	149	26	foxp3	foxp3	NOUN
iajs-3493	149	27	+	+	X
iajs-3493	149	28	regulatory	regulatory	ADJ
iajs-3493	149	29	t	t	NOUN
iajs-3493	149	30	cells	cell	NOUN
iajs-3493	149	31	.	.	PUNCT
iajs-3493	150	1	journal	journal	NOUN
iajs-3493	150	2	of	of	ADP
iajs-3493	150	3	immunology	immunology	NOUN
iajs-3493	150	4	2011	2011	NUM
iajs-3493	150	5	,	,	PUNCT
iajs-3493	150	6	186(4	186(4	NUM
iajs-3493	150	7	)	)	PUNCT
iajs-3493	150	8	,	,	PUNCT
iajs-3493	150	9	2262	2262	NUM
iajs-3493	150	10	-	-	SYM
iajs-3493	150	11	2272	2272	NUM
iajs-3493	150	12	.	.	PUNCT
iajs-3493	151	1	https://doi.org/10.4049/jimmunol.1002691	https://doi.org/10.4049/jimmunol.1002691	NOUN
iajs-3493	151	2	.	.	PUNCT
iajs-3493	152	1	9	9	X
iajs-3493	152	2	.	.	X
iajs-3493	152	3	ihle	ihle	PROPN
iajs-3493	152	4	,	,	PUNCT
iajs-3493	152	5	j.n	j.n	PROPN
iajs-3493	152	6	.	.	PROPN
iajs-3493	152	7	interleukin-3	interleukin-3	NUM
iajs-3493	152	8	and	and	CCONJ
iajs-3493	152	9	hematopoiesis	hematopoiesis	NOUN
iajs-3493	152	10	.	.	PUNCT
iajs-3493	153	1	chemical	chemical	ADJ
iajs-3493	153	2	immunology	immunology	NOUN
iajs-3493	153	3	1992	1992	NUM
iajs-3493	153	4	,	,	PUNCT
iajs-3493	153	5	51	51	NUM
iajs-3493	153	6	,	,	PUNCT
iajs-3493	153	7	65106	65106	NUM
iajs-3493	153	8	.	.	PUNCT
iajs-3493	154	1	https://doi.org/10.1159/000420755	https://doi.org/10.1159/000420755	X
iajs-3493	154	2	.	.	NOUN
iajs-3493	154	3	10	10	NUM
iajs-3493	154	4	.	.	X
iajs-3493	154	5	kawabata	kawabata	PROPN
iajs-3493	154	6	,	,	PUNCT
iajs-3493	154	7	h.	h.	PROPN
iajs-3493	154	8	;	;	PUNCT
iajs-3493	154	9	satoh	satoh	NOUN
iajs-3493	154	10	,	,	PUNCT
iajs-3493	154	11	m.	m.	NOUN
iajs-3493	154	12	;	;	PUNCT
iajs-3493	154	13	yatera	yatera	NOUN
iajs-3493	154	14	,	,	PUNCT
iajs-3493	154	15	k.	k.	PROPN
iajs-3493	154	16	development	development	PROPN
iajs-3493	154	17	of	of	ADP
iajs-3493	154	18	rheumatoid	rheumatoid	NOUN
iajs-3493	154	19	arthritis	arthritis	NOUN
iajs-3493	154	20	during	during	ADP
iajs-3493	154	21	anti	anti	ADJ
iajs-3493	154	22	-	-	ADJ
iajs-3493	154	23	interleukin5	interleukin5	ADJ
iajs-3493	154	24	therapy	therapy	NOUN
iajs-3493	154	25	in	in	ADP
iajs-3493	154	26	a	a	DET
iajs-3493	154	27	patient	patient	NOUN
iajs-3493	154	28	with	with	ADP
iajs-3493	154	29	refractory	refractory	NOUN
iajs-3493	154	30	chronic	chronic	ADJ
iajs-3493	154	31	eosinophilic	eosinophilic	ADJ
iajs-3493	154	32	pneumonia	pneumonia	NOUN
iajs-3493	154	33	.	.	PUNCT
iajs-3493	155	1	journal	journal	PROPN
iajs-3493	155	2	of	of	ADP
iajs-3493	155	3	asthma	asthma	PROPN
iajs-3493	155	4	allergy	allergy	PROPN
iajs-3493	155	5	2021	2021	NUM
iajs-3493	155	6	,	,	PUNCT
iajs-3493	155	7	14	14	NUM
iajs-3493	155	8	,	,	PUNCT
iajs-3493	155	9	1425	1425	NUM
iajs-3493	155	10	-	-	SYM
iajs-3493	155	11	1430	1430	NUM
iajs-3493	155	12	.	.	PUNCT
iajs-3493	156	1	https://doi.org/10.2147/jaa.s342993	https://doi.org/10.2147/jaa.s342993	X
iajs-3493	156	2	.	.	PUNCT
iajs-3493	157	1	11	11	NUM
iajs-3493	157	2	.	.	PUNCT
iajs-3493	158	1	hara	hara	PROPN
iajs-3493	158	2	,	,	PUNCT
iajs-3493	158	3	t.	t.	PROPN
iajs-3493	158	4	;	;	PUNCT
iajs-3493	158	5	miyajima	miyajima	PROPN
iajs-3493	158	6	,	,	PUNCT
iajs-3493	158	7	a.	a.	NOUN
iajs-3493	158	8	function	function	NOUN
iajs-3493	158	9	and	and	CCONJ
iajs-3493	158	10	signal	signal	ADJ
iajs-3493	158	11	transduction	transduction	NOUN
iajs-3493	158	12	mediated	mediate	VERB
iajs-3493	158	13	by	by	ADP
iajs-3493	158	14	the	the	DET
iajs-3493	158	15	interleukin	interleukin	NOUN
iajs-3493	158	16	receptor	receptor	NOUN
iajs-3493	158	17	system	system	NOUN
iajs-3493	158	18	in	in	ADP
iajs-3493	158	19	hematopoiesis	hematopoiesis	NOUN
iajs-3493	158	20	.	.	PUNCT
iajs-3493	159	1	stem	stem	NOUN
iajs-3493	159	2	cells	cell	NOUN
iajs-3493	159	3	1996	1996	NUM
iajs-3493	159	4	,	,	PUNCT
iajs-3493	159	5	14	14	NUM
iajs-3493	159	6	,	,	PUNCT
iajs-3493	159	7	605	605	NUM
iajs-3493	159	8	-	-	SYM
iajs-3493	159	9	618	618	NUM
iajs-3493	159	10	.	.	PUNCT
iajs-3493	160	1	https://doi.org/10.1002/stem.140605	https://doi.org/10.1002/stem.140605	NOUN
iajs-3493	160	2	.	.	PUNCT
iajs-3493	161	1	12	12	NUM
iajs-3493	161	2	.	.	X
iajs-3493	161	3	pelaia	pelaia	PROPN
iajs-3493	161	4	,	,	PUNCT
iajs-3493	161	5	c.	c.	PROPN
iajs-3493	161	6	;	;	PUNCT
iajs-3493	161	7	paoletti	paoletti	PROPN
iajs-3493	161	8	,	,	PUNCT
iajs-3493	161	9	g.	g.	PROPN
iajs-3493	161	10	;	;	PUNCT
iajs-3493	161	11	puggioni	puggioni	VERB
iajs-3493	161	12	,	,	PUNCT
iajs-3493	161	13	f.	f.	PROPN
iajs-3493	161	14	;	;	PUNCT
iajs-3493	161	15	racca	racca	PROPN
iajs-3493	161	16	,	,	PUNCT
iajs-3493	161	17	f.	f.	PROPN
iajs-3493	161	18	;	;	PUNCT
iajs-3493	161	19	pelaia	pelaia	PROPN
iajs-3493	161	20	,	,	PUNCT
iajs-3493	161	21	g.	g.	PROPN
iajs-3493	161	22	;	;	PUNCT
iajs-3493	161	23	canonica	canonica	PROPN
iajs-3493	161	24	,	,	PUNCT
iajs-3493	161	25	g.w	g.w	PROPN
iajs-3493	161	26	.	.	PROPN
iajs-3493	161	27	;	;	PUNCT
iajs-3493	161	28	heffler	heffler	NOUN
iajs-3493	161	29	,	,	PUNCT
iajs-3493	161	30	e.	e.	PROPN
iajs-3493	161	31	interleukin-5	interleukin-5	PROPN
iajs-3493	161	32	in	in	ADP
iajs-3493	161	33	the	the	DET
iajs-3493	161	34	pathophysiology	pathophysiology	NOUN
iajs-3493	161	35	of	of	ADP
iajs-3493	161	36	severe	severe	ADJ
iajs-3493	161	37	asthma	asthma	NOUN
iajs-3493	161	38	.	.	PUNCT
iajs-3493	162	1	frontiers	frontier	NOUN
iajs-3493	162	2	in	in	ADP
iajs-3493	162	3	physiology	physiology	NOUN
iajs-3493	162	4	2019	2019	NUM
iajs-3493	162	5	,	,	PUNCT
iajs-3493	162	6	10	10	NUM
iajs-3493	162	7	,	,	PUNCT
iajs-3493	162	8	1514	1514	NUM
iajs-3493	162	9	.	.	PUNCT
iajs-3493	163	1	https://doi.org/10.3389/fphys.2019.01514	https://doi.org/10.3389/fphys.2019.01514	NOUN
iajs-3493	163	2	.	.	PROPN
iajs-3493	163	3	13	13	NUM
iajs-3493	163	4	.	.	PUNCT
iajs-3493	164	1	diwan	diwan	PROPN
iajs-3493	164	2	,	,	PUNCT
iajs-3493	164	3	z.	z.	PROPN
iajs-3493	164	4	j.	j.	PROPN
iajs-3493	164	5	;	;	PUNCT
iajs-3493	164	6	al	al	PROPN
iajs-3493	164	7	-	-	PUNCT
iajs-3493	164	8	marsomy	marsomy	NOUN
iajs-3493	164	9	,	,	PUNCT
iajs-3493	164	10	w.a	w.a	PROPN
iajs-3493	164	11	.	.	PROPN
iajs-3493	164	12	evaluation	evaluation	NOUN
iajs-3493	164	13	of	of	ADP
iajs-3493	164	14	several	several	ADJ
iajs-3493	164	15	hematologic	hematologic	NOUN
iajs-3493	164	16	and	and	CCONJ
iajs-3493	164	17	serological	serological	ADJ
iajs-3493	164	18	parameters	parameter	NOUN
iajs-3493	164	19	in	in	ADP
iajs-3493	164	20	rheumatoid	rheumatoid	NOUN
iajs-3493	164	21	arthritis	arthritis	NOUN
iajs-3493	164	22	patients	patient	NOUN
iajs-3493	164	23	.	.	PUNCT
iajs-3493	165	1	ibn	ibn	PROPN
iajs-3493	165	2	al	al	PROPN
iajs-3493	165	3	-	-	PUNCT
iajs-3493	165	4	haitham	haitham	PROPN
iajs-3493	165	5	journal	journal	PROPN
iajs-3493	165	6	for	for	ADP
iajs-3493	165	7	pure	pure	ADJ
iajs-3493	165	8	and	and	CCONJ
iajs-3493	165	9	applied	applied	ADJ
iajs-3493	165	10	sciences	science	NOUN
iajs-3493	165	11	2024	2024	NUM
iajs-3493	165	12	,	,	PUNCT
iajs-3493	165	13	37(2	37(2	PRON
iajs-3493	165	14	)	)	PUNCT
iajs-3493	165	15	,	,	PUNCT
iajs-3493	165	16	129	129	NUM
iajs-3493	165	17	-	-	SYM
iajs-3493	165	18	135	135	NUM
iajs-3493	165	19	.	.	PUNCT
iajs-3493	166	1	https://doi.org/10.30526/37.2.3451	https://doi.org/10.30526/37.2.3451	NOUN
iajs-3493	166	2	.	.	PUNCT
iajs-3493	167	1	14	14	NUM
iajs-3493	167	2	.	.	X
iajs-3493	168	1	orr	orr	PROPN
iajs-3493	168	2	,	,	PUNCT
iajs-3493	168	3	c.k	c.k	PROPN
iajs-3493	168	4	.	.	PROPN
iajs-3493	168	5	;	;	PUNCT
iajs-3493	168	6	najm	najm	ADJ
iajs-3493	168	7	,	,	PUNCT
iajs-3493	168	8	a.	a.	NOUN
iajs-3493	168	9	;	;	PUNCT
iajs-3493	168	10	young	young	ADJ
iajs-3493	168	11	,	,	PUNCT
iajs-3493	168	12	f.	f.	PROPN
iajs-3493	168	13	;	;	PUNCT
iajs-3493	168	14	mcgarry	mcgarry	PROPN
iajs-3493	168	15	,	,	PUNCT
iajs-3493	168	16	t.	t.	PROPN
iajs-3493	168	17	;	;	PUNCT
iajs-3493	168	18	biniecka	biniecka	PROPN
iajs-3493	168	19	,	,	PUNCT
iajs-3493	168	20	m.	m.	NOUN
iajs-3493	168	21	;	;	PUNCT
iajs-3493	168	22	fearon	fearon	PROPN
iajs-3493	168	23	,	,	PUNCT
iajs-3493	168	24	u.	u.	PROPN
iajs-3493	168	25	;	;	PUNCT
iajs-3493	168	26	veale	veale	NOUN
iajs-3493	168	27	,	,	PUNCT
iajs-3493	168	28	d.j	d.j	PROPN
iajs-3493	168	29	.	.	PROPN
iajs-3493	168	30	the	the	DET
iajs-3493	168	31	utility	utility	NOUN
iajs-3493	168	32	and	and	CCONJ
iajs-3493	168	33	limitations	limitation	NOUN
iajs-3493	168	34	of	of	ADP
iajs-3493	168	35	crp	crp	PROPN
iajs-3493	168	36	,	,	PUNCT
iajs-3493	168	37	esr	esr	PROPN
iajs-3493	168	38	and	and	CCONJ
iajs-3493	168	39	das28	das28	PROPN
iajs-3493	168	40	-	-	PUNCT
iajs-3493	168	41	crp	crp	PROPN
iajs-3493	168	42	in	in	ADP
iajs-3493	168	43	appraising	appraise	VERB
iajs-3493	168	44	disease	disease	NOUN
iajs-3493	168	45	activity	activity	NOUN
iajs-3493	168	46	in	in	ADP
iajs-3493	168	47	rheumatoid	rheumatoid	NOUN
iajs-3493	168	48	arthritis	arthritis	NOUN
iajs-3493	168	49	.	.	PUNCT
iajs-3493	169	1	front	front	ADJ
iajs-3493	169	2	medical	medical	ADJ
iajs-3493	169	3	(	(	PUNCT
iajs-3493	169	4	lausanne	lausanne	PROPN
iajs-3493	169	5	)	)	PUNCT
iajs-3493	169	6	2018	2018	NUM
iajs-3493	169	7	,	,	PUNCT
iajs-3493	169	8	5	5	NUM
iajs-3493	169	9	,	,	PUNCT
iajs-3493	169	10	185	185	NUM
iajs-3493	169	11	.	.	PUNCT
iajs-3493	170	1	https://doi.org/10.3389/fmed.2018.00185	https://doi.org/10.3389/fmed.2018.00185	PROPN
iajs-3493	170	2	.	.	PROPN
iajs-3493	170	3	15	15	NUM
iajs-3493	170	4	.	.	PUNCT
iajs-3493	170	5	breda	breda	PROPN
iajs-3493	170	6	,	,	PUNCT
iajs-3493	170	7	l.	l.	PROPN
iajs-3493	170	8	;	;	PUNCT
iajs-3493	170	9	nozzi	nozzi	PROPN
iajs-3493	170	10	,	,	PUNCT
iajs-3493	170	11	m.	m.	NOUN
iajs-3493	170	12	;	;	PUNCT
iajs-3493	170	13	de	de	PROPN
iajs-3493	170	14	sanctis	sanctis	PROPN
iajs-3493	170	15	,	,	PUNCT
iajs-3493	170	16	s.	s.	PROPN
iajs-3493	170	17	;	;	PUNCT
iajs-3493	170	18	chiarelli	chiarelli	PROPN
iajs-3493	170	19	,	,	PUNCT
iajs-3493	170	20	f.	f.	PROPN
iajs-3493	170	21	laboratory	laboratory	PROPN
iajs-3493	170	22	tests	test	VERB
iajs-3493	170	23	in	in	ADP
iajs-3493	170	24	the	the	DET
iajs-3493	170	25	diagnosis	diagnosis	NOUN
iajs-3493	170	26	and	and	CCONJ
iajs-3493	170	27	follow	follow	VERB
iajs-3493	170	28	-	-	PUNCT
iajs-3493	170	29	up	up	NOUN
iajs-3493	170	30	of	of	ADP
iajs-3493	170	31	pediatric	pediatric	ADJ
iajs-3493	170	32	rheumatic	rheumatic	ADJ
iajs-3493	170	33	diseases	disease	NOUN
iajs-3493	170	34	:	:	PUNCT
iajs-3493	170	35	an	an	DET
iajs-3493	170	36	update	update	NOUN
iajs-3493	170	37	.	.	PUNCT
iajs-3493	171	1	in	in	ADP
iajs-3493	171	2	proceedings	proceeding	NOUN
iajs-3493	171	3	of	of	ADP
iajs-3493	171	4	the	the	DET
iajs-3493	171	5	seminars	seminar	NOUN
iajs-3493	171	6	in	in	ADP
iajs-3493	171	7	arthritis	arthritis	NOUN
iajs-3493	171	8	and	and	CCONJ
iajs-3493	171	9	rheumatism	rheumatism	NOUN
iajs-3493	171	10	,	,	PUNCT
iajs-3493	171	11	2010	2010	NUM
iajs-3493	171	12	,	,	PUNCT
iajs-3493	171	13	53	53	NUM
iajs-3493	171	14	-	-	SYM
iajs-3493	171	15	72	72	NUM
iajs-3493	171	16	.	.	PUNCT
iajs-3493	171	17	https://doi.org/10.1016/j.semarthrit.2008.12.001	https://doi.org/10.1016/j.semarthrit.2008.12.001	VERB
iajs-3493	171	18	.	.	PUNCT
iajs-3493	172	1	16	16	NUM
iajs-3493	172	2	.	.	PUNCT
iajs-3493	173	1	jonsson	jonsson	PROPN
iajs-3493	173	2	,	,	PUNCT
iajs-3493	173	3	m.k	m.k	PROPN
iajs-3493	173	4	.	.	PUNCT
iajs-3493	173	5	;	;	PUNCT
iajs-3493	173	6	sundlisæter	sundlisæter	NOUN
iajs-3493	173	7	,	,	PUNCT
iajs-3493	173	8	n.p	n.p	PROPN
iajs-3493	173	9	.	.	PROPN
iajs-3493	173	10	;	;	PUNCT
iajs-3493	173	11	nordal	nordal	NOUN
iajs-3493	173	12	,	,	PUNCT
iajs-3493	173	13	h.h	h.h	PROPN
iajs-3493	173	14	.	.	PROPN
iajs-3493	173	15	;	;	PUNCT
iajs-3493	173	16	hammer	hammer	NOUN
iajs-3493	173	17	,	,	PUNCT
iajs-3493	173	18	h.b	h.b	PROPN
iajs-3493	173	19	.	.	PROPN
iajs-3493	173	20	;	;	PUNCT
iajs-3493	173	21	aga	aga	PROPN
iajs-3493	173	22	,	,	PUNCT
iajs-3493	173	23	a.-b	a.-b	PROPN
iajs-3493	173	24	.	.	PROPN
iajs-3493	173	25	;	;	PUNCT
iajs-3493	173	26	olsen	olsen	PROPN
iajs-3493	173	27	,	,	PUNCT
iajs-3493	173	28	i.c	i.c	PROPN
iajs-3493	173	29	.	.	PROPN
iajs-3493	173	30	;	;	PUNCT
iajs-3493	173	31	brokstad	brokstad	PROPN
iajs-3493	173	32	,	,	PUNCT
iajs-3493	173	33	k.a	k.a	PROPN
iajs-3493	173	34	.	.	PROPN
iajs-3493	173	35	;	;	PUNCT
iajs-3493	173	36	van	van	PROPN
iajs-3493	173	37	der	der	NOUN
iajs-3493	173	38	heijde	heijde	NOUN
iajs-3493	173	39	,	,	PUNCT
iajs-3493	173	40	d.	d.	PROPN
iajs-3493	173	41	;	;	PUNCT
iajs-3493	173	42	kvien	kvien	PROPN
iajs-3493	173	43	,	,	PUNCT
iajs-3493	173	44	t.k	t.k	PROPN
iajs-3493	173	45	.	.	PROPN
iajs-3493	173	46	;	;	PUNCT
iajs-3493	173	47	fevang	fevang	PROPN
iajs-3493	173	48	,	,	PUNCT
iajs-3493	173	49	b.-t.s	b.-t.s	NOUN
iajs-3493	173	50	.	.	PUNCT
iajs-3493	173	51	calprotectin	calprotectin	NOUN
iajs-3493	173	52	as	as	ADP
iajs-3493	173	53	a	a	DET
iajs-3493	173	54	marker	marker	NOUN
iajs-3493	173	55	of	of	ADP
iajs-3493	173	56	inflammation	inflammation	NOUN
iajs-3493	173	57	in	in	ADP
iajs-3493	173	58	patients	patient	NOUN
iajs-3493	173	59	with	with	ADP
iajs-3493	173	60	early	early	ADJ
iajs-3493	173	61	rheumatoid	rheumatoid	NOUN
iajs-3493	173	62	arthritis	arthritis	NOUN
iajs-3493	173	63	.	.	PUNCT
iajs-3493	174	1	annals	annal	NOUN
iajs-3493	174	2	of	of	ADP
iajs-3493	174	3	the	the	DET
iajs-3493	174	4	rheumatic	rheumatic	ADJ
iajs-3493	174	5	diseases	disease	NOUN
iajs-3493	174	6	2017	2017	NUM
iajs-3493	174	7	,	,	PUNCT
iajs-3493	174	8	76	76	NUM
iajs-3493	174	9	,	,	PUNCT
iajs-3493	174	10	2031	2031	NUM
iajs-3493	174	11	-	-	SYM
iajs-3493	174	12	2037	2037	NUM
iajs-3493	174	13	.	.	PUNCT
iajs-3493	175	1	https://doi.org/10.1136/annrheumdis-2017-211695	https://doi.org/10.1136/annrheumdis-2017-211695	X
iajs-3493	175	2	.	.	PROPN
iajs-3493	175	3	17	17	NUM
iajs-3493	175	4	.	.	PUNCT
iajs-3493	176	1	shmerling	shmerle	VERB
iajs-3493	176	2	,	,	PUNCT
iajs-3493	176	3	r.h	r.h	PROPN
iajs-3493	176	4	.	.	PROPN
iajs-3493	176	5	testing	testing	NOUN
iajs-3493	176	6	for	for	ADP
iajs-3493	176	7	anti	anti	ADJ
iajs-3493	176	8	–	–	NOUN
iajs-3493	176	9	cyclic	cyclic	ADJ
iajs-3493	176	10	citrullinated	citrullinate	VERB
iajs-3493	176	11	peptide	peptide	NOUN
iajs-3493	176	12	antibodies	antibodie	VERB
iajs-3493	176	13	:	:	PUNCT
iajs-3493	176	14	is	be	AUX
iajs-3493	176	15	it	it	PRON
iajs-3493	176	16	time	time	NOUN
iajs-3493	176	17	to	to	PART
iajs-3493	176	18	set	set	VERB
iajs-3493	176	19	this	this	DET
iajs-3493	176	20	genie	genie	NOUN
iajs-3493	176	21	free	free	ADJ
iajs-3493	176	22	?	?	PUNCT
iajs-3493	177	1	archives	archive	NOUN
iajs-3493	177	2	of	of	ADP
iajs-3493	177	3	internal	internal	ADJ
iajs-3493	177	4	medicine	medicine	NOUN
iajs-3493	177	5	2009	2009	NUM
iajs-3493	177	6	,	,	PUNCT
iajs-3493	177	7	169	169	NUM
iajs-3493	177	8	,	,	PUNCT
iajs-3493	177	9	914	914	NUM
iajs-3493	177	10	.	.	PUNCT
iajs-3493	178	1	https://doi.org/10.1001/archinternmed.2008.522	https://doi.org/10.1001/archinternmed.2008.522	PROPN
iajs-3493	178	2	.	.	PUNCT
iajs-3493	179	1	18	18	NUM
iajs-3493	179	2	.	.	X
iajs-3493	179	3	avouac	avouac	PROPN
iajs-3493	179	4	,	,	PUNCT
iajs-3493	179	5	j.	j.	PROPN
iajs-3493	179	6	;	;	PUNCT
iajs-3493	179	7	gossec	gossec	PROPN
iajs-3493	179	8	,	,	PUNCT
iajs-3493	179	9	l.	l.	PROPN
iajs-3493	179	10	;	;	PUNCT
iajs-3493	179	11	dougados	dougado	NOUN
iajs-3493	179	12	,	,	PUNCT
iajs-3493	179	13	m.	m.	NOUN
iajs-3493	179	14	diagnostic	diagnostic	ADJ
iajs-3493	179	15	and	and	CCONJ
iajs-3493	179	16	predictive	predictive	ADJ
iajs-3493	179	17	value	value	NOUN
iajs-3493	179	18	of	of	ADP
iajs-3493	179	19	anti	anti	ADJ
iajs-3493	179	20	-	-	ADJ
iajs-3493	179	21	cyclic	cyclic	ADJ
iajs-3493	179	22	citrullinated	citrullinate	VERB
iajs-3493	179	23	protein	protein	NOUN
iajs-3493	179	24	antibodies	antibodie	VERB
iajs-3493	179	25	in	in	ADP
iajs-3493	179	26	rheumatoid	rheumatoid	NOUN
iajs-3493	179	27	arthritis	arthritis	NOUN
iajs-3493	179	28	:	:	PUNCT
iajs-3493	179	29	a	a	DET
iajs-3493	179	30	systematic	systematic	ADJ
iajs-3493	179	31	literature	literature	NOUN
iajs-3493	179	32	review	review	NOUN
iajs-3493	179	33	.	.	PUNCT
iajs-3493	180	1	annals	annal	NOUN
iajs-3493	180	2	of	of	ADP
iajs-3493	180	3	the	the	DET
iajs-3493	180	4	rheumatic	rheumatic	ADJ
iajs-3493	180	5	diseases	disease	NOUN
iajs-3493	180	6	2006	2006	NUM
iajs-3493	180	7	,	,	PUNCT
iajs-3493	180	8	65	65	NUM
iajs-3493	180	9	,	,	PUNCT
iajs-3493	180	10	845	845	NUM
iajs-3493	180	11	-	-	SYM
iajs-3493	180	12	851	851	NUM
iajs-3493	180	13	.	.	PUNCT
iajs-3493	181	1	https://doi.org/10.1136/ard.2006.051391	https://doi.org/10.1136/ard.2006.051391	PROPN
iajs-3493	181	2	.	.	PUNCT
iajs-3493	182	1	19	19	NUM
iajs-3493	182	2	.	.	X
iajs-3493	182	3	omran	omran	PROPN
iajs-3493	182	4	,	,	PUNCT
iajs-3493	182	5	r.h	r.h	PROPN
iajs-3493	182	6	.	.	PROPN
iajs-3493	182	7	;	;	PUNCT
iajs-3493	182	8	ahmed	ahmed	PROPN
iajs-3493	182	9	,	,	PUNCT
iajs-3493	182	10	z.a	z.a	PROPN
iajs-3493	182	11	.	.	PROPN
iajs-3493	182	12	;	;	PUNCT
iajs-3493	182	13	alrawi	alrawi	PROPN
iajs-3493	182	14	,	,	PUNCT
iajs-3493	182	15	a.a	a.a	PROPN
iajs-3493	182	16	.	.	PROPN
iajs-3493	182	17	evaluation	evaluation	NOUN
iajs-3493	182	18	of	of	ADP
iajs-3493	182	19	some	some	DET
iajs-3493	182	20	new	new	ADJ
iajs-3493	182	21	cytokines	cytokine	NOUN
iajs-3493	182	22	in	in	ADP
iajs-3493	182	23	rheumatoid	rheumatoid	NOUN
iajs-3493	182	24	arthritis	arthritis	NOUN
iajs-3493	182	25	.	.	PUNCT
iajs-3493	183	1	journal	journal	NOUN
iajs-3493	183	2	of	of	ADP
iajs-3493	183	3	faculty	faculty	NOUN
iajs-3493	183	4	of	of	ADP
iajs-3493	183	5	medicine	medicine	NOUN
iajs-3493	183	6	baghdad	baghdad	PROPN
iajs-3493	183	7	2022	2022	NUM
iajs-3493	183	8	,	,	PUNCT
iajs-3493	183	9	64	64	NUM
iajs-3493	183	10	,	,	PUNCT
iajs-3493	183	11	3	3	NUM
iajs-3493	183	12	.	.	PUNCT
iajs-3493	183	13	https://doi.org/10.32007/jfacmedbagdad.6431945	https://doi.org/10.32007/jfacmedbagdad.6431945	NOUN
iajs-3493	183	14	.	.	PROPN
iajs-3493	183	15	20	20	NUM
iajs-3493	183	16	.	.	X
iajs-3493	184	1	srivastava	srivastava	PROPN
iajs-3493	184	2	,	,	PUNCT
iajs-3493	184	3	r.k	r.k	PROPN
iajs-3493	184	4	.	.	PROPN
iajs-3493	184	5	;	;	PUNCT
iajs-3493	184	6	tomar	tomar	ADJ
iajs-3493	184	7	,	,	PUNCT
iajs-3493	184	8	g.b	g.b	PROPN
iajs-3493	184	9	.	.	PROPN
iajs-3493	184	10	;	;	PUNCT
iajs-3493	184	11	barhanpurkar	barhanpurkar	PROPN
iajs-3493	184	12	,	,	PUNCT
iajs-3493	184	13	a.p	a.p	PROPN
iajs-3493	184	14	.	.	PROPN
iajs-3493	184	15	;	;	PUNCT
iajs-3493	184	16	gupta	gupta	PROPN
iajs-3493	184	17	,	,	PUNCT
iajs-3493	184	18	n.	n.	NOUN
iajs-3493	184	19	;	;	PUNCT
iajs-3493	184	20	pote	pote	X
iajs-3493	184	21	,	,	PUNCT
iajs-3493	184	22	s.t	s.t	PROPN
iajs-3493	184	23	.	.	PROPN
iajs-3493	184	24	;	;	PUNCT
iajs-3493	185	1	mishra	mishra	PROPN
iajs-3493	185	2	,	,	PUNCT
iajs-3493	185	3	g.c	g.c	PROPN
iajs-3493	185	4	.	.	PROPN
iajs-3493	185	5	;	;	PUNCT
iajs-3493	185	6	wani	wani	PROPN
iajs-3493	185	7	,	,	PUNCT
iajs-3493	185	8	m.r	m.r	PROPN
iajs-3493	185	9	.	.	PROPN
iajs-3493	185	10	il-3	il-3	NOUN
iajs-3493	185	11	attenuates	attenuate	VERB
iajs-3493	185	12	collagen	collagen	NOUN
iajs-3493	185	13	-	-	PUNCT
iajs-3493	185	14	induced	induce	VERB
iajs-3493	185	15	arthritis	arthritis	NOUN
iajs-3493	185	16	by	by	ADP
iajs-3493	185	17	modulating	modulate	VERB
iajs-3493	185	18	the	the	DET
iajs-3493	185	19	development	development	NOUN
iajs-3493	185	20	of	of	ADP
iajs-3493	185	21	foxp3	foxp3	NOUN
iajs-3493	185	22	+	+	X
iajs-3493	185	23	regulatory	regulatory	ADJ
iajs-3493	185	24	t	t	NOUN
iajs-3493	185	25	cells	cell	NOUN
iajs-3493	185	26	.	.	PUNCT
iajs-3493	186	1	the	the	DET
iajs-3493	186	2	journal	journal	NOUN
iajs-3493	186	3	of	of	ADP
iajs-3493	186	4	immunology	immunology	NOUN
iajs-3493	186	5	2011	2011	NUM
iajs-3493	186	6	,	,	PUNCT
iajs-3493	186	7	186	186	NUM
iajs-3493	186	8	,	,	PUNCT
iajs-3493	186	9	2262	2262	NUM
iajs-3493	186	10	-	-	SYM
iajs-3493	186	11	2272	2272	NUM
iajs-3493	186	12	.	.	PUNCT
iajs-3493	187	1	https://doi.org/10.4049/jimmunol.1002691	https://doi.org/10.4049/jimmunol.1002691	NOUN
iajs-3493	187	2	.	.	PUNCT
iajs-3493	188	1	https://doi.org/10.1016/j.pop.2018.02.010	https://doi.org/10.1016/j.pop.2018.02.010	PROPN
iajs-3493	188	2	https://doi.org/10.1016/j.jmbbm.2019.05.037	https://doi.org/10.1016/j.jmbbm.2019.05.037	PROPN
iajs-3493	188	3	https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-2061-1	https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-2061-1	NOUN
iajs-3493	188	4	https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-2061-1	https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-2061-1	NOUN
iajs-3493	188	5	https://doi.org/10.4049/jimmunol.1002691	https://doi.org/10.4049/jimmunol.1002691	NOUN
iajs-3493	188	6	https://doi.org/10.1159/000420755	https://doi.org/10.1159/000420755	ADJ
iajs-3493	188	7	https://doi.org/10.2147/jaa.s342993	https://doi.org/10.2147/jaa.s342993	NOUN
iajs-3493	188	8	https://doi.org/10.1002/stem.140605	https://doi.org/10.1002/stem.140605	NOUN
iajs-3493	188	9	https://doi.org/10.3389/fphys.2019.01514	https://doi.org/10.3389/fphys.2019.01514	PROPN
iajs-3493	188	10	https://doi.org/10.30526/37.2.3451	https://doi.org/10.30526/37.2.3451	PUNCT
iajs-3493	188	11	https://doi.org/10.3389/fmed.2018.00185	https://doi.org/10.3389/fmed.2018.00185	PROPN
iajs-3493	188	12	https://doi.org/10.1016/j.semarthrit.2008.12.001	https://doi.org/10.1016/j.semarthrit.2008.12.001	VERB
iajs-3493	188	13	https://doi.org/10.1136/annrheumdis-2017-211695	https://doi.org/10.1136/annrheumdis-2017-211695	NOUN
iajs-3493	188	14	https://doi.org/10.1001/archinternmed.2008.522	https://doi.org/10.1001/archinternmed.2008.522	ADV
iajs-3493	188	15	https://doi.org/10.1136/ard.2006.051391	https://doi.org/10.1136/ard.2006.051391	PROPN
iajs-3493	188	16	https://doi.org/10.32007/jfacmedbagdad.6431945	https://doi.org/10.32007/jfacmedbagdad.6431945	ADJ
iajs-3493	188	17	https://doi.org/10.4049/jimmunol.1002691	https://doi.org/10.4049/jimmunol.1002691	ADJ
iajs-3493	188	18	ihjpas	ihjpa	NOUN
iajs-3493	188	19	.	.	PUNCT
iajs-3493	189	1	2024	2024	NUM
iajs-3493	189	2	,	,	PUNCT
iajs-3493	189	3	37(4	37(4	NOUN
iajs-3493	189	4	)	)	PUNCT
iajs-3493	189	5	51	51	NUM
iajs-3493	189	6	21	21	NUM
iajs-3493	189	7	.	.	PUNCT
iajs-3493	189	8	kawabata	kawabata	PROPN
iajs-3493	189	9	,	,	PUNCT
iajs-3493	189	10	h.	h.	PROPN
iajs-3493	189	11	;	;	PUNCT
iajs-3493	189	12	satoh	satoh	NOUN
iajs-3493	189	13	,	,	PUNCT
iajs-3493	189	14	m.	m.	NOUN
iajs-3493	189	15	;	;	PUNCT
iajs-3493	189	16	yatera	yatera	NOUN
iajs-3493	189	17	,	,	PUNCT
iajs-3493	189	18	k.	k.	PROPN
iajs-3493	189	19	development	development	PROPN
iajs-3493	189	20	of	of	ADP
iajs-3493	189	21	rheumatoid	rheumatoid	NOUN
iajs-3493	189	22	arthritis	arthritis	NOUN
iajs-3493	189	23	during	during	ADP
iajs-3493	189	24	anti	anti	ADJ
iajs-3493	189	25	-	-	ADJ
iajs-3493	189	26	interleukin5	interleukin5	ADJ
iajs-3493	189	27	therapy	therapy	NOUN
iajs-3493	189	28	in	in	ADP
iajs-3493	189	29	a	a	DET
iajs-3493	189	30	patient	patient	NOUN
iajs-3493	189	31	with	with	ADP
iajs-3493	189	32	refractory	refractory	NOUN
iajs-3493	189	33	chronic	chronic	ADJ
iajs-3493	189	34	eosinophilic	eosinophilic	ADJ
iajs-3493	189	35	pneumonia	pneumonia	NOUN
iajs-3493	189	36	.	.	PUNCT
iajs-3493	190	1	journal	journal	PROPN
iajs-3493	190	2	of	of	ADP
iajs-3493	190	3	asthma	asthma	NOUN
iajs-3493	190	4	and	and	CCONJ
iajs-3493	190	5	allergy	allergy	NOUN
iajs-3493	190	6	2021	2021	NUM
iajs-3493	190	7	,	,	PUNCT
iajs-3493	190	8	1425	1425	NUM
iajs-3493	190	9	-	-	SYM
iajs-3493	190	10	1430	1430	NUM
iajs-3493	190	11	.	.	PUNCT
iajs-3493	191	1	https://doi.org/10.2147/jaa.s34299	https://doi.org/10.2147/jaa.s34299	NOUN
iajs-3493	191	2	.	.	PROPN
iajs-3493	192	1	22	22	NUM
iajs-3493	192	2	.	.	PUNCT
iajs-3493	193	1	mikhaylenko	mikhaylenko	PROPN
iajs-3493	193	2	,	,	PUNCT
iajs-3493	193	3	d.s	d.s	PROPN
iajs-3493	193	4	.	.	PROPN
iajs-3493	193	5	;	;	PUNCT
iajs-3493	193	6	nemtsova	nemtsova	PROPN
iajs-3493	193	7	,	,	PUNCT
iajs-3493	193	8	m.v	m.v	PROPN
iajs-3493	193	9	.	.	PROPN
iajs-3493	193	10	;	;	PUNCT
iajs-3493	193	11	bure	bure	PROPN
iajs-3493	193	12	,	,	PUNCT
iajs-3493	193	13	i.v	i.v	PROPN
iajs-3493	193	14	.	.	PUNCT
iajs-3493	193	15	;	;	PUNCT
iajs-3493	193	16	kuznetsova	kuznetsova	PROPN
iajs-3493	193	17	,	,	PUNCT
iajs-3493	193	18	e.b	e.b	PROPN
iajs-3493	193	19	.	.	PROPN
iajs-3493	193	20	;	;	PUNCT
iajs-3493	193	21	alekseeva	alekseeva	PROPN
iajs-3493	193	22	,	,	PUNCT
iajs-3493	193	23	e.a	e.a	PROPN
iajs-3493	193	24	.	.	PROPN
iajs-3493	193	25	;	;	PUNCT
iajs-3493	193	26	tarasov	tarasov	PROPN
iajs-3493	193	27	,	,	PUNCT
iajs-3493	193	28	v.v	v.v	PROPN
iajs-3493	193	29	.	.	PROPN
iajs-3493	193	30	;	;	PUNCT
iajs-3493	193	31	lukashev	lukashev	PROPN
iajs-3493	193	32	,	,	PUNCT
iajs-3493	193	33	a.n	a.n	PROPN
iajs-3493	193	34	.	.	PROPN
iajs-3493	193	35	;	;	PUNCT
iajs-3493	193	36	beloukhova	beloukhova	X
iajs-3493	193	37	,	,	PUNCT
iajs-3493	193	38	m.i	m.i	PROPN
iajs-3493	193	39	.	.	PROPN
iajs-3493	193	40	;	;	PUNCT
iajs-3493	193	41	deviatkin	deviatkin	PROPN
iajs-3493	193	42	,	,	PUNCT
iajs-3493	193	43	a.a	a.a	PROPN
iajs-3493	193	44	.	.	PROPN
iajs-3493	193	45	;	;	PUNCT
iajs-3493	194	1	zamyatnin	zamyatnin	PROPN
iajs-3493	194	2	,	,	PUNCT
iajs-3493	194	3	a.a	a.a	PROPN
iajs-3493	194	4	.	.	PROPN
iajs-3493	194	5	jr	jr	PROPN
iajs-3493	194	6	.	.	PUNCT
iajs-3493	195	1	genetic	genetic	ADJ
iajs-3493	195	2	polymorphisms	polymorphism	NOUN
iajs-3493	195	3	associated	associate	VERB
iajs-3493	195	4	with	with	ADP
iajs-3493	195	5	rheumatoid	rheumatoid	NOUN
iajs-3493	195	6	arthritis	arthritis	NOUN
iajs-3493	195	7	development	development	NOUN
iajs-3493	195	8	and	and	CCONJ
iajs-3493	195	9	antirheumatic	antirheumatic	ADJ
iajs-3493	195	10	therapy	therapy	NOUN
iajs-3493	195	11	response	response	NOUN
iajs-3493	195	12	.	.	PUNCT
iajs-3493	196	1	international	international	ADJ
iajs-3493	196	2	journal	journal	NOUN
iajs-3493	196	3	of	of	ADP
iajs-3493	196	4	molecular	molecular	ADJ
iajs-3493	196	5	science	science	NOUN
iajs-3493	196	6	2020	2020	NUM
iajs-3493	196	7	,	,	PUNCT
iajs-3493	196	8	21(14	21(14	NUM
iajs-3493	196	9	)	)	PUNCT
iajs-3493	196	10	,	,	PUNCT
iajs-3493	196	11	4911	4911	NUM
iajs-3493	196	12	.	.	PUNCT
iajs-3493	197	1	https://doi.org/10.3390/ijms21144911	https://doi.org/10.3390/ijms21144911	PROPN
iajs-3493	197	2	.	.	PUNCT
iajs-3493	198	1	23	23	NUM
iajs-3493	198	2	.	.	PUNCT
iajs-3493	198	3	brühl	brühl	NOUN
iajs-3493	198	4	,	,	PUNCT
iajs-3493	198	5	h.	h.	PROPN
iajs-3493	198	6	;	;	PUNCT
iajs-3493	198	7	cihak	cihak	PROPN
iajs-3493	198	8	,	,	PUNCT
iajs-3493	198	9	j.	j.	PROPN
iajs-3493	198	10	;	;	PUNCT
iajs-3493	198	11	niedermeier	niedermeier	NOUN
iajs-3493	198	12	,	,	PUNCT
iajs-3493	198	13	m.	m.	NOUN
iajs-3493	198	14	;	;	PUNCT
iajs-3493	198	15	denzel	denzel	PROPN
iajs-3493	198	16	,	,	PUNCT
iajs-3493	198	17	a.	a.	PROPN
iajs-3493	198	18	;	;	PUNCT
iajs-3493	198	19	gomez	gomez	PROPN
iajs-3493	198	20	,	,	PUNCT
iajs-3493	198	21	m.r	m.r	PROPN
iajs-3493	198	22	.	.	PROPN
iajs-3493	198	23	;	;	PUNCT
iajs-3493	198	24	talke	talke	NOUN
iajs-3493	198	25	,	,	PUNCT
iajs-3493	198	26	y.	y.	NOUN
iajs-3493	198	27	;	;	PUNCT
iajs-3493	198	28	goebel	goebel	NOUN
iajs-3493	198	29	,	,	PUNCT
iajs-3493	198	30	n.	n.	NOUN
iajs-3493	198	31	;	;	PUNCT
iajs-3493	198	32	plachý	plachý	PROPN
iajs-3493	198	33	,	,	PUNCT
iajs-3493	198	34	j.	j.	PROPN
iajs-3493	198	35	;	;	PUNCT
iajs-3493	198	36	stangassinger	stangassinger	NOUN
iajs-3493	198	37	,	,	PUNCT
iajs-3493	198	38	m.	m.	NOUN
iajs-3493	198	39	;	;	PUNCT
iajs-3493	198	40	mack	mack	PROPN
iajs-3493	198	41	,	,	PUNCT
iajs-3493	198	42	m.	m.	NOUN
iajs-3493	198	43	important	important	ADJ
iajs-3493	198	44	role	role	NOUN
iajs-3493	198	45	of	of	ADP
iajs-3493	198	46	interleukin‐3	interleukin‐3	NOUN
iajs-3493	198	47	in	in	ADP
iajs-3493	198	48	the	the	DET
iajs-3493	198	49	early	early	ADJ
iajs-3493	198	50	phase	phase	NOUN
iajs-3493	198	51	of	of	ADP
iajs-3493	198	52	collagen‐induced	collagen‐induce	VERB
iajs-3493	198	53	arthritis	arthritis	NOUN
iajs-3493	198	54	.	.	PUNCT
iajs-3493	199	1	arthritis	arthritis	NOUN
iajs-3493	199	2	&	&	CCONJ
iajs-3493	199	3	rheumatism	rheumatism	NOUN
iajs-3493	199	4	2009	2009	NUM
iajs-3493	199	5	,	,	PUNCT
iajs-3493	199	6	60	60	NUM
iajs-3493	199	7	,	,	PUNCT
iajs-3493	199	8	1352	1352	NUM
iajs-3493	199	9	-	-	SYM
iajs-3493	199	10	1361	1361	NUM
iajs-3493	199	11	.	.	PUNCT
iajs-3493	200	1	https://doi.org/10.1002/art.24441	https://doi.org/10.1002/art.24441	ADJ
iajs-3493	200	2	.	.	PUNCT
iajs-3493	201	1	24	24	NUM
iajs-3493	201	2	.	.	PUNCT
iajs-3493	202	1	fawzy	fawzy	PROPN
iajs-3493	202	2	,	,	PUNCT
iajs-3493	202	3	r.m	r.m	PROPN
iajs-3493	202	4	.	.	PROPN
iajs-3493	202	5	;	;	PUNCT
iajs-3493	202	6	said	say	VERB
iajs-3493	202	7	,	,	PUNCT
iajs-3493	202	8	e.a	e.a	PROPN
iajs-3493	202	9	.	.	PROPN
iajs-3493	202	10	;	;	PUNCT
iajs-3493	202	11	mansour	mansour	PROPN
iajs-3493	202	12	,	,	PUNCT
iajs-3493	202	13	a.i	a.i	PROPN
iajs-3493	202	14	.	.	PROPN
iajs-3493	202	15	association	association	PROPN
iajs-3493	202	16	of	of	ADP
iajs-3493	202	17	neutrophil	neutrophil	NOUN
iajs-3493	202	18	to	to	ADP
iajs-3493	202	19	lymphocyte	lymphocyte	ADJ
iajs-3493	202	20	ratio	ratio	NOUN
iajs-3493	202	21	with	with	ADP
iajs-3493	202	22	disease	disease	NOUN
iajs-3493	202	23	activity	activity	NOUN
iajs-3493	202	24	indices	index	NOUN
iajs-3493	202	25	and	and	CCONJ
iajs-3493	202	26	musculoskeletal	musculoskeletal	ADJ
iajs-3493	202	27	ultrasound	ultrasound	NOUN
iajs-3493	202	28	findings	finding	NOUN
iajs-3493	202	29	in	in	ADP
iajs-3493	202	30	recent	recent	ADJ
iajs-3493	202	31	onset	onset	NOUN
iajs-3493	202	32	rheumatoid	rheumatoid	VERB
iajs-3493	202	33	arthritis	arthritis	NOUN
iajs-3493	202	34	patients	patient	NOUN
iajs-3493	202	35	.	.	PUNCT
iajs-3493	203	1	the	the	DET
iajs-3493	203	2	egyptian	egyptian	ADJ
iajs-3493	203	3	rheumatologist	rheumatologist	NOUN
iajs-3493	203	4	2017	2017	NUM
iajs-3493	203	5	,	,	PUNCT
iajs-3493	203	6	39	39	NUM
iajs-3493	203	7	,	,	PUNCT
iajs-3493	203	8	203	203	NUM
iajs-3493	203	9	-	-	SYM
iajs-3493	203	10	206	206	NUM
iajs-3493	203	11	.	.	PUNCT
iajs-3493	204	1	http://dx.doi.org/10.1016/j.ejr.2017.05.001	http://dx.doi.org/10.1016/j.ejr.2017.05.001	X
iajs-3493	204	2	.	.	PUNCT
iajs-3493	205	1	25	25	NUM
iajs-3493	205	2	.	.	X
iajs-3493	205	3	wilson	wilson	PROPN
iajs-3493	205	4	,	,	PUNCT
iajs-3493	205	5	a.	a.	PROPN
iajs-3493	205	6	;	;	PUNCT
iajs-3493	205	7	yu	yu	PROPN
iajs-3493	205	8	,	,	PUNCT
iajs-3493	205	9	h.-t	h.-t	NOUN
iajs-3493	205	10	.	.	PUNCT
iajs-3493	205	11	;	;	PUNCT
iajs-3493	205	12	goodnough	goodnough	NOUN
iajs-3493	205	13	,	,	PUNCT
iajs-3493	205	14	l.t	l.t	PROPN
iajs-3493	205	15	.	.	PROPN
iajs-3493	205	16	;	;	PUNCT
iajs-3493	205	17	nissenson	nissenson	X
iajs-3493	205	18	,	,	PUNCT
iajs-3493	205	19	a.r	a.r	PROPN
iajs-3493	205	20	.	.	PROPN
iajs-3493	205	21	prevalence	prevalence	NOUN
iajs-3493	205	22	and	and	CCONJ
iajs-3493	205	23	outcomes	outcome	NOUN
iajs-3493	205	24	of	of	ADP
iajs-3493	205	25	anemia	anemia	NOUN
iajs-3493	205	26	in	in	ADP
iajs-3493	205	27	rheumatoid	rheumatoid	NOUN
iajs-3493	205	28	arthritis	arthritis	NOUN
iajs-3493	205	29	:	:	PUNCT
iajs-3493	205	30	a	a	DET
iajs-3493	205	31	systematic	systematic	ADJ
iajs-3493	205	32	review	review	NOUN
iajs-3493	205	33	of	of	ADP
iajs-3493	205	34	the	the	DET
iajs-3493	205	35	literature	literature	NOUN
iajs-3493	205	36	.	.	PUNCT
iajs-3493	206	1	the	the	DET
iajs-3493	206	2	american	american	PROPN
iajs-3493	206	3	journal	journal	PROPN
iajs-3493	206	4	of	of	ADP
iajs-3493	206	5	medicine	medicine	NOUN
iajs-3493	206	6	2004	2004	NUM
iajs-3493	206	7	,	,	PUNCT
iajs-3493	206	8	116	116	NUM
iajs-3493	206	9	,	,	PUNCT
iajs-3493	206	10	50	50	NUM
iajs-3493	206	11	-	-	SYM
iajs-3493	206	12	57	57	NUM
iajs-3493	206	13	.	.	PUNCT
iajs-3493	207	1	https://doi.org/10.1016/j.amjmed.2003.12.012	https://doi.org/10.1016/j.amjmed.2003.12.012	NOUN
iajs-3493	207	2	.	.	PUNCT
iajs-3493	208	1	26	26	NUM
iajs-3493	208	2	.	.	PUNCT
iajs-3493	209	1	yoshida	yoshida	PROPN
iajs-3493	209	2	y	y	PROPN
iajs-3493	209	3	,	,	PUNCT
iajs-3493	209	4	tanaka	tanaka	PROPN
iajs-3493	209	5	t.	t.	PROPN
iajs-3493	209	6	interleukin	interleukin	NOUN
iajs-3493	209	7	6	6	NUM
iajs-3493	209	8	and	and	CCONJ
iajs-3493	209	9	rheumatoid	rheumatoid	VERB
iajs-3493	209	10	arthritis	arthritis	NOUN
iajs-3493	209	11	.	.	PUNCT
iajs-3493	210	1	biomedical	biomedical	ADJ
iajs-3493	210	2	research	research	PROPN
iajs-3493	210	3	international	international	PROPN
iajs-3493	210	4	2014	2014	NUM
iajs-3493	210	5	,	,	PUNCT
iajs-3493	210	6	2014	2014	NUM
iajs-3493	210	7	,	,	PUNCT
iajs-3493	210	8	698313	698313	NUM
iajs-3493	210	9	.	.	PUNCT
iajs-3493	211	1	doi	doi	NOUN
iajs-3493	211	2	:	:	PUNCT
iajs-3493	211	3	https://doi.org/10.1155/2014/698313	https://doi.org/10.1155/2014/698313	NOUN
iajs-3493	211	4	.	.	PUNCT
iajs-3493	212	1	27	27	NUM
iajs-3493	212	2	.	.	PUNCT
iajs-3493	213	1	avci	avci	PROPN
iajs-3493	213	2	,	,	PUNCT
iajs-3493	213	3	a.b	a.b	PROPN
iajs-3493	213	4	.	.	PROPN
iajs-3493	213	5	;	;	PUNCT
iajs-3493	213	6	feist	feist	PROPN
iajs-3493	213	7	,	,	PUNCT
iajs-3493	213	8	e.	e.	PROPN
iajs-3493	213	9	;	;	PUNCT
iajs-3493	213	10	burmester	burmester	PROPN
iajs-3493	213	11	,	,	PUNCT
iajs-3493	213	12	g.r	g.r	PROPN
iajs-3493	213	13	.	.	PUNCT
iajs-3493	213	14	targeting	target	VERB
iajs-3493	213	15	il-6	il-6	PRON
iajs-3493	213	16	or	or	CCONJ
iajs-3493	213	17	il-6	il-6	NOUN
iajs-3493	213	18	receptor	receptor	NOUN
iajs-3493	213	19	in	in	ADP
iajs-3493	213	20	rheumatoid	rheumatoid	NOUN
iajs-3493	213	21	arthritis	arthritis	NOUN
iajs-3493	213	22	:	:	PUNCT
iajs-3493	213	23	what	what	PRON
iajs-3493	213	24	have	have	AUX
iajs-3493	213	25	we	we	PRON
iajs-3493	213	26	learned	learn	VERB
iajs-3493	213	27	?	?	PUNCT
iajs-3493	213	28	.	.	PUNCT
iajs-3493	214	1	biodrugs	biodrug	NOUN
iajs-3493	214	2	,	,	PUNCT
iajs-3493	214	3	2024	2024	NUM
iajs-3493	214	4	,	,	PUNCT
iajs-3493	214	5	38	38	NUM
iajs-3493	214	6	,	,	PUNCT
iajs-3493	214	7	61–71	61–71	NOUN
iajs-3493	214	8	.	.	PUNCT
iajs-3493	215	1	https://doi.org/10.1007/s40259-023-00634-1	https://doi.org/10.1007/s40259-023-00634-1	NUM
iajs-3493	215	2	.	.	PUNCT
iajs-3493	216	1	28	28	NUM
iajs-3493	216	2	.	.	PUNCT
iajs-3493	217	1	wu	wu	PROPN
iajs-3493	217	2	,	,	PUNCT
iajs-3493	217	3	y.	y.	PROPN
iajs-3493	217	4	;	;	PUNCT
iajs-3493	217	5	chen	chen	PROPN
iajs-3493	217	6	,	,	PUNCT
iajs-3493	217	7	y.	y.	PROPN
iajs-3493	217	8	;	;	PUNCT
iajs-3493	217	9	yang	yang	PROPN
iajs-3493	217	10	,	,	PUNCT
iajs-3493	217	11	x.	x.	PROPN
iajs-3493	217	12	;	;	PUNCT
iajs-3493	217	13	chen	chen	PROPN
iajs-3493	217	14	,	,	PUNCT
iajs-3493	217	15	l.	l.	PROPN
iajs-3493	217	16	;	;	PUNCT
iajs-3493	217	17	yang	yang	PROPN
iajs-3493	217	18	,	,	PUNCT
iajs-3493	217	19	y.	y.	PROPN
iajs-3493	217	20	neutrophil	neutrophil	PROPN
iajs-3493	217	21	-	-	PUNCT
iajs-3493	217	22	to	to	ADP
iajs-3493	217	23	-	-	PUNCT
iajs-3493	217	24	lymphocyte	lymphocyte	NOUN
iajs-3493	217	25	ratio	ratio	NOUN
iajs-3493	217	26	(	(	PUNCT
iajs-3493	217	27	nlr	nlr	PROPN
iajs-3493	217	28	)	)	PUNCT
iajs-3493	217	29	and	and	CCONJ
iajs-3493	217	30	plateletto	plateletto	NOUN
iajs-3493	217	31	-	-	PUNCT
iajs-3493	217	32	lymphocyte	lymphocyte	ADJ
iajs-3493	217	33	ratio	ratio	NOUN
iajs-3493	217	34	(	(	PUNCT
iajs-3493	217	35	plr	plr	NOUN
iajs-3493	217	36	)	)	PUNCT
iajs-3493	217	37	were	be	AUX
iajs-3493	217	38	associated	associate	VERB
iajs-3493	217	39	with	with	ADP
iajs-3493	217	40	disease	disease	NOUN
iajs-3493	217	41	activity	activity	NOUN
iajs-3493	217	42	in	in	ADP
iajs-3493	217	43	patients	patient	NOUN
iajs-3493	217	44	with	with	ADP
iajs-3493	217	45	systemic	systemic	ADJ
iajs-3493	217	46	lupus	lupus	PROPN
iajs-3493	217	47	erythematosus	erythematosus	PROPN
iajs-3493	217	48	.	.	PUNCT
iajs-3493	218	1	international	international	ADJ
iajs-3493	218	2	immunopharmacology	immunopharmacology	NOUN
iajs-3493	218	3	2016	2016	NUM
iajs-3493	218	4	,	,	PUNCT
iajs-3493	218	5	36	36	NUM
iajs-3493	218	6	,	,	PUNCT
iajs-3493	218	7	94	94	NUM
iajs-3493	218	8	-	-	SYM
iajs-3493	218	9	99	99	NUM
iajs-3493	218	10	.	.	PUNCT
iajs-3493	219	1	https://doi.org/10.1016/j.intimp.2016.04.006	https://doi.org/10.1016/j.intimp.2016.04.006	X
iajs-3493	219	2	.	.	NOUN
iajs-3493	220	1	29	29	NUM
iajs-3493	220	2	.	.	PUNCT
iajs-3493	221	1	pope	pope	PROPN
iajs-3493	221	2	,	,	PUNCT
iajs-3493	221	3	j.e	j.e	PROPN
iajs-3493	221	4	.	.	PROPN
iajs-3493	221	5	;	;	PUNCT
iajs-3493	221	6	choy	choy	NOUN
iajs-3493	221	7	,	,	PUNCT
iajs-3493	221	8	e.h	e.h	PROPN
iajs-3493	221	9	.	.	PROPN
iajs-3493	221	10	c	c	NOUN
iajs-3493	221	11	-	-	PUNCT
iajs-3493	221	12	reactive	reactive	ADJ
iajs-3493	221	13	protein	protein	NOUN
iajs-3493	221	14	and	and	CCONJ
iajs-3493	221	15	implications	implication	NOUN
iajs-3493	221	16	in	in	ADP
iajs-3493	221	17	rheumatoid	rheumatoid	NOUN
iajs-3493	221	18	arthritis	arthritis	NOUN
iajs-3493	221	19	and	and	CCONJ
iajs-3493	221	20	associated	associated	ADJ
iajs-3493	221	21	comorbidities	comorbiditie	NOUN
iajs-3493	221	22	.	.	PUNCT
iajs-3493	222	1	seminars	seminar	NOUN
iajs-3493	222	2	in	in	ADP
iajs-3493	222	3	arthritis	arthritis	NOUN
iajs-3493	222	4	and	and	CCONJ
iajs-3493	222	5	rheumatism	rheumatism	NOUN
iajs-3493	222	6	2021	2021	NUM
iajs-3493	222	7	,	,	PUNCT
iajs-3493	222	8	51(1	51(1	NUM
iajs-3493	222	9	)	)	PUNCT
iajs-3493	222	10	,	,	PUNCT
iajs-3493	222	11	219229	219229	NUM
iajs-3493	222	12	.	.	PUNCT
iajs-3493	223	1	https://doi.org/10.1016/j.semarthrit.2020.11.005	https://doi.org/10.1016/j.semarthrit.2020.11.005	NOUN
iajs-3493	223	2	.	.	PUNCT
iajs-3493	224	1	30	30	NUM
iajs-3493	224	2	.	.	PUNCT
iajs-3493	225	1	peng	peng	PROPN
iajs-3493	225	2	,	,	PUNCT
iajs-3493	225	3	y.-f	y.-f	PROPN
iajs-3493	225	4	.	.	PUNCT
iajs-3493	225	5	;	;	PUNCT
iajs-3493	225	6	cao	cao	PROPN
iajs-3493	225	7	,	,	PUNCT
iajs-3493	225	8	l.	l.	PROPN
iajs-3493	225	9	;	;	PUNCT
iajs-3493	225	10	zeng	zeng	PROPN
iajs-3493	225	11	,	,	PUNCT
iajs-3493	225	12	y.-h	y.-h	PROPN
iajs-3493	225	13	.	.	PUNCT
iajs-3493	225	14	;	;	PUNCT
iajs-3493	225	15	zhang	zhang	PROPN
iajs-3493	225	16	,	,	PUNCT
iajs-3493	225	17	z.-x	z.-x	PROPN
iajs-3493	225	18	.	.	PUNCT
iajs-3493	225	19	;	;	PUNCT
iajs-3493	225	20	chen	chen	PROPN
iajs-3493	225	21	,	,	PUNCT
iajs-3493	225	22	d.	d.	PROPN
iajs-3493	225	23	;	;	PUNCT
iajs-3493	225	24	zhang	zhang	PROPN
iajs-3493	225	25	,	,	PUNCT
iajs-3493	225	26	q.	q.	PROPN
iajs-3493	225	27	;	;	PUNCT
iajs-3493	225	28	zhu	zhu	PROPN
iajs-3493	225	29	,	,	PUNCT
iajs-3493	225	30	y.-s	y.-	NOUN
iajs-3493	225	31	.	.	PUNCT
iajs-3493	226	1	platelet	platelet	NOUN
iajs-3493	226	2	to	to	ADP
iajs-3493	226	3	lymphocyte	lymphocyte	ADJ
iajs-3493	226	4	ratio	ratio	NOUN
iajs-3493	226	5	and	and	CCONJ
iajs-3493	226	6	neutrophil	neutrophil	NOUN
iajs-3493	226	7	to	to	ADP
iajs-3493	226	8	lymphocyte	lymphocyte	ADJ
iajs-3493	226	9	ratio	ratio	NOUN
iajs-3493	226	10	in	in	ADP
iajs-3493	226	11	patients	patient	NOUN
iajs-3493	226	12	with	with	ADP
iajs-3493	226	13	rheumatoid	rheumatoid	NOUN
iajs-3493	226	14	arthritis	arthritis	NOUN
iajs-3493	226	15	.	.	PUNCT
iajs-3493	227	1	open	open	ADJ
iajs-3493	227	2	medicine	medicine	NOUN
iajs-3493	227	3	2015	2015	NUM
iajs-3493	227	4	,	,	PUNCT
iajs-3493	227	5	10	10	NUM
iajs-3493	227	6	.	.	PUNCT
iajs-3493	227	7	https://doi.org/10.1515/med-2015-0037	https://doi.org/10.1515/med-2015-0037	PROPN
iajs-3493	227	8	.	.	PUNCT
iajs-3493	228	1	31	31	NUM
iajs-3493	228	2	.	.	PUNCT
iajs-3493	229	1	nazar	nazar	PROPN
iajs-3493	229	2	,	,	PUNCT
iajs-3493	229	3	l.a	l.a	PROPN
iajs-3493	229	4	.	.	PROPN
iajs-3493	229	5	;	;	PUNCT
iajs-3493	229	6	al	al	PROPN
iajs-3493	229	7	-	-	PUNCT
iajs-3493	229	8	aati	aati	PROPN
iajs-3493	229	9	,	,	PUNCT
iajs-3493	229	10	e.	e.	PROPN
iajs-3493	229	11	a.	a.	PROPN
iajs-3493	229	12	study	study	PROPN
iajs-3493	229	13	of	of	ADP
iajs-3493	229	14	il-33	il-33	ADJ
iajs-3493	229	15	and	and	CCONJ
iajs-3493	229	16	il-1r4	il-1r4	NOUN
iajs-3493	229	17	in	in	ADP
iajs-3493	229	18	iraqi	iraqi	ADJ
iajs-3493	229	19	rheumatoid	rheumatoid	NOUN
iajs-3493	229	20	arthritis	arthritis	NOUN
iajs-3493	229	21	female	female	ADJ
iajs-3493	229	22	patient	patient	NOUN
iajs-3493	229	23	's	's	PART
iajs-3493	229	24	with	with	ADP
iajs-3493	229	25	and	and	CCONJ
iajs-3493	229	26	without	without	ADP
iajs-3493	229	27	dyslipidemia	dyslipidemia	NOUN
iajs-3493	229	28	prone	prone	ADJ
iajs-3493	229	29	to	to	ADP
iajs-3493	229	30	atherosclerosis	atherosclerosis	NOUN
iajs-3493	229	31	.	.	PUNCT
iajs-3493	230	1	ibn	ibn	PROPN
iajs-3493	230	2	al	al	PROPN
iajs-3493	230	3	-	-	PUNCT
iajs-3493	230	4	haitham	haitham	PROPN
iajs-3493	230	5	journal	journal	PROPN
iajs-3493	230	6	for	for	ADP
iajs-3493	230	7	pure	pure	ADJ
iajs-3493	230	8	and	and	CCONJ
iajs-3493	230	9	applied	applied	ADJ
iajs-3493	230	10	sciences	science	NOUN
iajs-3493	230	11	2019	2019	NUM
iajs-3493	230	12	,	,	PUNCT
iajs-3493	230	13	32(1	32(1	NUM
iajs-3493	230	14	)	)	PUNCT
iajs-3493	230	15	,	,	PUNCT
iajs-3493	230	16	48	48	NUM
iajs-3493	230	17	-	-	SYM
iajs-3493	230	18	56	56	NUM
iajs-3493	230	19	.	.	PUNCT
iajs-3493	231	1	https://doi.org/10.30526/32.1.1920	https://doi.org/10.30526/32.1.1920	NOUN
iajs-3493	231	2	.	.	PUNCT
iajs-3493	232	1	https://doi.org/10.2147/jaa.s342993	https://doi.org/10.2147/jaa.s342993	X
iajs-3493	233	1	https://doi.org/10.3390/ijms21144911	https://doi.org/10.3390/ijms21144911	NOUN
iajs-3493	233	2	https://doi.org/10.1002/art.24441	https://doi.org/10.1002/art.24441	ADJ
iajs-3493	233	3	http://dx.doi.org/10.1016/j.ejr.2017.05.001	http://dx.doi.org/10.1016/j.ejr.2017.05.001	PROPN
iajs-3493	233	4	https://doi.org/10.1016/j.amjmed.2003.12.012	https://doi.org/10.1016/j.amjmed.2003.12.012	PROPN
iajs-3493	233	5	https://doi.org/10.1155/2014/698313	https://doi.org/10.1155/2014/698313	NOUN
iajs-3493	233	6	https://doi.org/10.1007/s40259-023-00634-1	https://doi.org/10.1007/s40259-023-00634-1	NUM
iajs-3493	233	7	https://doi.org/10.1016/j.intimp.2016.04.006	https://doi.org/10.1016/j.intimp.2016.04.006	X
iajs-3493	233	8	https://doi.org/10.1016/j.semarthrit.2020.11.005	https://doi.org/10.1016/j.semarthrit.2020.11.005	VERB
iajs-3493	233	9	https://doi.org/10.1515/med-2015-0037	https://doi.org/10.1515/med-2015-0037	NOUN
iajs-3493	233	10	https://www.researchgate.net/scientific-contributions/lara-ali-nazar-2153413266?_sg%5b0%5d=kn385xqoc4j03vd5zgsse3rscol4ub-qdctaworpfngqgq9plf0anfrrqovkjmvfhpcwerc.tmygvds4qoat4xwbsdwsv9hgz8epinslminbxr9vjp3ggipta8zqstt8t7i7zhtbqsmn1pkf-tmjjiqqepbj0w&_sg%5b1%5d=ipfulxc9la_xguk07rlc4jmic2v5lieesv2zhvz6uv4ywgl7peteextabqfcmympjkdae9w.5m80dzdjqxvazm6gxydln-to2ucprcc4uczic1qhsdve85dso-axzu_glaww9mjfstbxwyuo9bhis2dsskisbw&_tp=eyjjb250zxh0ijp7imzpcnn0ugfnzsi6inb1ymxpy2f0aw9uiiwicgfnzsi6inb1ymxpy2f0aw9uiiwicg9zaxrpb24ioijwywdlsgvhzgvyin19	https://www.researchgate.net/scientific-contributions/lara-ali-nazar-2153413266?_sg%5b0%5d=kn385xqoc4j03vd5zgsse3rscol4ub-qdctaworpfngqgq9plf0anfrrqovkjmvfhpcwerc.tmygvds4qoat4xwbsdwsv9hgz8epinslminbxr9vjp3ggipta8zqstt8t7i7zhtbqsmn1pkf-tmjjiqqepbj0w&_sg%5b1%5d=ipfulxc9la_xguk07rlc4jmic2v5lieesv2zhvz6uv4ywgl7peteextabqfcmympjkdae9w.5m80dzdjqxvazm6gxydln-to2ucprcc4uczic1qhsdve85dso-axzu_glaww9mjfstbxwyuo9bhis2dsskisbw&_tp=eyjjb250zxh0ijp7imzpcnn0ugfnzsi6inb1ymxpy2f0aw9uiiwicgfnzsi6inb1ymxpy2f0aw9uiiwicg9zaxrpb24ioijwywdlsgvhzgvyin19	NOUN
iajs-3493	233	11	https://www.researchgate.net/profile/eiman-abass-al-aati-2?_sg%5b0%5d=kn385xqoc4j03vd5zgsse3rscol4ub-qdctaworpfngqgq9plf0anfrrqovkjmvfhpcwerc.tmygvds4qoat4xwbsdwsv9hgz8epinslminbxr9vjp3ggipta8zqstt8t7i7zhtbqsmn1pkf-tmjjiqqepbj0w&_sg%5b1%5d=ipfulxc9la_xguk07rlc4jmic2v5lieesv2zhvz6uv4ywgl7peteextabqfcmympjkdae9w.5m80dzdjqxvazm6gxydln-to2ucprcc4uczic1qhsdve85dso-axzu_glaww9mjfstbxwyuo9bhis2dsskisbw&_tp=eyjjb250zxh0ijp7imzpcnn0ugfnzsi6inb1ymxpy2f0aw9uiiwicgfnzsi6inb1ymxpy2f0aw9uiiwicg9zaxrpb24ioijwywdlsgvhzgvyin19	https://www.researchgate.net/profile/eiman-abass-al-aati-2?_sg%5b0%5d=kn385xqoc4j03vd5zgsse3rscol4ub-qdctaworpfngqgq9plf0anfrrqovkjmvfhpcwerc.tmygvds4qoat4xwbsdwsv9hgz8epinslminbxr9vjp3ggipta8zqstt8t7i7zhtbqsmn1pkf-tmjjiqqepbj0w&_sg%5b1%5d=ipfulxc9la_xguk07rlc4jmic2v5lieesv2zhvz6uv4ywgl7peteextabqfcmympjkdae9w.5m80dzdjqxvazm6gxydln-to2ucprcc4uczic1qhsdve85dso-axzu_glaww9mjfstbxwyuo9bhis2dsskisbw&_tp=eyjjb250zxh0ijp7imzpcnn0ugfnzsi6inb1ymxpy2f0aw9uiiwicgfnzsi6inb1ymxpy2f0aw9uiiwicg9zaxrpb24ioijwywdlsgvhzgvyin19	NOUN
iajs-3493	233	12	https://doi.org/10.30526/32.1.1920	https://doi.org/10.30526/32.1.1920	X